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A B S T R A C T
Background
This review represents one in a family of three reviews focusing on the effectiveness of interventions in reducing drug use and criminal
activity for offenders.
Objectives
To assess the effectiveness of interventions for female drug-using offenders in reducing criminal activity, or drug use, or both.
Search methods
We searched 12 electronic bibliographic databases up to February 2019.
Selection criteria
We included randomised controlled trials (RCTs).
Data collection and analysis
We used standard methodological procedures expected by Cochrane.
Main results
We included 13 trials with 2560 participants. Interventions were delivered in prison (7/13 studies, 53%) and community (6/13 studies, 47%)
settings. The rating of bias was affected by the lack of clear reporting by authors, and we rated many items as 'unclear'.
In two studies (190 participants) collaborative case management in comparison to treatment as usual did not reduce drug use (risk ratio
(RR) 0.65, 95% confidence interval (CI) 0.20 to 2.12; 1 study, 77 participants; low-certainty evidence), reincarceration at nine months (RR
0.71, 95% CI 0.32 to 1.57; 1 study, 77 participants; low-certainty evidence), and number of subsequent arrests at 12 months (RR 1.11, 95%
CI 0.83 to 1.49; 1 study, 113 participants; low-certainty evidence).
One study (36 participants) comparing buprenorphine to placebo showed no significant reduction in self-reported drug use at end of
treatment (RR 0.57, 95% CI 0.27 to 1.20) and three months (RR 0.58, 95% CI 0.25 to 1.35); very low-certainty evidence. No adverse events
were reported.
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One study (38 participants) comparing interpersonal psychotherapy to a psychoeducational intervention did not find reduction in drug
use at three months (RR 0.67, 95% CI 0.30 to 1.50; low-certainty evidence).
One study (31 participants) comparing acceptance and commitment therapy (ACT) to a waiting list showed no significant reduction in self-
reported drug use using the Addiction Severity Index (mean difference (MD) -0.04, 95% CI -0.37 to 0.29) and abstinence from drug use at
six months (RR 2.89, 95% CI 0.73 to 11.43); low-certainty evidence.
One study (314 participants) comparing cognitive behavioural skills to a therapeutic community programme and aLercare showed no
significant reduction in self-reported drug use (RR 0.86, 95% CI 0.58 to 1.27), re-arrest for any type of crime (RR 0.73, 95% CI 0.52 to 1.03);
criminal activity (RR 0.80, 95% CI 0.63 to 1.03), or drug-related crime (RR 0.95, 95% CI 0.68 to 1.32). A significant reduction for arrested (not
for parole) violations at six months follow-up was significantly in favour of cognitive behavioural skills (RR 0.43, 95% CI 0.25 to 0.77; very
low-certainty evidence). A second study with 115 participants comparing cognitive behavioural skills to an alternative substance abuse
treatment showed no significant reduction in reincarceration at 12 months (RR 0.70, 95% CI 0.43 to 1.12; low certainty-evidence.
One study (44 participants) comparing cognitive behavioural skills and standard therapy versus treatment as usual showed no significant
reduction in Addiction Severity Index (ASI) drug score at three months (MD 0.02, 95% CI -0.05 to 0.09) and six months (MD -0.02, 95% CI
-0.09 to 0.05), and incarceration at three months (RR 0.46, 95% CI 0.04 to 4.68) and six months (RR 0.51, 95% CI 0.20 to 1.27); very low-
certainty evidence.
One study (171 participants) comparing a single computerised intervention versus case management showed no significant reduction in
the number of days not using drugs at three months (MD -0.89, 95% CI -4.83 to 3.05; low certainty-evidence).
One study (116 participants) comparing dialectic behavioural therapy and case management (DBT-CM) versus a health promotion
intervention showed no significant reduction at six months follow-up in positive drug testing (RR 0.67, 95% CI 0.43 to 1.03), number of
people not using marijuana (RR 1.23, 95% CI 0.95 to 1.59), crack (RR 1.00, 95% CI 0.87 to 1.14), cocaine (RR 1.02, 95% CI 0.93 to 1.12), heroin
(RR 1.05, 95% CI 0.98 to 1.13), methamphetamine (RR 1.02, 95% CI 0.87 to 1.20), and self-reported drug use for any drug (RR 1.20, 95% CI
0.92 to 1.56); very low-certainty evidence.
One study (211 participants) comparing a therapeutic community programme versus work release showed no significant reduction in
marijuana use at six months (RR 1.03, 95% CI 0.19 to 5.65), nor 18 months (RR 1.00, 95% CI 0.07 to 14.45), heroin use at six months (RR
1.59, 95% CI 0.49 to 5.14), nor 18 months (RR 1.92, 95% CI 0.24 to 15.37), crack use at six months (RR 2.07, 95% CI 0.41 to 10.41), nor 18
months (RR 1.64, 95% CI 0.19 to 14.06), cocaine use at six months (RR 1.09, 95% CI 0.79 to 1.50), nor 18 months (RR 0.93, 95% CI 0.64 to
1.35). It also showed no significant reduction in incarceration for drug offences at 18 months (RR 1.45, 95% CI 0.87 to 2.42); with overall
very low- to low-certainty evidence.
One study (511 participants) comparing intensive discharge planning and case management versus prison only showed no significant
reduction in use of marijuana (RR 0.79, 95% CI 0.53 to 1.16), hard drugs (RR 1.12, 95% CI 0.88 to 1.43), crack cocaine (RR 1.08, 95% CI 0.75
to 1.54), nor positive hair testing for marijuana (RR 0.75, 95% CI 0.55 to 1.03); it found a significant reduction in arrests (RR 0.19, 95% CI
0.04 to 0.87), but no significant reduction in drug charges (RR 1.07, 95% CI 0.75 to 1.53) nor incarceration (RR 1.09, 95% CI 0.86 to 1.39);
moderate-certainty evidence.
One narrative study summary (211 participants) comparing buprenorphine pre- and post-release from prison showed no significant
reduction in drug use at 12 months post-release; low certainty-evidence. No adverse effects were reported.
Authors' conclusions
The studies showed a high degree of heterogeneity for types of comparisons, outcome measures and small samples. Descriptions of
treatment modalities are required. On one outcome of arrest (no parole violations), we identified a significant reduction when cognitive
behavioural therapy (CBT) was compared to a therapeutic community programme. But for all other outcomes, none of the interventions
were effective. Larger trials are required to increase the precision of confidence about the certainty of evidence.
P L A I N   L A N G U A G E   S U M M A R Y
Interventions for female drug-using offenders
What is the aim?
To assess the effectiveness of interventions to reduce drug use, criminal activity, or both, in women involved in the criminal justice system.
What is the key message?
We are uncertain whether the treatments reduce subsequent drug use, criminal activity, or both. We identified too few studies to evaluate
whether the treatment
setting (for example, court or community) had an impact on the success of such programmes. The study sample sizes were small and the
certainty of this evidence was very low. High quality research is required to evaluate the effectiveness of different treatment options.
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What was studied?
We studied any intervention aimed at reducing drug use, criminal activity, or both. Many more people involved in the criminal justice
system experience drug use compared to people who have no contact with the criminal justice system. Most of the interventions that are
used to support the rehabilitation of drug use in the criminal justice system are aimed at men and not women. Women have different
needs to men and existing schemes need to be evaluated and adapted to deal with the complexity of the kinds of problems that women
experience in order to reduce female drug use, criminal activity, or both
What are the main results?
We found 13 trials including 2560 participants. The 13 trials included people who were assigned at random to one of two interventions,
conducted mainly in the USA. Studies were conducted in prison and the community. Study participants received a range of different
interventions in comparison to nothing, another intervention or treatment as usual.
The review shows that:
- when women engage with collaborative case management, it may make little or no difference to reducing drug use, reincarceration or
rearrest in comparison to treatment as usual (low-certainty evidence);
- when women take buprenorphine, we are uncertain whether it reduces drug use in comparison to a placebo (very low-certainty evidence);
- when women take buprenorphine pre-release from prison, it may make little or no difference to reducing drug use or criminal activity in
comparison to taking buprenorphine post-release from prison (low-certainty evidence);
- when women engage with interpersonal psychotherapy, it may make little or no difference to reducing a relapse into drug use in
comparison to a psychoeducational intervention (low-certainty evidence);
- when women engage in acceptance and commitment therapy, it may make little or no difference to reducing drug use/ abstinence from
drug use in comparison to a waiting list control (low-certainty evidence);
- when women engage with cognitive skills in comparison to a therapeutic community intervention, we are uncertain whether it produces
a reduction in subsequent drug use, being rearrested, committing criminal activity or drug-related crimes (very low-certainty evidence);
- when women engage with cognitive skills in comparison to a therapeutic community intervention, it may reduce subsequent arrest (not
parole violations) (very low-certainty evidence);
- when women engage with cognitive skills in comparison to standard therapy, we are uncertain whether it reduces subsequent drug use
(very low-certainty evidence);
- when women engage with a single session of a computerised intervention, it may make little or no difference to reducing subsequent
drug use (low-certainty evidence) in comparison to face-to-face case management;
- when women engage with dialectic behavioural therapy and case management, we are uncertain whether it produces a reduction in
subsequent drug use in comparison to a health promotion scheme (very low-certainty evidence);
- when women engage in a therapeutic community programme, we are uncertain whether it reduces subsequent drug use and criminal
activity in comparison to a work release programme (very low- to low-certainty evidence);
- when women engage with intensive discharge planning upon release, it probably does not reduce subsequent drug use and criminal
activity in comparison to prison only (moderate-certainty evidence).
Funding sources were reported by all studies and included government and research/charitable foundations.
How up-to-date is this review?
February 2019.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Collaborative case management compared to treatment as usual
Collaborative case management compared to treatment as usual
Patient or population: female offenders
Setting: probation in the community
Intervention: collaborative case management
Comparison: treatment as usual
Anticipated absolute effects* (95% CI)Outcomes











Study populationUse of primary drug during 9
month follow-up







Study populationReincarceration at 9 months
follow-up







Study populationNumber of arrests







*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.























































































































Summary of findings 2.   Community-based buprenorphine compared to placebo
Community-based buprenorphine compared to placebo




Anticipated absolute effects* (95% CI)Outcomes











Study populationEnd of treatment
drug use







Study populationDrug use at 3 months
follow-up







*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aDowngraded one level for high risk of bias on selection bias and incomplete outcome data.























































































































Summary of findings 3.   Interpersonal psychotherapy compared to psychoeducational control
Interpersonal psychotherapy compared to psychoeducational control




Anticipated absolute effects* (95% CI)Outcomes
Risk with psychoeducational
control











Study populationRelapse to drug
use at 3 months







*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aDowngraded two levels for imprecision as optimal information size not met.
 
 
Summary of findings 4.   Acceptance and commitment therapy (ACT) compared to waiting list control
Acceptance and commitment therapy (ACT) compared to waiting list control
Patient or population: summary findings of female review
Setting: prison
Intervention: ACT





















































































































Anticipated absolute effects* (95% CI)Outcomes










Study populationAbstinence from drug use
at 6 months







ASI drug score at 6 months - MD 0.04 lower




*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aDowngraded two levels for imprecision as optimal information size not met.
 
 
Summary of findings 5.   Cognitive behavioural therapy and other therapies compared to prison therapeutic community
Cognitive behavioural therapy and other therapies compared to prison therapeutic community
Patient or population: summary findings of female review
Setting: prison
Intervention: cognitive behavioural therapy and other therapies
Comparison: prison therapeutic community
Anticipated absolute effects* (95% CI)Outcomes
Risk with prison thera-
peutic community
































































































































Study populationReincarcerated at 12 months after
parole







Study populationArrested for any crime at 6 months







Study populationCriminal activity at 6 months







Study populationDrug-related crime at 6 months







Arrested (not parole violation) at 6
months
212 per 1000 91 per 1000
(53 to 163)
RR 0.43 (0.25 to 0.77) 314 (1 study) Very lowa,b  
Study populationSelf-reported drug use at 6 months







*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aDowngraded one level for imprecision as optimal information size not met.























































































































Summary of findings 6.   Cognitive behavioural therapy and standard therapy compared to treatment as usual
Cognitive behavioural therapy and standard therapy compared to treatment as usual
Patient or population: summary findings of female review
Setting: prison
Intervention: cognitive behavioural therapy and standard therapy
Comparison: treatment as usual
Anticipated absolute effects* (95% CI)Outcomes
Risk with treatment
as usual
Risk with cognitive behavioural










Study populationIncarceration at 3 months







Study populationIncarceration at 6 months







ASI drug score at 3 months - MD 0.02 higher




ASI drug score at 6 months - MD 0.02 lower




*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
ASI: Addiction Severity Index CI: confidence interval; MD: mean difference: RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.






















































































































bDowngraded for high risk of bias (detection bias).
 
 
Summary of findings 7.   Single computerised session compared to single session of case management
Single computerised session compared to single session of case management
Patient or population: summary findings of female review
Setting: community
Intervention: single computerised session
Comparison: single session of case management
Anticipated absolute effects* (95% CI)Outcomes
Risk with single session of
case management












Number of days not using drugs
(in the past 30 days) at 3 months
- MD 0.89 lower




*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; MD: mean difference.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aDowngraded two levels for imprecision.
 
 
Summary of findings 8.   Dialectic behaviour therapy with case management compared to a health promotion scheme
Dialectic behaviour therapy with case management compared to a health promotion scheme
Patient or population: summary findings of female review
Setting: community
Intervention: dialectic behaviour therapy with case management






















































































































Anticipated absolute effects* (95% CI)Outcomes















Study populationPositive drug test using urine sample
at 6 months







Study populationNumber not using marijuana at 6
months







Study populationNumber not using crack at 6 months







Study populationNumber not using cocaine at 6 months







Study populationNumber not using heroin at 6 months







Study populationNumber not using methamphetamine
at 6 months







Study populationSelf-report of no drug use at 6 months





























































































































CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aDowngraded two levels for imprecision as optimal information size not met.
bDowngraded one level for high risk of bias (incomplete outcome data).
 
 
Summary of findings 9.   Therapeutic community compared to work release
Therapeutic community compared to work release




Anticipated absolute effects* (95% CI)Outcomes











Study populationIncarcerated for drug of-
fences at 18 months







Study populationMarijuana use at 6 months







Study populationMarijuana use at 18 months





























































































































114 per 1000 182 per 1000
(56 to 587)
(0.49 to 5.14) (1 study)
Study populationHeroin use at 18 months







Study populationCrack use at 6 months







Study populationCrack use at 18 months







Study populationCocaine use at 6 months







Study populationCocaine use at 18 months







*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aDowngraded two levels for imprecision as optimal information size not met.
























































































































Summary of findings 10.   Intensive discharge planning and case management compared to prison only
Intensive discharge planning and case management compared to prison only
Patient or population: summary findings of female review
Setting: prison into the community
Intervention: intensive discharge planning and case management
Comparison: prison only
Anticipated absolute effects* (95% CI)Outcomes
Risk with prison only Risk with intensive dis-



















Study populationHard drug use







Study populationPositive hair test for
crack cocaine







Study populationPositive hair test for
marijuana use




















































































































































*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; OR: odds ratio; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aDowngraded for risk of bias (detection bias).
 
 
Summary of findings 11.   Pre- versus post-release buprenorphine use
Pre-release buprenorphine compared with post-release buprenorphine from prison in the community
Patient or population: 211 adults
Settings: in prison transition to the community
Intervention: pre-release buprenorphine
Comparison: post-release buprenorphine
Illustrative comparative risks* (95% CI)












Heroin use and posi-
tive urine screen test-
ing
Narrative summary of the findings only. No differential effects were found on gender. All
outcomes were P > 0.18
211 (1 study) Lowa,b  
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is























































































































GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect
aDowngraded one level for imprecision as optimal information size not met.
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B A C K G R O U N D
This review forms part of a family of three reviews, providing
a close examination of the types of interventions that are
effective in reducing drug use and criminal activity in drug-using
offenders. The three reviews report on trials generating a number
of publications and numerous comparisons (Perry 2015a; Perry
2019).  Two of the three reviews represent a specific interest
in pharmacological interventions, and offenders with concurrent
mental health problems. All three reviews stem from an updated
Cochrane Review (Perry 2006). We consider the effectiveness of
interventions based on two key outcomes: drug use and criminal
activity. We have presented here the revised methodology for this
individual review focusing on the impact of interventions for female
drug-using offenders.
Description of the condition
Within the criminal justice system, the number of women
incarcerated for drug offences has significantly increased over the
last decade (Carson 2018). The numbers of women in UK prisons
has doubled since 1993, with women making up around 5% of
the UK and 7% of the USA incarcerated population (Carson 2018;
Guerino 2011; Ministry of Justice 2017). Around a quarter of all
arrests are attributed to crimes committed by women (Carson 2018;
FBI 2011).
Among women offenders, recidivism associated with drug-related
violations is greater than those of men (32% versus 21%; Leukefeld
2009). Patterns of drug use in female offenders differs from that
of the male population. Females have been observed to use
cannabis less on average than men, but are more prone to using
so-called 'harder' drugs, such as heroin and amphetamines. In
the UK, nearly half of all women report needing help with a
drug problem on entry to prison compared with one-third of
all men (Forsythe 2009; Light 2013). Other factors that impact
on drug use for women include mental illness, raising children,
employment prospects, and patterns of offending (Salem 2013; Tsai
2013). Additionally, early victimisation and severity of addiction are
stronger predictors of criminal activity and subsequent mental and
physical health problems for women than for men (Bloom 2004;
Messina 2007). Furthermore, women entering substance abuse
treatment programmes in prison are at a substantial disadvantage
compared with their male counterparts, because few programmes
have been adapted to deal with the needs of women (Messina
2007). Few gender-sensitive programmes address drug use and
recidivism behaviours, and a study using male parolees comments
on how additional knowledge is required (Salem 2013).
Description of the intervention
There are many different treatments available for substance misuse
(e.g. detoxification, and therapeutic communities) in the criminal
justice system. This review includes any intervention that was
designed to reduce, eliminate or prevent relapse to drug use
or criminal activity, or both. This resulted in the inclusion of a
wide range of treatment interventions focusing on: therapeutic
community and gender-responsive treatment programmes,
community-based management, cognitive skills and cognitive
behavioural therapy, including acceptance and commitment
therapy (ACT) and dialectic behaviour therapy, pharmacological
interventions (using buprenorphine), computerised interventions
and interpersonal psychotherapy. The evidence supporting the
effectiveness of these interventions differs and is dependent upon
the quality of the experimental evaluations employed to assess
whether they are successful in reducing drug use or criminal
activity, or both.
Previous meta-analyses and systematic reviews of therapeutic
community interventions, specifically with aLercare, have shown
modest effects in the reduction of recidivism and drug use
(Mitchell 2012; Pearson 1999), and gender-responsive treatment
programmes are designed to provide a secure environment for
women offenders to safely discuss histories of trauma, abuse, and
addiction without fear of judgement (Grella 2008).
Community-based management evolved traditionally to address
the needs of prisoner re-entry programmes covering employment,
education, health, housing, and family support via assessment
and connecting clients with the appropriate services (Austin
1994). Case management in the USA has been applied
in Treatment Accountability for Safer Communities (TASC)
programmes (Marlowe 2003a), and has shown initial effectiveness,
but without systematic evidence in support of the process.
Contingency management, alongside voucher incentives have
shown some modest effects. Meta-analyses work including 30
studies, showed that overall, use of voucher incentives generated
significantly better outcomes than did control treatments. These
results further support the efficacy of voucher incentive schemes
and help to quantify the magnitude of its effects and suggest
potential directions for future research (Lussier 2006).
Cognitive behavioural approaches, including self-monitoring, goal
setting, self-control training, interpersonal skills training, relapse
prevention, group work, lifestyle modification, and ACT, have
shown signs of success with offenders generally (Lipsey 2007), but
the evidence excluded evaluations focused specifically on drug-
using offenders. Use of dialectical behavioural therapy (DBT) in
prison settings has been used to teach those who are incarcerated
how to dialectically think through and problem solve during
conflicting situations (Berzins 2004).
There have been a number of pharmacological reviews focusing
on the non-correctional population. Naltrexone maintenance
treatment for opioid dependence (Amato 2005; Lobmaier 2008;
Minozzi 2011), and the efficacy of methadone maintenance
(Faggiano 2003; Marsch 1998; Mattick 2009), and buprenorphine
maintenance (Mattick 2009), have been examined. Minozzi
2013 systematically reviewed the evidence on pharmacological
maintenance for non-correctional pregnant women and identified
three small trials from which they were unable to draw
firm conclusions about the effectiveness of treatment. Other
non-correctional reviews have investigated pharmacological
interventions, but not specifically for female offenders. These have
included evaluations of naltrexone maintenance treatment for
opioid dependence (Lobmaier 2008), the efficacy of methadone
maintenance including the management of opioid withdrawal
(Amato 2013; Faggiano 2003; Marsch 1998, Mattick 2009), and
buprenorphine maintenance and impact on dosage (Fareed 2012;
Mattick 2009).
Internationally, methadone maintenance has been the primary
choice for chronic opioid dependence in prisons and prisons,
including those in the Netherlands, Australia, Spain and Canada,
and it is being increasingly implemented in the criminal justice
setting (Moller 2007; Stallwitz 2007). The USA has not generally
Interventions for female drug-using offenders (Review)









Cochrane Database of Systematic Reviews
endorsed the use of methadone treatment, and only 12% of
correctional settings offer this option for incarcerated inmates
(Fiscella 2004). Reasons for this lack of expansion suggest that
methadone amongst the public and criminal justice system
providers has been considered a substitute for another addiction.
In contrast, buprenorphine appears not to carry the same social
stigma associated with methadone treatment and has been used
in France, Austria and Puerto Rico (Catania 2003; Garcia 2007;
Reynaud-Maurupt 2005). Naltrexone treatment has shown some
promising findings, but associated problems surrounding high
attrition and low medication compliance in the community and
high mortality rates pose concerns (Gibson 2007; Minozzi 2011).
Trials conducted in the criminal justice setting are still lacking,
and continuity of care is considered crucial in the treatment of
drug-involved offenders who move between the prison and the
community.
Systematic reviews of self-paced computerised screening tools
have been found to increase disclosure of personal information
among women in healthcare settings, and two previous
randomised controlled trials (RCTs) showed that they helped to
initiate patient-provider discussions (Ahmed 2009; McMillan 2009;
Nelson 2012), however, previous work with substance misusing
women involved in the criminal justice system are yet to be
explored (Gilbert 2015). Interpersonal psychotherapy has been
used in the community with proven effectiveness with non-
criminal justice settings. Such studies have not found interpersonal
psychotherapy to be superior to other treatments, but few of these
studies include female offenders (Johnson 2012).
How the intervention might work
Therapeutic community programmes have been used in the USA
since the 1960s, and combined with work release programmes,
they attempt to rehabilitate offenders via a supportive environment
over a relatively long period of time (up to and beyond 5 years),
typically encompassing the transition between the prison and
the community (Prendergast 2011). The ethos of therapeutic
community interventions is to focus on treatment of the whole
self, such that residents are instrumental in running the therapeutic
community (Mitchell 2012). Gender-responsive treatment is a
theoretically-based programme which is used to develop trauma-
informed services for women. In this review the development
of gender-responsive treatments were based on the relational–
cultural theory (Miller 1976), whereby the programme helps
the women to describe the psychological development of their
relationships and helps the connection to others.
Case management is used in the literature to describe a range of
diverse practices and supervision models spanning a number of
different services, including probation and those on parole. The
process of case management is used to co-ordinate and integrate
all aspects of community supervision, from the initial offender-
needs assessment, through to programme delivery and completion
of an order or sentencing requirement (Partridge 2004). Use of
DBT-CM techniques in this review were derived from a nursing
orientated theoretical framework linked to health-seeking and
coping mechanisms (Lazarus 1984). The method includes modules
of mindfulness, interpersonal effectiveness, distress tolerance and
emotion regulation. The processes involved help to facilitate
change in thoughts and emotions to produce the use of adaptive
behaviours and cognitive ability which prevents the escalation of
maladaptive behaviours (Shelton 2011). These techniques have
shown a significant improvement in the numbers of factors which
might link to an individuals level of risk (e.g. impulsivity, anger,
locus of control, self-esteem and emotional regulation (Nee 2005).
The trial within this review represents the first to be tested
in a group of women with substance misuse problems under
supervision in the community (Nyamathi 2017).
Cognitive behavioural approaches using programmes based on
psychological theory have been employed to try and help
people address their offending behaviour, and generally have
good support from the literature in their reduction of recidivism
(Andrews 1990; Lipsey 1998; Lipsey 2007). Two major meta-
analyses have examined the efficacy of ACT (Ost 2008; Powers
2009), and it is now recognised as 'empirically supported'
by the United States Substance Abuse and Mental Health
Sevice Administration (SAMHSA 2012). Nevertheless, the long-term
evidence to support the efficacy of ACT is limited (Lanza 2014).
Interpersonal psychotherapy addresses personal stress and life
changes. The emphasis is to engage with clients to develop their
network of social and peer support. A lack of support has been
shown to associate with dropping out of addiction treatment and
failure to maintain abstinence (Dobkin 2002; Holahan 2004).
Without exception, these programmes and community-based
interventions have been used to a greater extent with male
drug-using offenders, but to our knowledge little evidence has
been collated about how these programmes and other available
interventions have been adapted or used with female drug-using
offenders. Given that very little is known about what interventions
exist for female drug-using offenders, the focus of this review is
to include all known interventions that have been applied, or
specifically adapted for use with female drug-using offenders. Our
only requirement of these programmes is that they are aimed at
reducing drug use or criminal activity, or both.
Why it is important to do this review
The increasing numbers of females involved with the criminal
justice system have high levels of drug use in combination with
many other complex problems. Whilst previous research has
evaluated treatment programmes for offenders more broadly, we
know little about the challenges, treatment and rehabilitation
opportunities for female offenders with drug misuse problems. We
therefore believe that an evaluation of existing evidence on the
impact of interventions for female drug-using offenders might be
helpful in identifying treatments for reducing drug use and criminal
activity in this vulnerable population.
O B J E C T I V E S
To assess the effectiveness of interventions for female drug-using
offenders in reducing criminal activity, or drug use, or both.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
We included female drug-using offenders in the review, regardless
of age or ethnicity. Drug misuse included individuals using
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occasional drugs, or who were dependent, or known to abuse
drugs. We defined offenders as individuals who were subject to
the criminal justice system. Individuals could reside in special
hospitals, prisons, the community, or be diverted from court or
placed on arrest referral schemes for treatment. The study setting
could change throughout the process of the study. For example,
people involved in the criminal justice system could begin in prison
but progress through a work release project into a community
setting. We included studies containing male participants in the
review only when the trial results reported the outcomes separately
by gender; in these instances we included only the results for the
female participants in the review.
Types of interventions
Included interventions were designed, wholly or in part, to reduce,
eliminate or prevent relapse to drug use or criminal activity, or both,
among participants. We defined relapse in the case of individuals
who may have returned to an incarcerated setting, or subsequently
been arrested, or relapsed into drug misuse. We included a range of
different types of interventions in the review.
Experimental interventions included in the review
• Any pharmacological intervention (e.g. buprenorphine,
methadone)
• Any psychosocial intervention (e.g. therapeutic community
programme, case management, cognitive behavioural therapy,
interpersonal psychotherapy and motivational interviewing)
Control Interventions included in the review
• No treatment or waiting list control
• Minimal and/or alternative treatment (e.g. reporting use of
a similar intervention, but less intense or using a different
theoretical approach, but the same components and/or a
different alternative intervention)
• Treatment as usual included any study that reported a
combination and/or component of a (i) a psychological
base intervention (e.g. anger management, motivational
interviewing, counselling, aggression replacement, family
therapy), (ii) an educational programme (e.g. health, substance
abuse education on risky behaviour), and/or (iii) life skills
(e.g. financial planning, employment skills, computer skills,
interpersonal skills in interview)
Types of outcome measures
Primary outcomes
Where papers reported a number of different follow-up periods, we
reported the longest time period, as we felt that such measures
provided the most conservative estimate of effectiveness. Studies
need not report both drug and criminal activity outcomes. If either
of these were reported we included the study in the review.
• Drug use measures were reported as:
* self-reported drug use (unspecified drug use, specific drug
use not including alcohol, Addiction Severity Index (ASI) drug
composite scores); and
* biological drug use (measured by drug testing, using either
urine or hair analysis).
• Criminal activity was measured by:
* self-report or official report of criminal activity, (including
arrest for any offence, drug offences and/or re-incarceration).
Search methods for identification of studies
Electronic searches
The updated searches identified records from 2014 to 6 February
2019.
• Cochrane Central Register of Controlled Trials (CENTRAL; 1980
to February 2019)
• MEDLINE (1966 to February 2019)
• Embase (1980 to February 2019)
• PsycINFO (1978 to February 2019)
• SciSearch (Science Citation Index) (1974 to February 2019)
• Social SciSearch (Social Science Citation Index) (1972 to
February 2019)
• ASSIA (1987 to February 2019)
• NTIS (1964 to March 2014)a
• Sociological Abstracts (1963 to March 2014)b
• HMIC (to February 2019)
• PAIS (1972 to February 2019)
• Criminal Justice Abstracts (1968 to February 2019)
• LILACS (2004 to February 2019)
• Current Controlled Trials (December 2009)c
• SPECTR (March 2004)d
• CINAHLplus (to February 2019)
• ClinicalTrials.gov (clinicaltrials.gov) (to February 2019)
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (apps.who.int/trialsearch/) (to
February 2019)
aPaid access only - insufficient resources to search.
bNot available to search through York University.
cNo longer available to search.
dNo public access through Campbell Collaboration website which
previously hosted the database.
To update the review, we restricted the search strategy to studies
that were published since the end date of the previous search
(May 2014). We did not search a number of original databases
indicated by the key at the end of the database list. One database
(NTIS) was fee charging, the other three databases (Sociological
Abstracts, Current controlled trials and SPECTR) were not available
for searching due to changes in the provision of databases through
the University of York.
We developed search strategies for each database to exploit the
search engine most effectively and to make use of any controlled
vocabulary. We included methodological search filters designed to
identify RCTs. Whenever possible, we used filters retrieved from the
InterTASC Information Specialists' Sub-Group (ISSG) Search Filter
Resource site (www.york.ac.uk/inst/crd/intertasc/). If filters were
unavailable from this site, we substituted search terms based on
existing versions. We did not place any language restrictions on
identification and inclusion of studies in the review.
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Details of the updated search strategies are listed in Appendix
1; Appendix 2; Appendix 3; Appendix 4; Appendix 5; Appendix 6;
Appendix 7; Appendix 8; Appendix 9; Appendix 10; and Appendix 11.
Searching other resources
Reference checking
We scrutinised the reference lists of all retrieved articles for further
references.
Personal communication
We contacted experts for their knowledge of other studies,
published or unpublished, relevant to the review.
Data collection and analysis
Selection of studies
A team of review authors independently inspected the search
hits by reading the titles and abstracts. Each potentially relevant
study was obtained as a full-text article. Each article was
independently assessed for inclusion. In the case of discordance,
a third independent review author arbitrated. One review author
undertook translation of articles not written in the English
language.
We divided the screening process into two key phases. Phase one
used eight key questions reported in the original review.
Prescreening criteria: phase one
• Is the document an empirical study? If not, exclude the
document.
• Does the study evaluate an intervention, a component of which
is designed to reduce, eliminate, or prevent relapse with drug-
using offenders?
• Are the participants referred by the criminal justice system at
baseline?
• Does the study report pre- and postprogramme measures of
drug use?
• Does the study report pre- and postprogramme measures of
criminal behaviour?
• Is the study a RCT?
• Do the outcome measures refer to the same length of follow-up
for the two groups?
We then scrutinised papers included aLer phase one screening to
assess phase two.
Prescreening: phase two
• Is the study population composed wholly of female
participants? (If not, then refer to question below).
• Are the results of the study reported separately by gender? (If
yes, then include the document).
See Figure 1 for the flow chart of the process.
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Figure 1.   Study flow diagram.
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Data extraction and management
We used data extraction forms to standardise the reporting
of data from all studies obtained as potentially relevant. Two
review authors independently extracted data and subsequently
checked them for agreement. The narrative tables included a
presentation of the study details (for example author, year of
publication, and country of study origin), study methods (for
example, random assignment), participants (for example, number
in sample, age, gender, ethnicity), interventions (for example,
description, duration, intensity and setting), outcomes (for
example, description, follow-up period, and reporting mechanism),
and notes (for example, country and funding).
Assessment of risk of bias in included studies
The review team independently assessed the risk of bias of
all included studies using the 'Risk of bias' assessment criteria
recommended in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011).
The recommended approach for assessing risk of bias in studies
included in a Cochrane Review is a two-part process, addressing
seven specific domains, namely sequence generation and
allocation concealment (selection bias), blinding of participants
and providers (performance bias), blinding of outcome assessors
(detection bias), incomplete outcome data (attrition bias), selective
outcome reporting (reporting bias), and other potential sources
of bias. The first part of the process involves describing what
was reported to have happened in the study. The second part
involves assigning a judgement relating to the risk of bias for that
domain, in terms of low, high or unclear risk of bias. To make
these judgements we used the criteria indicated by the Cochrane
Handbook for Systematic Reviews of Interventions adapted to  the
addiction field (Higgins 2011). See Appendix 12 for details.
We addressed the domains of sequence generation and allocation
concealment (avoidance of selection bias) by a single entry for each
study.
In psychosocial interventions participants and personnel cannot be
blinded to the intervention; moreover we think that being aware of
receiving a psychosocial treatment is part itself of the therapeutic
effect; for these reasons, we rated them at low risk of performance
bias.
We considered detection bias separately for objective outcomes
(e.g. drop out, use of substance abuse (measured by urine analysis),
participants relapsed at the end of follow-up, participants engaged
in further treatments), and for subjective outcomes (e.g. duration
and severity of signs and symptoms of withdrawal, participants'
self-reported use of substance, side effects, social functioning as
integration at school or at work, family relationships).
We considered incomplete outcome data (avoidance of attrition
bias) for all outcomes except for drop out from the treatment, which
is very oLen the primary outcome measure in trials of addiction.
For studies identified in the search, the review authors attempted
to contact study authors to establish whether a study protocol was
available.
Measures of treatment effect
We used mean differences (MDs) with 95% confidence intervals
(CIs) for continuous outcomes measured on the same scale and
standardised mean differences (SMDs) for outcomes measured
on different scales. Higher scores for continuous measures are
representative of greater harm. We present dichotomous outcomes
as risk ratios (RRs), with 95% confidence interval (CIs).
Unit of analysis issues
To avoid double-counting of outcome measures (e.g. arrest and
parole violation) and follow-up time periods (e.g. 12, 18 months)
we checked all trials to ensure that multiple studies reporting the
same evaluation did not contribute towards multiple estimates
of programme effectiveness. We followed Cochrane guidance,
and where appropriate, we combined intervention and control
groups to create a single pair-wise comparison. Where this was
not appropriate, we selected one treatment arm and excluded the
others.
Dealing with missing data
We attempted to contact the study authors via email where missing
data occurred in the original publication.
Assessment of heterogeneity
We assessed heterogeneity using the I2 statistic and Chi2 statistic
(Higgins 2011). We regarded heterogeneity as substantial if the I2
statistic was greater than 50% or the P value lower than 0.10 for
the Chi2 test for heterogeneity (Deeks 2017). Following the guidance
in the Cochrane Handbook for Systematic Reviews of Interventions
(Deeks 2017), we distinguished the following values to denote no
important, moderate, substantial, and considerable heterogeneity,
respectively: 0% to 40%, 30% to 60%, 50% to 90%, and 75% to
100%.
Data synthesis
We planned to use Review Manager 5 soLware to perform a
series of meta-analyses for continuous and dichotomous outcome
measures (Review Manager 2014). We planned to use a random-
effects model to account for the fact that participants did not
come from a single underlying population. However, the studies in
this review represented many heterogeneous interventions, and no
meta-analysis was possible.
Sensitivity analysis
We had planned to conduct sensitivity analyses to assess the
impact of studies at high risk of bias compared with those at low or
unclear risk of bias.
Grading of evidence and 'Summary of findings' tables
We assessed the overall certainty of the evidence for the following
primary outcomes using the GRADE system: relapse, frequency
of use, amount of use, any adverse events and dropout from
treatment. The GRADE Working Group developed a system for
grading the certainty of evidence (Schunemann 2013), which takes
into account issues not only related to internal validity but also to
external validity, such as directness of results.
We have presented the main findings of the review in 11 'Summary
of findings' tables. This is a transparent and simple tabular form
that provides key information concerning the certainty of evidence,
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the magnitude of effect of the interventions examined and the sum
of available data on the main outcomes.
The GRADE system uses the following criteria for assigning grades
of evidence.
• High certainty: we are very confident that the true effect lies
close to that of the estimate of the effect.
• Moderate certainty: we are moderately confident in the effect
estimate; the true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different.
• Low certainty: our confidence in the effect estimate is limited;
the true effect may be substantially different from the estimate
of the effect.
• Very low certainty: we have very little confidence in the effect
estimate; the true effect is likely to be substantially different
from the estimate of effect.
Grading is decreased for the following reasons.
• Serious (-1) or very serious (-2) study limitations for risk of bias.
• Serious (-1) or very serious (-2) inconsistency between study
results.
• Some (-1) or major (-2) uncertainty about directness (the
correspondence between the population, the intervention, or
the outcomes measured in the studies actually found and those
under consideration in our systematic review).
• Serious (-1) or very serious (-2) imprecision of the pooled
estimate.
• Publication bias strongly suspected (-1).
R E S U L T S
Description of studies
Results of the search
As shown in Figure 1, our updated searches identified 9653 records.
We screened out 9410 references based on the titles and abstracts.
We examined the remaining 243 records in full-text, and excluded
239. We included four new trials (Gordan 2017; Gilbert 2015;
Needles 2005; Nyamathi 2017), and one follow-up study to an
existing trial within the review (Lanza 2014), along with nine studies
from the previous review; the total number of studies was 13 (see
Characteristics of included studies).
Included studies
Population
The 13 trials (described in 15 publications) were published
between 1996 and 2017 and included 2560 participants. The 13
studies included adult drug-using women offenders. One study
investigated the impact of a therapeutic community programme
with adults and young offenders (Nielsen 1996). Three studies
also included male offenders (Gordan 2017; Johnson 2011; Nielsen
1996), but results for the women were reported separately, enabling
us to extract data specifically for this review. The mean age of the
study participants ranged from 31.8 years to 39.08 years. In all but
three studies, the participants were of white ethnic origin (Gilbert
2015; Nielsen 1996; Nyamathi 2017).
Settings
We categorised the studies by setting, with six community-based
studies (Cropsey 2011; Gilbert 2015; Guydish 2011; Johnson 2011;
Needles 2005; Nyamathi 2017), and seven secure-based studies
(Gordan 2017; Johnson 2012; Lanza 2014; Messina 2010; Nielsen
1996; Sacks 2008; Zlotnick 2009). Twelve studies were set in the USA
and one study was conducted in Spain (Lanza 2014).
Duration of trials
The trial duration varied between three (Cropsey 2011; Gilbert 2015;
Johnson 2012; Zlotnick 2009) and 18 months (Nielsen 1996). The
remaining studies reported outcomes between six and 12 months
(Lanza 2014; Gordan 2017; Guydish 2011; Johnson 2011; Messina
2010; Needles 2005; Nyamathi 2017; Sacks 2008).
Outcome measures
Five out of 13 (38%) trials reported drug outcomes and 7/13 (53%)




Two studies evaluated community-based case management
compared to treatment as usual (standard probation and standard
parole supervision) (Guydish 2011; Johnson 2011), respectively.
Pharmacological intervention
Two studies used a pharmacological intervention in comparison to
a placebo (Cropsey 2011), and in comparison to post-release from
prison (Gordan 2017).
Interpersonal psychotherapy
One study compared interpersonal psychotherapy to a
psychoeducational comparison group (Johnson 2012).
Acceptance and commitment therapy (ACT)
One study compared ACT to a waiting list control (Lanza 2014).
Cognitive behavioural therapy
Three studies evaluate: i) a cognitive behavioural programme
versus a therapeutic community programme and aLercare (Sacks
2008), treatment as usual (Zlotnick 2009), and in comparison to a
substance abuse treatment (Messina 2010).
Computer-assisted intervention
One study evaluated the use of a single computer-assisted
session for intimate partner violence compared to a single session
delivered by a case manager (Gilbert 2015).
Dialectic behaviour therapy
One study compared dialectic behaviour therapy and case
management versus a health promotion initiative (Nyamathi 2017).
Therapeutic interventions and aIercare
One study compared a therapeutic intervention versus work
release Nielsen 1996.
Interventions for female drug-using offenders (Review)









Cochrane Database of Systematic Reviews
Intensive discharge planning
One study evaluated the use of intensive discharge planning and
community services for people leaving prison compared to less
intensive planning and no community services (Needles 2005).
Excluded studies
We excluded 239 full-text studies (see Characteristics of excluded
studies for further details). Reasons for exclusion were: not
reporting relevant drug or crime outcome measures, or both, in
both the pre- and post-intervention periods; and allocation of
participants to study groups that were not strictly randomised or
did not contain original trial data. We excluded studies because the
study population did not include female participants, or they were
not offenders, or the studies did not report the data for the female
participants separately.
Risk of bias in included studies
See Figure 2 and Figure 3.
 
Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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All 13 studies were described as randomised. A number of different
methods were used to perform the random assignment. These
included use of a random number table (sometimes computerised)
(Cropsey 2011; Gordan 2017; Gilbert 2015; Lanza 2014), urn
randomisation (Johnson 2011; Nyamathi 2017), the use of odd
and even identification numbers (Guydish 2011; Messina 2010),
and wave randomisation (Johnson 2012). The description of the
randomisation methodology remained unclear in the case of four
studies (Needles 2005; Nielsen 1996; Sacks 2008; Zlotnick 2009).
Characteristics at baseline
All studies except Nielsen 1996 and Needles 2005 reported on
similar drug use and criminal behaviour at baseline.
Allocation concealment
For allocation concealment, two studies noted use of sealed
envelopes (Gordan 2017; Guydish 2011), and one study noted
concealment from personnel within the study (Johnson 2012), one
deliberately allocated the first nine participants to intervention
for practical reasons but used sealed envelopes for the remaining
sample; we rated this at high risk of bias (Cropsey 2011). In
the remaining nine studies, no information was reported about
allocation concealment and we therefore rated them at unclear
risk of bias (Gilbert 2015; Johnson 2011; Lanza 2014; Messina 2010;
Needles 2005; Nielsen 1996; Nyamathi 2017; Sacks 2008; Zlotnick
2009).
Blinding
We rated performance bias in two pharmacological studies as
unclear and low risk for subjective and objective measures (Cropsey
2011; Gordan 2017); we rated all other psychosocial intervention
studies as low risk. We assessed risk of detection bias for all studies
across subjective and objective measures (see Appendix 12). We
rated 9/13 studies as unclear (Cropsey 2011; Gordan 2017; Gilbert
2015; Guydish 2011; Johnson 2011; Messina 2010; Nielsen 1996;
Nyamathi 2017; Sacks 2008). We rated two studies at low risk
(Johnson 2012; Lanza 2014), and two studies at high risk of bias
(Needles 2005; Zlotnick 2009).
Incomplete outcome data
Loss to follow-up was reported in eight of the 13 studies (Cropsey
2011; Gilbert 2015; Guydish 2011; Johnson 2011; Johnson 2012;
Lanza 2014; Needles 2005; Nyamathi 2017). Six studies reported
adequately on loss to follow-up with minimal attrition noted
(Gilbert 2015; Guydish 2011; Johnson 2012; Lanza 2014; Messina
2010; Zlotnick 2009). We rated five studies at high risk of bias
(Cropsey 2011; Gordan 2017 Needles 2005; Nyamathi 2017; Sacks
2008), and in two studies the reporting was unclear (Johnson 2011;
Nielsen 1996).
Selective reporting
We rated four studies as being at unclear risk of reporting bias
(Cropsey 2011; Guydish 2011; Needles 2005; Zlotnick 2009), two
studies at high risk of selective reporting (Johnson 2012; Nyamathi
2017), and seven studies at low risk of bias (Gilbert 2015; Gordan
2017; Johnson 2011; Lanza 2014; Messina 2010; Nielsen 1996; Sacks
2008).
Effects of interventions
See: Summary of findings for the main comparison Collaborative
case management compared to treatment as usual; Summary
of findings 2 Community-based buprenorphine compared to
placebo; Summary of findings 3 Interpersonal psychotherapy
compared to psychoeducational control; Summary of findings
4 Acceptance and commitment therapy (ACT) compared to
waiting list control; Summary of findings 5 Cognitive behavioural
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therapy and other therapies compared to prison therapeutic
community; Summary of findings 6 Cognitive behavioural
therapy and standard therapy compared to treatment as usual;
Summary of findings 7 Single computerised session compared
to single session of case management; Summary of findings 8
Dialectic behaviour therapy with case management compared to
a health promotion scheme; Summary of findings 9 Therapeutic
community compared to work release; Summary of findings 10
Intensive discharge planning and case management compared to
prison only; Summary of findings 11 Pre- versus post-release
buprenorphine use
1. Collaborative case management versus treatment as usual
Impact on self-reported drug use
See Summary of findings for the main comparison.
Johnson 2011 showed no significant reduction in self-reported
drug use at nine months follow-up (risk ratio (RR) 0.65, 95%
confidence interval (CI) 0.20 to 2.12; 77 participants; low-certainty
evidence; Analysis 1.1).
Impact on self-reported criminal activity
Johnson 2011 showed no significant reduction in reincarceration
at nine months (RR 0.71, 95% CI 0.32 to 1.57; 77 participants; low-
certainty evidence; Analysis 1.2).
Guydish 2011 showed no significant reduction in number of arrests
(RR 1.11, 95% CI 0.83 to 1.49; 113 participants; low-certainty
evidence; Analysis 1.3).
2. Community-based buprenorphine versus placebo
See Summary of findings 2.
Impact on self-reported drug use
Cropsey 2011 showed no significant reduction in self-reported
drug use at end of treatment (RR 0.57, 95% CI 0.27 to 1.20; 36
participants; very low-certainty evidence; Analysis 2.1); nor at three
months (RR 0.58, 95% CI 0.25 to 1.35; 36 participants; very low-
certainty evidence Analysis 2.2).
Impact on self-reported criminal activity
Not reported.
3. Interpersonal psychotherapy versus a psychoeducational
control
See Summary of findings 3.
Impact on self-reported drug use
Johnson 2012 reported no significant reduction in relapse to drug
use at three months (RR 0.67, 95% CI 0.30 to 1.50; 38 participants;
low-certainty evidence; Analysis 3.1).
Impact on self-reported criminal activity
Not reported.
4. Acceptance and commitment therapy (ACT) versus waiting
list control
See Summary of findings 4.
Impact on self-reported drug use
The Lanza 2014 study reported no significant reduction in self-
reported drug use at six months using the Addiction Severity
Index (ASI) (mean difference (MD) -0.04, 95% CI -0.37 to 0.29; 31
participants; low-certainty evidence; Analysis 4.1) and abstinence
from drug use (RR 2.89, 95% CI 0.73 to 11.43; 31 participants; low-
certainty evidence; Analysis 4.2).
Impact on self-reported criminal activity
Not reported.
5. Cognitive behavioural therapy and other therapies versus
prison therapeutic community
See Summary of findings 5.
Impact on self-reported drug use
Sacks 2008 showed no significant reduction in self-reported drug
use at six months (RR 0.86, 95% CI 0.58 to 1.27; 314 participants;
low-certainty evidence; Analysis 5.5).
Impact on self-reported criminal activity
Messina 2010 showed no significant reduction in reincarceration
at 12 months (RR 0.70, 95% CI 0.43 to 1.12; 115 participants; low-
certainty evidence; Analysis 5.1). Sacks 2008 showed no significant
reduction in arrest at six months for any type of crime (RR 0.73,
95% CI 0.52 to 1.03; 314 participants; very low-certainty evidence;
Analysis 5.2), criminal activity (RR 0.80, 95% CI 0.63 to 1.03; 314
participants; very low-certainty evidence; Analysis 5.3), or drug-
related crime (RR 0.95, 95% CI 0.68 to 1.32; 314 participants; very
low-certainty evidence; Analysis 5.4), and a significant reduction in
subsequent arrest (not parole violations) (RR 0.43, 95% CI 0.25 to
0.77; 314 participants; very low-certainty evidence; Analysis 5.6).
6. Cognitive behavioural therapy and standard therapy versus
treatment as usual
See Summary of findings 6.
Impact on self-reported drug use
Zlotnick 2009 showed no significant reduction in ASI drug score
at three months (MD 0.02, 95% CI -0.05 to 0.09; 44 participants;
very low-certainty evidence; Analysis 6.3), nor six months (MD -0.02,
95% CI -0.09 to 0.05; 44 participants; very low-certainty evidence;
Analysis 6.4).
Impact on self-reported criminal activity
Zlotnick 2009 showed no significant reduction in incarceration
at three months (RR 0.46, 95% CI 0.04 to 4.68; 44 participants;
very low-certainty evidence; Analysis 6.1), nor six months (RR 0.51,
95% CI 0.20 to 1.27; 44 participants; very low-certainty evidence;
Analysis 6.2).
7. Single computerised session versus single session of case
management
See Summary of findings 7.
Interventions for female drug-using offenders (Review)









Cochrane Database of Systematic Reviews
Impact on self-reported drug use
Gilbert 2015 showed no significant reduction in the number of days
not using drugs at three months follow-up (MD -0.89, 95% CI -4.83
to 3.05; 171 participants; low-certainty evidence; Analysis 7.1).
Impact on self-reported criminal activity
Not reported.
8. Dialectic behavioural therapy with case management (DBT-
CM) versus a health promotion scheme
See Summary of findings 8.
Impact on self-reported drug use
Nyamathi 2017 showed no significant reduction in positive drug
testing at six months follow-up via urine samples (RR 0.67, 95% CI
0.43 to 1.03; 116 participants; very low-certainty evidence; Analysis
8.1), number of people not using marijuana (RR 1.23, 95% CI 0.95
to 1.59; 116 participants; very low-certainty evidence; Analysis 8.2),
number of people not using crack (RR 1.00, 95% CI 0.87 to 1.14;
116 participants; very low-certainty evidence; Analysis 8.3), number
of people not using cocaine (RR 1.02, 95% CI 0.93 to 1.12; 116
participants; very low-certainty evidence; Analysis 8.4), number
of people not using heroin (RR 1.05, 95% CI 0.98 to 1.13; 116
participants; very low-certainty evidence; Analysis 8.5), number of
people not using methamphetamine (RR 1.02, 95% CI 0.87 to 1.20;
116 participants; very low-certainty evidence; Analysis 8.6), self-
reported drug use for any drug (RR 1.20, 95% CI 0.92 to 1.56; 116
participants; very low-certainty evidence; Analysis 8.7).
Impact on self-reported criminal activity
Not reported.
9. Therapeutic community programme versus work release
See Summary of findings 9.
Impact on self-reported drug use
Nielsen 1996 showed no significant reduction in marijuana use
at six months (RR 1.03, 95% CI 0.19 to 5.65; 51 participants; very
low-certainty evidence; Analysis 9.2), nor 18 months (RR 1.00,
95% CI 0.07 to 14.45; 28 participants; very low-certainty evidence;
Analysis 9.3), heroin use at six months (RR 1.59, 95% CI 0.49 to 5.14;
68 participants; very low-certainty evidence; Analysis 9.4), nor 18
months (RR 1.92, 95% CI 0.24 to 15.37; 37 participants; very low-
certainty evidence; Analysis 9.5), crack use at six months (RR 2.07,
95% CI 0.41 to 10.41; 55 participants; very low-certainty evidence;
Analysis 9.6), nor at 18 months (RR 1.64, 95% CI 0.19 to 14.06; 34
participants; very low-certainty evidence; Analysis 9.7), cocaine use
at six months (RR 1.09, 95% CI 0.79 to 1.50; 211 participants; low-
certainty evidence; Analysis 9.8), nor at 18 months (RR 0.93, 95% CI
0.64 to 1.35; 139 participants; very low-certainty evidence; Analysis
9.9).
Impact on self-reported criminal activity
Nielsen 1996 showed no significant reduction in incarceration for
drug offences at 18 months (RR 1.45, 95% CI 0.87 to 2.42; 112
participants; low-certainty evidence; Analysis 9.1).
10. Intensive discharge planning and case management versus
prison only
See Summary of findings 10.
Impact on self-reported drug use
Needles 2005 showed no significant reduction in marijuana use
(RR 0.79, 95% CI 0.53 to 1.16; 511 participants; moderate-certainty
evidence; Analysis 10.1), hard drug use (RR 1.12, 95% CI 0.88 to
1.43; 511 participants; moderate-certainty evidence; Analysis 10.2),
positive hair test for crack cocaine (RR 1.08, 95% CI 0.75 to 1.54;
511 participants; moderate-certainty evidence; Analysis 10.3), nor
positive hair test for marijuana use (RR 0.75, 95% CI 0.55 to 1.03; 511
participants; moderate-certainty evidence; Analysis 10.4).
Impact on self-reported criminal activity
Needles 2005 showed a significant reduction in arrests (RR 0.19,
95% CI 0.04 to 0.87; 511 participants; moderate-certainty evidence;
Analysis 10.5), but no significant reduction in drug charges (RR 1.07,
95% CI 0.75 to 1.53; 511 participants; moderate-certainty evidence;
Analysis 10.6), nor incarceration (RR 1.09, 95% CI 0.86 to 1.39;
Analysis 10.7).
11. Buprenorphine pre-release from prison versus
buprenorphine post-release
Gordan 2017 reported a narrative summary of the gender
differences between males and females in how they responded to
the intervention. Authors contacted for further information, but did
not reply. In the paper they report that no significant gender effects
with P > 0.18.
Treatment setting
Too few studies were included in the meta-analyses to make a
subgroup analysis for type of setting meaningful.
D I S C U S S I O N
Summary of main results
This review provided evidence from 13 trials involving 2560
participants. The 13 trials evaluated 11 different comparisons. The
certainty of the evidence was generally low to very low; we rated
one study as moderate-certainty evidence. Most interventions
were delivered in prison-based settings (7/13 studies, 53%) or
the community (6/13 studies, 47%). Most studies compared an
intervention to another intervention (8/13, 61%).
The 11 different treatment comparisons were as follows.
• Collaborative case management compared to treatment as
usual (Guydish 2011; Johnson 2011).
Evaluations of case management and standard parole showed
disappointing results. The Guydish 2011 probation case
management study found no differential effect. Women in both
groups were equally likely to be arrested during the one-year
follow-up period. The study authors note that although the results
indicated no advantage for probation case management over
standard probation, this finding is similar to other research showing
mixed effects (e.g. Sorenson 2003). The authors note that one
key limitation of the probation case management was the low-
level, face-to-face contact. Although probation case management
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is designed to be more engaging than standard probation, only
54% of the probation case management participants reported
face-to-face contact with their manager in the six months aLer
programme entry. The implications suggest that case management
based on reduced caseloads, specialised probation officer training
and efforts to increase contact between probation officer and
probationer may not be effective. Similarily, the study conducted
by Needles and colleagues concluded that while well executed case
management programmes can make a difference in the short-term
outcomes for former inmates, their programme did not change the
life course or basic health status of most of those involved; a change
in such outcomes would be needed to indicate greater success in
community integration or improved health (Needles 2005).
Use of collaborative behavioural management techniques in
comparison to standard parole did not significantly reduce
reincarceration (21% of the collaborative behavioural management
participants versus 29% of the control participants) in the nine-
month follow-up (Johnson 2011). The study did show a reduction
in monthly primary drug use. This is consistent with past findings
which have indicated that women who engage in prison substance
use treatment programmes have lower drug use rates than men
in the months aLer release from prison (Pelissier 2003). Other
researchers have highlighted this gender effect, suggesting that
factors predicting aLercare treatment completion, post-treatment
drug use and recidivism were slightly different for women than
for men, suggesting the possibility of gender-specific pathways
to successful community re-entry (Pelissier 2003). This finding is
important because it may support the idea that optimal transitional
treatments may differ for men and women, however more
randomised trials of transitional interventions for drug-involved
offenders are required (Taxman 2002). The authors suggest that
any gender differences displayed between men and women should
be revisited to assess what important lessons can be applied
for the successful integration of theory- and gender-responsive
treatment. Some successful elements of treatment seemed to
include a recognition of success, an emphasis on consistency and
fairness from within the programme, and a focus on overall life
functioning and support (Johnson 2011).
• Community-based buprenorphine compared to a placebo
(Cropsey 2011), and in comparison to pre- and post-release from
prison (Gordan 2017).
Pharmacological interventions using buprenorphine for opioid-
dependent women with a HIV risk found that use of buprenorphine
in prison and continued use of the drug in the community was
not beneficial in preventing or delaying relapse to opioid use
(Cropsey 2011). The findings were not sustained post-treatment,
with most women relapsing to active opioid use at the three-month
follow-up point. The study did not measure criminal activity, so
we do not know whether such interventions are likely to reduce
subsequent criminal activity in the future. Pre- and post-release
use of buprenorphine was compared in another study showing no
beneficial effect of gender on any outcome measures at 12 months
post-release from prison (Gordan 2017).
• Interpersonal psychotherapy compared to a psychoeducational
control (Johnson 2012).
Interpersonal psychotherapy was evaluated using a pilot study
with women suffering from major depression and substance use
disorder (Johnson 2012). This study is primarily a feasibility study
to assess the applicability of using interpersonal psychotherapy in
a prison environment. Despite being small, it is one of the largest
trials including women with co-occurring substance misuse and
mental health problems. The findings showed that interpersonal
psychotherapy participants did not significantly reduce levels of
substance misuse over the attention matched control. The study
authors note that the intensity of treatment delivered, once
released into the community, is key to maintaining good outcomes.
However, they go on to state that women oLen experience delays
in treatment and service provision on release and they suggest that
alternative service provision such as phone treatment might be
helpful in providing a more intensive post-release treatment, and
may form a useful contact in times of crisis.
• Acceptance and commitment therapy (ACT) compared to a
waiting list control (Lanza 2014).
The study evaluating ACT and a control group found no difference
between the two groups (Lanza 2014). The authors note the ACT
applies the 'co-joint' work between the therapist and client. The
aim of which is to increase the flexibility and structure of the
therapy, allowing the client to have greater autonomy over making
decisions (Lanza 2014).
• Cognitive behavioural therapy and other therapies compared
to a prison-based therapeutic community programme (Sacks
2008), and compared to treatment as usual (Messina 2010), and
a substance abuse treatment programme (Zlotnick 2009).
The specifically adapted gender-responsive therapeutic
community programme for women offenders was evaluated by
Sacks and colleagues. This study compared women assigned to
the therapeutic community programme or standard treatment
(referred to in the system as the Intensive Outpatient Programme),
or cognitive behavioural therapy. This consisted of a cognitive
behavioural recovery and relapse prevention curriculum (Sacks
2008). At six months the study found that there was one significant
difference between the groups for arrested (not parole violation).
They note that further exploration of each model for different
offender groups is required to permit a more precise utility of
each model. The study authors conclude that these preliminary
findings suggest the importance of providing gender-specific
sensitive and comprehensive approaches within the correctional
system to respond to the complex substance abuse needs of
female offenders (Sacks 2008). The more recent follow-up study
investigated outcomes at six months and 12 months. The outcomes
followed a similar pattern with both groups of women benefiting
from treatment. The therapeutic community programme was
found to be more beneficial than cognitive behavioural therapy
at improving reincarceration rates and lengthening the amount of
time spent in the community before subsequent reincarceration
(Sacks 2012).
The Messina 2010 study showed that gender-responsive treatment
participants voluntarily remain in aLercare treatment for longer
periods and are less likely than those in standard therapeutic
community care to be reincarcerated within 12 months of parole.
One of the main differences between gender-responsive treatment
and therapeutic community programmes was the recognition of
trauma. The authors argue that trauma seemed to impact on a
range of other outcomes and was an important aspect of recovery
which needed to be addressed. The possible reason for this benefit
may be due to the overall enhanced treatment satisfaction of
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participants compared with those in the standard treatment group.
This finding is supported by other qualitative research which
showed that women attending the gender-responsive treatment
programme were extremely invested and satisfied with treatment
outcomes, and felt supported by other group members, which may
have increased treatment adherence and recovery (Calhoun 2009;
Messina 2010). Additionally, the authors noted that those women
who stayed in treatment voluntarily remained in aLercare for a
longer period of time. A number of implementation barriers were
presented in the study, including the need for ongoing staff training,
technical assistance and monitoring of adherence to the study
protocol.
The final study evaluated in this group of analyses compared the
use of a cognitive skills and cognitive behavioural therapy, referred
to as the Seeking Safety Programme. The study compared seeking
safety to standard prison-based substance abuse treatment, and
found no significant differences between conditions on any
measure in the primary analysis (Zlotnick 2009). This finding
is contrary to other research conducted using the Seeking
Safety Programme with non-correctional clients in the community
(Najavits 2006). The authors note that future research should focus
specifically on whether dosage has an impact on the successful
outcome of seeking safety, with participants randomly assigned to
different lengths of treatment. Further difficulties in the evaluation
of the study led to concerns about adherence to the programme
once the women were released into the community. A series of
12 booster sessions were offered, but on average women only
attended three sessions. The challenge of programme adherence is
common across the criminal justice system, especially with those
programmes conducted in the community. Given this context, the
authors suggest that perhaps longer treatment during prison and
increased frequency of treatment following release may be helpful.
A major question for future research relates to the development
of models for dealing with simultaneous problems and concurrent
mental health issues (Zlotnick 2009).
• A computerised intervention compared to a single session of
case management (Gilbert 2015).
The study of a single computerised session in comparison
to a single session delivered by a case manager showed no
significant differences (Gilbert 2015). The authors note that further
research should consider whether the costs of implementing
the computerised intervention might increase the likelihood of
it being scaled up for use in community supervision sessions.
Future research in this area, therefore needs to incorporate cost-
effectiveness information and longer-term follow-ups to support
the evidence of the efficacy of any such programme (Gilbert 2015).
• Dialectic behavioural therapy (DBT) with case management
compared to a health promotion scheme (Nyamathi 2017).
Combining case management with DBT showed no significant
differences compared to the health promotion scheme in a
group of women under supervision in the probation and parole
systems (Nyamathi 2017). The study failed to describe the
detailed components regarding the amount of DBT-CM (dialectic
behavioural therapy with case management) received, so it is
difficult to ascertain whether the impact of these findings is due
to the combination of effects or one single component(s) of the
intervention.
• Therapuetic community programme compared to work release
(Nielsen 1996).
In these studies the Continual Recovery through Education and
Skills Training (CREST) work release programme was compared
to participants in the Delaware conventional work release
programme. The evaluation showed that it is possible to
successfully combine the elements of therapeutic community
treatment with the goals of work release (Nielsen 1996).
• Intensive discharge planning and case management in
comparison to prison only (Needles 2005).
This study did observe reductions in rearrest rates. The authors
concluded that a well-executed case management programme can
make modest differences in a few short-term outcomes of former
inmates. However, the intervention did not lead to the hoped for
changes across a range of outcomes that would clearly indicate
greater success in community reintegration or improved health
(Needles 2005).
Overall completeness and applicability of evidence
The paucity of evidence within the review is covered in three key
areas.
General applicability
The applicability of this evidence is hindered in general by the
number of small trials representing a range of different treatment
options for female offenders with drug misuse problems. All trials,
apart from one, were conducted in the USA and therefore, they have
limited external validity to other criminal justice systems outside of
the USA.
Adaptation of programmes for female offenders
Most of the studies described the programmes under evaluation
as 'adapted' or 'amended' programmes tailored to the needs of
women, but few studies described how the programmes had been
adapted or what considerations had been taken into account.
It is therefore difficult to draw conclusions about the successful
elements of treatment programmes for female offenders.
Certainty of evidence
We rated the majority of studies as being at 'unclear' risk of bias
with poor reporting of information by study authors, making it
difficult for the authors of this review to assess the extent of
potential bias within the studies. Since poor reporting lowers the
certainty of evidence, in all but one study we judged the evidence to
be of very low to low certainty, which means that further research
is very likely to have an important impact on our confidence in
the estimate of effect (imprecision of the estimate) and is likely to
change the estimate based on the small sample sizes of the existing
trials. Additional concerns with the research included attrition
bias, and the limited external generalisation associated with such
studies and contamination effects.
A number of studies posed a threat to attrition bias, with over 50%
rated at high risk of attrition. Five of the nine studies were classified
as pilot studies, using sample sizes of 55 or less. The Cropsey 2011
study identified a sample of 36 women, randomly allocating 27 (15
to the intervention and 12 to the placebo group). They note that
although the potency of buprenorphine for control of opioid use
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is clearly demonstrated, a larger sample size may be needed to
detect significant differences between groups on other variables of
interest. The study was limited to three months of treatment, and
future studies should explore the provision of buprenorphine for
longer periods of time, to prolong opioid abstinence and to prevent
associated criminal activity.
The Zlotnick 2009 study used a slightly larger sample of 55
women with post-traumatic stress disorder in an incarcerated
setting, comparing cognitive behavioural therapy plus treatment
as usual to treatment as usual alone. The Messina 2010 study
called for larger sample sizes and bigger experimental studies.
Similarily, the Lanza 2014 study assigned only 50 participants with
complex needs; they note that future research should include larger
samples. The Johnson 2012 study assigned 19 participants to each
arm of the trial and also had difficulties in measuring relapse rates,
as 26% of the sample remained in residential treatment for the
entire follow-up period.
Other potential biases were presented in the Zlotnick 2009
study, which noted potential contamination problems between
the treatment and control conditions across the prison setting.
Offenders from different wings or locations within the prison
frequently mixed or moved locations. Finally, they noted that
the facilitators delivered both the treatment intervention and
treatment as usual, and that an immediate post-assessment was
not completed. The authors argue this could have had an unknown
effect on the immediate impact of the intervention.
Potential biases in the review process
Besides the limitations already discussed, the search methodology
was limited to databases that could be accessed via the University
of York and extensive website searches were not conducted. As a
result, some literature may have been missed from this updated
version.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
The current evidence suggests that there is little evidence to
support the use of any of the described interventions with
women offenders with drug use problems and as such we do
not know how and what treatments facilitate the rehabilitation
of female offenders. Overall, the studies showed a high degree of
heterogeneity for types of comparisons and outcome measures
assessed, which limited the possibility to pool the data. Only one
significant outcome for arrest (not parole violations) was identified
for a cognitive behavioural therapy in comparison to a therapeutic
community programme. None of the other interventions seemed to
be effective and additionally, some of the sample sizes were very
small. Larger trials (although difficult to achieve in this population)
are required to increase the precision of confidence about the
certainty of evidence on the impact of treatments for female drug-
using offenders. Descriptions of treatment modalities are required
to identify the important elements for treatment success in drug-
using female offenders.
Implications for research
Specific questions in the research literature identify a number of
different gaps in current research.
• Future work should consider the most appropriate use of
outcomes and produce some standardisation from which
comparisons can be made across the literature.
• Researchers should also explore the needs and experiences
of women (e.g. child care restrictions, previous trauma).
Qualitative research into the experiences of women attending,
or starting and not finishing programmes, could help
researchers to learn important lessons in the design of
interventions that are appropriate for this population.
• Larger-scale trial evaluations need to include information about
the exact nature of the programme, the content, intensity,
delivery and administration. Specific information about how
programmes are adapted or amended for women will provide
important theoretical gender differences for future treatment
programmes targeting female offenders.
• Longer-term follow-up outcomes are required to evaluate the
ongoing impact of interventions which might reduce drug use
and criminal activity in female offenders.
• More studies are required to consider the transitional links
between court, prison and release from prison in the
community.
• Randomised controlled trials (RCTs) should be encouraged by
policy makers and supported by funding bodies outside of
the USA to generate an evidence base that will have greater
generalisability and replication to other criminal justice systems
worldwide.
A C K N O W L E D G E M E N T S
We would like to acknowledge the help of the York Health
Economics Consortium and the Health Sciences Department at
the University of York, Centre for Reviews and Dissemination and
Cochrane Drugs and Alcohol. We would like to thank peer reviewers
Mishka Terplan and Dominique de Andrade for their comments and
feedback.
Interventions for female drug-using offenders (Review)









Cochrane Database of Systematic Reviews
R E F E R E N C E S
 
References to studies included in this review
Cropsey 2011 {published data only}
Cropsey KL, Lane PS, Hale GJ, Jackson DO, Clark CB,
Ingersoll KS, et al. Results of a pilot randomized controlled trial
of buprenorphine for opioid dependent women in the criminal
justice system. Drug and Alcohol Dependence 2011;119(3):172-8.
Gilbert 2015 {published data only}
Gilbert L, Shaw SA, Goddard-Eckrich D, Chang M, Rowe J,
McCrimmon T, et al. Project WINGS (Women Initiating New
Goals of Safety): a randomised controlled trial of a screening,
brief intervention and referral to treatment (SBIRT) service to
identify and address intimate partner violence victimisation
among substance-using women receiving community
supervision. Criminology 2015;25(4):314-29.
Gordan 2017 {published data only}
Gordon MS, Kinlock TW, Schwartz RP, O'Grady KE, Fitzgerald TT,
Vocci FJ. A randomized clinical trial of buprenorphine for
prisoners: findings at 12-months post-release. Drug and Alcohol
Dependence 2017;172:34-42.
Guydish 2011 {published data only}
Guydish J, Chan M, Bostrom A, Jessup M, Davis T, Marsh C.
A randomized trial of probation case management for
drug-involved women offenders. Crime and Delinquency
2011;57(2):167-98.
Johnson 2011 {published data only}
Johnson JE, Friedmann PD, Green TC, Harrington M, Taxman FS.
Gender and treatment response in substance use treatment-
mandated parolees. Journal of Substance Abuse Treatment
2011;40(3):313-21.
Johnson 2012 {published data only}
Johnson JE, Zlotnick C. Pilot study of treatment for major
depression among women prisoners with substance use
disorder. Journal of Psychiatric Research 2012;46(9):1174-83.
[DOI: 10.1016/j.jpsychires.2012.05.007]
Lanza 2014 {published data only}
Gonzalez-Menendez A, Fernández P, Rodríguez F, Villagrá P.
Long-term outcomes of acceptance and commitment therapy
in drug-dependent female inmates: a randomized controlled
trial. International Journal of Clinical and Health Psychology
2014;14(1):18-27.
* Lanza PV, García PF, Lamelas FR, González-Menéndez A.
Acceptance and commitment therapy versus cognitive
behavioral therapy in the treatment of substance use disorder
with incarcerated women. Journal of Clinical Psychology
2014;70(7):1-14. [DOI: 10.1002/jcip.22060]
Villagrá Lanza P, González Menéndez A. Acceptance and
Commitment Therapy for drug abuse in incarcerated women.
Psicothema 2013;25(3):307-12.
Messina 2010 {published data only}
Messina N, Grella CE, Cartier J, Torres S. A randomized
experimental study of gender-responsive substance abuse
treatment for women in prison. Journal of Substance Abuse
Treatment 2010;38(2):97-107.
Needles 2005 {published data only}
Needels K, James-Burdumy S, Burghardt J. Community
case management for former jail inmates: Its impacts on
rearrest, drug use, and HIV risk. Journal of Urban Health
2005;82(3):420-33.
Nielsen 1996 {published data only}
Farrell A. Women, crime and drugs: Testing the effect of
therapeutic communities. Women and Criminal Justice
2000;11(1):21-48.
* Nielsen AL, Scarpitti FR, Inciardi JA. Integrating the
therapeutic community and work release for drug-involved
offenders. The CREST Program. Journal of Substance Abuse
Treatment 1996;13(4):349-58.
Nyamathi 2017 {published data only}
Nyamathi AM, Shin SS, Smeltzer J, Salem BE, Yadav K,
Ekstrand ML, et al. Achieving drug and alcohol abstinence
among recently incarcerated homeless women: a randomized
controlled trial comparing dialectical behavioral therapy-
case management with a health promotion program. Nurse
Researcher 2017;66(6):432-41.
Sacks 2008 {published data only}
Sacks JY, McKendrick K, Hamilton Z. A randomized clinical trial
of a therapeutic community treatment for female inmates:
outcomes at 6 and 12 months aLer prison release. Journal of
Addictive Diseases 2012;31(3):258-69.
* Sacks JY, Sacks S, McKendrick K, Banks S, Schoeneberger M,
Hamilton Z, et al. Prison therapeutic community treatment
for female offenders: Profiles and preliminary findings for
mental health and other variables (crime, substance use and
HIV risk). Journal of Offender Rehabilitation 2008;46(3-4):233-61.
[1050-9674]
Zlotnick 2009 {published data only}
Zlotnick C, Johnson J, Najavits LM. Randomized controlled
pilot study of cognitive-behavioral therapy in a sample of
incarcerated women with substance use disorder and PTSD.
Behavior Therapy 2009;40(4):325-36. [0005-7894]
 
References to studies excluded from this review
AAAP 2017 {published data only}
AAAP 2017. 28th Annual Meeting and Symposium of the
American Academy of Addiction Psychiatry, AAAP 2017,
December 7-10; San Diego (CA). 2017.
Alemagno 2009 {published data only}
Alemagno SA, Stephens RC, Stephens P, Shaffer-King P,
White P. Brief motivational intervention to reduce HIV
Interventions for female drug-using offenders (Review)









Cochrane Database of Systematic Reviews
risk and to increase HIV testing among offenders under
community supervision. Journal of Correctional Health Care
2009;15(3):210-21.
Alemi 2010 {published data only}
Alemi F, Haack M, Nemes S, Harge A, Baghi H. Impact of online
counseling on drug use: a pilot study. Quality Management in
Healthcare 2010;19(1):62-9.
Allen 2017 {published data only}
Allen AA, Chen DT, Bonnie RJ, Ko TM, Suratt CE, Lee JD,
et al. Assessing informed consent in an opioid relapse
prevention study with adults under current or recent criminal
justice supervision. Journal of Substance Abuse Treatment
2017;81:66-72.
Andersen 2018 {published data only}
Andersen TS. Social support and one-year outcomes for women
participating in prison-based substance abuse treatment
programming. Criminal Justice Studies: A Critical Journal of
Crime, Law & Society 2018;31(1):80-94.
Anonymous 2004 {published data only}
Anonymous. Auricular acupuncture for drug use in prison
inmates (n=163). Acupunture in Medicine 2004;22(4):222-6.
Anonymous 2015 {published data only}
Anonymous. Strategy and action plan on dementia in older
people: A presentation [https://www.alz.co.uk/sites/default/
files/barbados2016/Cayatano-Plan-of-Action-Dementia.pdf].
Not reported. Washington DC: Organizacion Panamericana de la
Salud, 2015; Vol. not reported:no pagination.
Anonymous 2016a {published data only}
Anonymous. A test of core psychopathic traits as a moderator of
the efficacy of a brief motivational intervention for substance-
using offenders: Correction to Swogger et al. (2016). Erratum for
Journal of Consulting and Clinical Psychology 2016;84(3):210.
Anonymous 2018 {published data only (unpublished sought but
not used)}
Shamra NK, Singh A. Recreational activity and yoga: an avenue
to prevent criminal propensity among drug addicts. National
Conference on Recent Trends in Biomedical Sciences, RTBS-
P-11. Asian Journal of Pharmaceutical & Clinical Research, 2018.
Barrett 2015 {published data only}
Barrett EL, Indig D, Sunjic S, Sannibale C, Sindicich N,
Rosenfeld J, et al. Treating comorbid substance use and
traumatic stress among male prisoners: A pilot study of
the acceptability, feasibility, and preliminary efficacy of
Seeking Safety. International Journal of Forensic Mental Health
2015;14(1):45-55.
Bartlett 2015 {published data only}
Bartlett A, Jhanji E, White S, Harty MA, Scammell J, Allen S.
Interventions with women offenders: a systematic review
and meta-analysis of mental health gain. Journal of Forensic
Psychiatry and Psychology 2015;26(2):133.
Bawor 2014 {published data only}
Bawor M, Dennis BB, Anglin R, Steiner M, Thabane L, Samaan Z.
Sex differences in outcomes of methadone maintenance
treatment for opioid addiction: a systematic review protocol.
Systematic Reviews 2014;3:45.
Bazazi 2017 {published data only}
Bazazi AR, Wickersham JA, Wegman MP, Culbert GJ, Pillai V,
Shrestha R, et al. Design and implementation of a factorial
randomized controlled trial of methadone maintenance therapy
and an evidence-based behavioral intervention for incarcerated
people living with HIV and opioid dependence in Malaysia.
Contemporary Clinical Trials 2017;59:1-12.
Berman 2004 {published data only}
Berman AH, Lundberg U, Krook AL, Gyllenhammar C. Treating
drug using prison inmates with auricular acupuncture: a
randomized controlled trial. Journal of Substance Abuse
Treatment 2004;26(2):95-102.
Brahen 1976 {published data only}
Brahen L, Wiechert V, Capone T. Narcotic antagonist treatment
of the criminal justice patient-institutional vs outpatient-
including a 24 hour detox naltrexone induction regimen with
oral medication. NIDA Research Monograph 1976;9:93-8.
Brinkley 2018 {published data only}
Brinkley-Rubinstein L, McKenzie M, Macmadu A, Larney S,
Zaller N, Dauria E, et al. A randomized, open label trial of
methadone continuation versus forced withdrawal in a
combined US prison and jail: Findings at 12 months post-
release. Drug Alcohol Dependence 2018;184:57-63.
Brodie 2009 {published data only}
Brodie JD, Case BG, Figueroa E, Dewey SL, Robinson JA,
Wanderling JA, et al. Randomized, double-blind, placebo-
controlled trial of vigabatrin for the treatment of cocaine
dependence in Mexican parolees. American Journal of
Psychiatry 2009;166(11):1269-77.
Brovko 2016 {published data only}
Brovko JM. Increasing sexual offenders' motivation to engage
in mandated substance abuse treatment: a brief motivational
intervention. digitalrepository.unm.edu/psy_etds/13/ 2016.
Brown 2013 {published data only}
Brown R, Gassman M, Hetzel S, Berger L. Community-based
treatment for opioid dependent offenders: A pilot study.
American Journal of Addiction 2013;22(5):500-2.
Brown 2014 {published data only}
Brown R. Judging addicts: drug courts and coercion in the
justice system. Addiction 2014;109(5):855.
Burraston 2014 {published data only}
Burraston BO, Bahr SJ, Cherrington DJ. Reducing juvenile
delinquency with automated cell phone calls. International
Journal of Offender Therapy and Comparative Criminology
2014;58(5):522-36.
Interventions for female drug-using offenders (Review)









Cochrane Database of Systematic Reviews
Bustos 2016 {published data only}
Bustos Y, Harvey R, Jason LA. Important activities among
justice-involved individuals with substance use disorders in
posttreatment aLercare settings. Alcholism Treatment Quarterly
2016;34(4):415-24.
Calcaterra 2014 {published data only}
Calcaterra S, Mueller S, Beatty B, Binswanger IA. The role of
social support in drug and alcohol use among former prison
inmates. Substance Abuse 2014;35(2):214.
Calsyn 2005 {published data only}
Calsyn RJ, Yonker RD, Lemming MR, Morse GA, Klinkenberg WD.
Impact of assertive community treatment and client
characteristics on criminal justice outcomes in dual disorder
homeless individuals. Criminal Behaviour and Mental Health
2005;15(4):236-48.
Carrieri 2017 {published data only}
Carrieri P, Vilotitch A, Nordmann S, Lions C, Michel L, Mora M,
et al. Decrease in self-reported offences and incarceration rates
during methadone treatment: a comparison between patients
switching from buprenorphine to methadone and maintenance
treatment incident users (ANRS-Methaville trial). International
Journal of Drug Policy 2017;39:86-91.
Carroll 2006 {published data only}
Carroll KM, Easton CJ, Nich C, Hunkele KA, Neavins TM, Sinha R,
et al. The use of contingency management and motivational/
skills-building therapy to treat young adults with marijuana
dependence. Journal of Consulting and Clinical Psychology
2006;74(5):955-66.
Carroll 2012 {published data only}
Carroll KM, Nich C, Lapaglia DM, Peters EN, Easton CJ, Petry NM.
Combining cognitive behavioral therapy and contingency
management to enhance their effects in treating cannabis
dependence: less can be more, more or less. Addiction
2012;107(9):1650-9.
Chaple 2014 {published data only}
Chaple M, Sacks S, McKendrick K, Marsch LA, Belenko S,
Leukefeld C, et al. Feasibility of a computerized intervention
for offenders with substance use disorders: A research note.
Journal of Experimental Criminology 2014;10(1):105-27.
Chaple 2016 {published data only}
Chaple M, Sacks S, McKendrick K, Marsch LA, Belenko S,
Leukefeld C, et al. A comparative study of the therapeutic
education system for incarcerated substance-abusing offenders.
The Prison Journal 2016;96(3):485-508.
Cheesman 2016 {published data only}
Cheesman FL, Graves SE, Holt K, Kunkel TL, Lee CG, White MT.
Drug court effectiveness and efficiency: findings for virginia.
Alcholism Treatment Quarterly 2016;34(2):143-69.
Cihlar 2014 {published data only}
Cihlar BE. The trauma recovery and empowerment model: a
trauma-informed treatment program for female offenders in
the community. Dissertation Abstracts International Section
B: The Sciences and Engineering. Vol. 75, 2014:No Pagination
Specified-.
Clair 2013 {published data only}
Clair M, Stein LA, Soenksen S, Martin RA, Lebeau R,
Golembeske C. Ethnicity as a moderator of motivational
interviewing for incarcerated adolescents aLer release. Journal
of Substance Abuse Treatment 2013;45(4):370-5.
Clair-Michaud 2016 {published data only}
Clair-Michaud M, Martin RA, Stein LA, Bassett S, Lebeau R,
Golembeske C. The impact of motivational interviewing on
delinquent behaviors in incarcerated adolescents. Journal of
Substance Abuse Treatment 2016;65:13-9.
Clark 2002 {published data only}
Clark HW, MacNeill Horton A, Dennis M, Babor TF. Moving from
research to practice just in time: the treatment of cannabis use
disorders comes of age. Addiction 2002;97(Suppl 1):1-3.
Clayton 2013 {published data only}
Clayton A, O'Connell MJ, Bellamy C, Benedict P, Rowe M. The
Citizenship Project Part II: Impact of a citizenship intervention
on clinical and community outcomes for persons with mental
illness and criminal justice involvement. American Journal of
Community Psychology 2013;51(1-2):114-22.
Compton 2016 {published data only}
Compton MT, Kelley ME, Pope A, Smith K, Broussard B, Reed TA,
et al. Opening doors to recovery: recidivism and recovery
among persons with serious mental illnesses and repeated
hospitalizations. Psychiatric Services 2016;67(2):169-75.
Cowell 2018 {published data only}
Cowell AJ, Barnosky A, Lattimore PK, Cartwright JK,
DeMichele M. Economic evaluation of the HOPE demonstration
field experiment. Criminology & Public Policy 2018;17(4):875-99.
CPDD 2014 {published data only}
College on Problems of Drug Dependence. Abstracts from
the 2014 Annual Meeting of the College on Problems of Drug
Dependence Conference, 2014 June 14-19, San Juan. cpdd.org/
Pages/Meetings/CPDD14AbstractBook.pdf 2014.
Cullen 2012 {published data only}
Cullen AE, Clarke AY, Kuipers E, Hodgins S, Dean K, Fahy T. A
multisite randomized trial of a cognitive skills program for male
mentally disordered offenders: violence and antisocial behavior
outcomes. Journal of Consulting and Clinical Psychology
2012;80(6):1114-20.
Curtis 2015 {published data only}
Curtis SV, Wodarski JS. The East Tennessee assertive adolescent
family treatment program: a three-year evaluation. Social Work
in Public Health 2015;30(3):225-35.
Czuchry 2000 {published data only}
Czuchry M, Dansereau DF. Drug abuse treatment in criminal
justice settings: enhancing community engagement and
helpfulness. American Journal of Drug and Alcohol Abuse
2000;26(4):537-52.
Interventions for female drug-using offenders (Review)









Cochrane Database of Systematic Reviews
Czuchry 2003 {published data only}
Czuchry M, Dansereau DF. Cognitive skills training: Impact on
drug abuse counseling and readiness for treatment. American
Journal of Drug and Alcohol Abuse 2003;29(1):1-18.
D'Amico 2013 {published data only}
D'Amico EJ, Hunter SB, Miles JN, Ewing BA, Osilla KC.
A randomized controlled trial of a group motivational
interviewing intervention for adolescents with a first time
alcohol or drug offence. Journal of Substance Abuse Treatment
2013;45(5):400-8.
Dakof 2010 {published data only}
Dakof GA, Cohen JB, Henderson CE, Duarte E, Boustani M,
Blackburn A, et al. A randomized pilot study of the Engaging
Moms Program for family drug court. Journal of Substance
Abuse Treatment 2010;38(3):263-74.
Dakof 2015 {published data only}
Dakof GA, Henderson CE, Rowe CL, Boustani M, Greenbaum PE,
Wang W, et al. A randomized clinical trial of family therapy
in juvenile drug court. Journal of Family Psychology
2015;29(2):232-41.
Daughters 2018 {published data only}
Daughters SB, Magidson JF, Anand D, Seitz-Brown CJ, Chen Y,
Baker S. The effect of a behavioral activation treatment for
substance use on post-treatment abstinence: a randomized
controlled trial. Addiction 2018;113(3):535-44.
Davis 2015 {published data only}
Davis M, Sheidow AJ, McCart MR. Reducing recidivism and
symptoms in emerging adults with serious mental health
conditions and justice system involvement. Journal of
Behaviour Health Services and Research 2015;42(2):172-90.
Day 2006 {published data only}
Day E. Rapid access to methadone improved entry and
outcomes in heroin addicts awaiting methadone treatment.
Evidence Based Medicine 2006;11(4):112.
Demaret 2015 {published data only}
Demaret I, Quertemont E, Litran G, Magoga C, Deblire C,
Dubois N, et al. Efficacy of heroin-assisted treatment in Belgium:
a randomised controlled trial. European Addiction Research
2015;21(4):179-87.
Dickson 2017 {published data only}
Dickson MF, Staton-Tindall M, Smith KE, Leukefeld C, Webster J,
Oser CB. A Facebook follow-up strategy for rural drug-using
women. Journal of Rural Health 2017;33(3):250-6.
Di Paola 2014 {published data only}
Di Paola A, Lincoln T, Skiest DJ, Desabrais M, Altice FL,
Springer SA. Design and methods of a double blind randomized
placebo-controlled trial of extended-release naltrexone for HIV-
infected, opioid dependent prisoners and jail detainees who
are transitioning to the community. Contemporary Clinical Trials
2014;39(2):256-68.
Dolan 2003 {published data only}
Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W,
Wodak AD. A randomised controlled trial of methadone
maintenance treatment versus wait list control in an Australian
prison system. Drug and Alcohol Dependence 2003;72(1):59-65.
Dolan 2005 {published data only}
Dolan KA, Shearer J, White B, Zhou J, Kaldor J, Wodak AD. Four-
year follow-up of imprisoned male heroin users and methadone
treatment: mortality, re-incarceration and hepatitis C infection.
Addiction 2005;100(6):820-8.
Dole 1969 {published data only}
Dole VP, Robinson JW, Orraca J, Towns E, Searcy P, Caine E.
Methadone treatment of randomly selected criminal addicts.
The New England Journal of Medicine 1969;280(25):1372-5.
Doyle 2015 {published data only}
Doyle M, Butler T, Guthrie J, ShakeshaL A. Prison based
treatment for alcohol and related other drug use among
indigenous and non-indigenous men. Drug and Alcohol Review
2015;34:24.
Doyle 2016 {published data only}
Doyle M, Butler T, Guthrie J, ShakeshaL A. Prison based
treatment for alcohol and related other drug use among
indigenous and non indigenous men. Drug and Alcohol Review
2016;35:35.
Dunlop 2017 {published data only}
Dunlop AJ, Brown AL, Oldmeadow C, Harris A, Gill A, Sadler C,
et al. Effectiveness and cost-effectiveness of unsupervised
buprenorphine-naloxone for the treatment of heroin
dependence in a randomized wait list controlled trial. Drug and
Alcohol Dependence 2017;174:181-91.
Easton 2007 {published data only}
Easton CJ, Babuscio T, Carroll KM. Treatment retention and
outcome among cocaine-dependent patients with and without
active criminal justice involvement. Journal of American
Academy of Psychiatry and the Law 2007;35(1):83-91.
Easton 2018 {published data only}
Easton CJ, Crane CA, Mandel D. A randomized controlled
trial assessing the efficacy of cognitive behavioral therapy
for substance-dependent domestic violence offenders: an
integrated substance abuse-domestic violence treatment
approach (SADV). Journal of Marital and Family Therapy
2018;44(3):483-98.
Egg 2000 {published data only}
Egg R, Pearson FS, Cleland CM, Lipton DS. Evaluations
of correctional treatment programs in Germany: a
review and meta-analysis. Substance Use and Misuse
2000;35(12-14):1967-2009.
Ellison 2018 {published data only}
Elison-Davies S, Davies G, Ward J, Dugdale S, Weston S, Jones A,
et al. Protocol for a randomized controlled trial of the Breaking
Free Online Health and Justice program for substance misuse in
prison settings. Health Justice 2018;6(1):20.
Interventions for female drug-using offenders (Review)









Cochrane Database of Systematic Reviews
Europad 2016 {published data only}
Europad 2016. Heroin Addiction and Related Clinical Problems.
12th European Opiate Addiction Treatment Association
Conference, EUROPAD 2016 May 27-29; Leiden. medialibrary-
diretteweb-it.s3.amazonaws.com/eventi/124/program/
Leiden2016-Book_final.pdf 2016.
Friedmann 2015 {published data only}
Friedmann PD, Lee JD, Nunes EV, Kinlock TW, O'Brien CP.
Patient selection for extended-release naltrexone among
criminal justice-involved persons with opioid use disorder. Drug
and Alcohol Dependence 2015;156(11):e74-5.
Friedmann 2017 {published data only}
Friedmann PD, Wilson D, Hoskinson R, Poshkus M, Clarke JG.
Initiation of extended release naltrexone (xr-ntx) for opioid
use disorder prior to release from prison. Journal of Substance
Abuse Treatment 2018;85:45-8.
Ginsberg 2012 {published data only}
Ginsberg Y, Hirvikoski T, Grann M, Lindefors N. Long-term
functional outcome in adult prison inmates with ADHD
receiving OROS-methylphenidate. European Archive of
Psychiatry and Clinical Neuroscience 2012;262(8):705-24.
Ginsberg 2015 {published data only}
Ginsberg Y. Pharmacological treatment of offenders with ADHD.
ADHD Attention Deficit and Hyperactivity Disorders 2015;1:S4.
Ginsberg 2015a {published data only}
Ginsberg Y, Langstrom N, Larsson H, Lindefors N. Long-term
treatment outcome in adult male prisoners with attention-
deficit/hyperactivity disorder: three-year naturalistic follow-
up of a 52-week methylphenidate trial. Journal of Clinical
Psychopharmacology 2015;35(5):535-43.
Gisev 2015 {published data only}
Gisev N, Larney S, Gibson A, Kimber J, Burns L, Butler T, et al.
The effect of treatment and retention with opioid substitution
therapy in reducing crime among opioid-dependent people.
Pharmacoepidemiology and Drug Safety 2015;24:28-9.
Gisev 2015a {published data only}
Gisev N, Shanahan M, Weatherburn DJ, Mattick RP, Larney S,
Burns L, et al. A cost-effectiveness analysis of opioid
substitution therapy upon release in reducing mortality
among prisoners with a history of opioid dependence.
Pharmacoepidemiology and Drug Safety 2015;24:481-2.
Gisev 2015b {published data only}
Gisev N, Shanahan M, Weatherburn D, Mattick RP, Larney S,
Burns L, et al. A Cost effectiveness analysis of opioid
substitution therapy upon release from prison. Drug and Alcohol
Review 2015;34:29.
Goddard-Eckrich 2018 {published data only}
Goddard-Eckrich DA. An evaluation of a group wellness
intervention delivered to drug-involved women under criminal
justice supervision in New York city: predictors of high program
ratings and positive health indicators at twelve-month follow-
up. Dissertation Abstracts International Section A: Humanities
and Social Sciences 2018;78(12-A(E)):No Pagination Specified-.
Goorden 2015 {published data only}
Goorden M, Van Der Schee E, Hendriks VM, Hakkaart-van
Roijen L. Cost-effectiveness of multidimensional family therapy
for adolescents with a cannabis use disorder. Journal of Mental
Health Policy and Economics 2015;1:S17.
Gordon 2014 {published data only}
Gordon MS, Kinlock TW, Schwartz RP, Fitzgerald TT, O'Grady KE,
Vocci FJ. A randomized controlled trial of prison-initiated
buprenorphine: prison outcomes and community treatment
entry. Drug and Alcohol Dependence 2014;142:33-40.
Gordon 2015 {published data only}
Gordon MS, Kinlock TW, Vocci FJ, Fitzgerald TT, Memisoglu A,
Silverman B. A phase 4, pilot, open-label study of VIVITROL
(extended-release naltrexone XR-NTX) for prisoners. Journal of
Substance Abuse Treatment 2015;59:52-8.
Gordon 2018 {published data only}
Gordon MS, Blue TR, Couvillion K, Schwartz RP, O'Grady KE,
Fitzgerald, TT, et al. Initiating buprenorphine treatment prior to
versus aLer release from prison: arrest outcomes. Drug Alcohol
Dependence 2018;188:232-8.
Gottfredson 2005 {published data only}
Gottfredson DC, Kearley BW, Najaka SS, Rocha CM. The
Baltimore City Drug Treatment Court: 3-year self-report
outcome study. Evaluation Review 2005;29(1):42-64.
Gould 2014 {published data only}
Gould RL, Coulson MC, Patel N, Highton-Williamson E,
Howard RJ. Interventions for reducing benzodiazepine use in
older people: Meta-analysis of randomised controlled trials. The
British Journal of Psychiatry 2014;204(2):98-107.
Haig 2003 {published data only}
Haig T. Randomized controlled trial proves effectiveness of
methadone maintenance treatment in prison. Canadian HIV/
AIDS Policy and Law Review/Canadian HIV/AIDS Legal Network
2003;8(3):48.
Hanlon 1975 {published data only}
Hanlon TE, McCabe OL, Savage C, Kurland AA. A controlled
comparison of cyclazocine and naloxone treatment of the
paroled narcotic addict. International Pharmacopsychiatry
1975;10(4):240-50.
Hanlon 1977 {published data only}
Hanlon TE, McCabe OL, Savage C, Kurland AA. Narcotic
antagonist treatment of addict parolees. The failure of an
effective approach. Comprehensive Psychiatry 1977;18(3):211-9.
Harada 2012 {published data only}
Harada T. The randomized controlled trial of the prison-based
Japanese Matrix Program (J-MAT) for methamphetamine
abusers. Japanese Journal of Alcohol Studies & Drug Dependence
2012;47(6):298-307.
Interventions for female drug-using offenders (Review)









Cochrane Database of Systematic Reviews
Heimer 2006 {published data only}
Heimer R, Catania H, Newman RG, Zambrano J, Brunet A,
Ortiz AM. Methadone maintenance in prison: evaluation of a
pilot program in Puerto Rico. Drug and Alcohol Dependence
2006;83(2):122-9.
Henderson 2010 {published data only}
Henderson CE, Dakof GA, Greenbaum PE, Liddle HA.
Effectiveness of multidimensional family therapy with higher
severity substance-abusing adolescents: Report from two
randomized controlled trials. Journal of Consulting and Clinical
Psychology 2010;78(6):885-97.
Henderson 2016 {published data only}
Henderson CE, Wevodau AL, Henderson SE, Colbourn SL,
Gharagozloo L, North LW, et al. An independent replication
of the adolescent-community reinforcement approach
with justice-involved youth. American Journal of Addiction
2016;25(3):233-40.
Hendriks 2011 {published data only}
Hendriks V, van der Schee E, Blanken P. Treatment of
adolescents with a cannabis use disorder: Main findings of a
randomized controlled trial comparing multidimensional family
therapy and cognitive behavioral therapy in The Netherlands.
Drug and Alcohol Dependence 2011;119(1-2):64-71.
Henggeler 2006 {published data only}
Henggeler SW, Halliday-Boykins CA, Cunningham PB, Randall J,
Shapiro SB, Chapman JE. Juvenile drug court: Enhancing
outcomes by integrating evidence-based treatments. Journal of
Consulting and Clinical Psychology 2006;74(1):42-54.
Herrman 2016 {published data only}
Herrman H, Humphreys C, Halperin S, Monson K, Harvey C,
Mihalopoulos C, et al. A controlled trial of implementing a
complex mental health intervention for carers of vulnerable
young people living in out-of-home care: the ripple project. BMC
Psychiatry 2016;16(1):436.
Himelstein 2014 {published data only}
Himelstein S, Saul S, Garcia-Romeu A, Pinedo D. Mindfulness
training as an intervention for substance user incarcerated
adolescents: A pilot grounded theory study. Substance Use and
Misuse 2014;49(5):560-70.
Himelstein 2015 {published data only}
Himelstein S, Saul S, Garcia-Romeu A. Does mindfulness
meditation increase effectiveness of substance abuse treatment
with incarcerated youth? A pilot randomized controlled trial.
Mindfulness 2015;6(6):1472-80.
Hoffman 1996 {published data only}
Hoffman JA, Caudill BD, Koman Iii JJ, Luckey JW, Flynn PM,
Mayo DW. Psychosocial treatments for cocaine abuse: 12-month
treatment outcomes. Journal of Substance Abuse Treatment
1996;13(1):3-11.
Holloway 2006 {published data only}
Holloway KR, Bennett TH, Farrington DP. The effectiveness
of drug treatment programs in reducing criminal behavior: A
meta-analysis. Psicothema 2006;18(3):620-9.
Horn 2018 {published data only}
Horn BP, Li X, Mamun S, McCrady B, French MT. The economic
costs of jail-based methadone maintenance treatment.
American Journal of Drug Alcohol Abuse 2018;44(6):611-8.
Hser 2013 {published data only}
Hser YI, Fu L, Wu F, Du J, Zhao M. Pilot trial of a recovery
management intervention for heroin addicts released from
compulsory rehabilitation in China. Journal of Substance Abuse
Treatment 2013;44(1):78-83.
Jalali 2017 {published data only}
Jalali F, Hashemi SF, Hasani A, Fakoor SN. The effectiveness of
cognitive group therapy based on schema-focused approach on
self-esteem and emotion regulation in drug addicted prisoners
under the methadone maintenance treatment (MMT). Journal of
Groups in Addiction and Recovery 2017;12(4):284-95.
Jason 2007 {published data only}
Jason LA, Olson BD, Ferrari JR, Majer JM, Alvarez J, Stout J.
An examination of main and interactive effects of substance
abuse recovery housing on multiple indicators of adjustment.
Addiction 2007;102(7):1114-21.
Jason 2015 {published data only}
Jason LA, Olson BD, Harvey R. Evaluating Alternative
ALercare Models for Ex-Offenders. Journal of Drug Issues
2015;45(1):53-68.
Jason 2016 {published data only}
Jason LA, Salina D, Ram D. Oxford recovery housing: Length of
stay correlated with improved outcomes for women previously
involved with the criminal justice system. Substance Abuse
2016;37(1):248-54.
Jerrell 1995 {published data only}
Jerrell JM, Ridgely MS. Evaluating changes in symptoms
and functioning of dually diagnosed clients in specialized
treatment. Psychiatric Services 1995;46(3):233-8.
Joe 1997 {published data only}
Joe GW, Dansereau DF, Pitre U, Simpson DD. Effectiveness of
node-link mapping enhanced counseling for opiate addicts:
a 12-month posttreatment follow-up. Journal of Nervous and
Mental Disease 1997;185(5):306-13.
Jouhanneau 2018 {published data only}
Jouhanneau M, Meroueh F. Inventory of opiates addiction
treatment (Oat) in prisons in France in 2017. Heroin Addiction
and Related Clinical Problems 2018;20:67.
Kearley 2018 {published data only}
Kearley BW. Long term effects of drug court participation:
evidence from a 15-year follow-up of a randomized controlled
trial. Dissertation Abstractions International Section A:
Interventions for female drug-using offenders (Review)









Cochrane Database of Systematic Reviews
Humanities and Social Sciences 2018;78(12-A(E)):No Pagination
Specified-.
Kelly 2016 {published data only}
Kelly CE, Welsh WN. Examining treatment climate across prison-
based substance abuse treatment groups. Substance Use and
Misuse 2016;51(7):902-11.
Khawcharoenporn 2018 {published data only}
Khawcharoenporn T, Cole J, Claus J, Bell T, Lewis A, Zawitz C,
et al. A randomized controlled study of intervention to improve
continuity care engagement among HIV-infected persons
aLer release from jails. AIDS Care 2018;31(7):777-84. [DOI:
10.1080/09540121.2018.1533236]
Kinlock 2007 {published data only}
Kinlock TW, Gordon MS, Schwartz RP, O'Grady K, Fitzgerald TT,
Wilson M. A randomized clinical trial of methadone
maintenance for prisoners: results at 1-month post-release.
Drug and Alcohol Dependence 2007;91(2-3):220-7.
Kinlock 2009 {published data only}
Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT, O'Grady KE.
A randomized clinical trial of methadone maintenance
for prisoners: results at 12 months postrelease. Journal of
Substance Abuse Treatment 2009;37(3):277-85.
Kirkpatrick 2018 {published data only}
Kirkpatrick T, Lennox C, Taylor R, Anderson R, Maguire M,
Haddad M, et al. Evaluation of a complex intervention (Engager)
for prisoners with common mental health problems, near to
and aLer release: study protocol for a randomised controlled
trial. BMJ Open 2018;8(2):e017931.
Knight 2016 {published data only}
Knight DK, Belenko S, Wiley T, Robertson AA, Arrigona N,
Dennis M, et al. Juvenile Justice-Translational Research on
Interventions for Adolescents in the Legal System (JJ-TRIALS): a
cluster randomized trial targeting system-wide improvement in
substance use services. Implementation Science 2016;11:57.
Knudsen 2014 {published data only}
Knudsen HK, Staton-Tindall M, Oser CB, Havens JR,
Leukefeld CG. Reducing risky relationships: a multisite
randomized trial of a prison-based intervention for reducing HIV
sexual risk behaviors among women with a history of drug use.
AIDS Care 2014;26(9):1071-9.
Knudsen 2016 {published data only}
Knudsen KJ, Wingenfeld S. A specialized treatment court for
veterans with trauma exposure: Implications for the field.
Community Mental Health Journal 2016;52(2):127-35.
Kongsakon 2005 {published data only}
Kongsakon R, Papadopoulos KI, Saguansiritham R. Mirtazapine
in amphetamine detoxification: a placebo-controlled
pilot study. International Clinical Psychopharmcology
2005;20(5):253-6.
Konstenius 2014 {published data only}
Konstenius M, Jayaram-Lindstrom N, Guterstam J, Beck O,
Philips B, Franck J. Methylphenidate for attention deficit
hyperactivity disorder and drug relapse in criminal offenders
with substance dependence: a 24-week randomized placebo-
controlled trial. Addiction 2014;109(3):440-9.
Kopak 2015 {published data only}
Kopak AM, Dean LV, Proctor SL, Miller L, Hoffmann NG.
Effectiveness of the rehabilitation for addicted prisoners trust
(RAPt) programme. Journal of Substance Use 2015;20(4):254-61.
Korchmaros 2018 {published data only}
Korchmaros JD. Examining the effectiveness of the Seven
Challenges: a comprehensive counseling program with
adolescents. Journal of Social Work Practice in the Addictions
2018;18(4):411-31.
Korchmaros 2018b {published data only}
Korchmaros JD. The Seven Challenges: comprehensive
counseling program: effectiveness for adults with substance use
problems. Journal of Drug Issues 2018;48(4):590-607.
Krebs 2017 {published data only}
Krebs E, Huang DY, Evans E, Urada D, Hser YI, Nosyk B. The effect
of treatment for opioid use disorders on the costs of crime. Drug
and Alcohol Dependence 2017;171:e110-1.
Kubiak 2016 {published data only}
Kubiak S, Fedock G, Kim WJ, Bybee D. Long-term outcomes of a
RCT intervention study for women with violent crimes. Journal
of the Society for Social Work and Research 2016;7(4):661-79.
Kurland 1975 {published data only}
Kurland AA, McCabe L, Hanlon TE. Contingent naloxone (N
allylnoroxymorphone) treatment of the paroled narcotic addict.
International Pharmacopsychiatry 1975;10(3):157-68.
Kurniasanti 2014 {published data only}
Kurniasanti K, Alia D, Zyzlavsky S. Neurocognitive disorder on
prisoners using cannabis in Cipinang Jakarta prison. Alcohol
and Alcoholism 2014;49(Suppl 1):1.
Lee 2011 {published data only}
Lee KH, Bowen S, An-Fu B. Psychosocial outcomes of
mindfulness-based relapse prevention in incarcerated
substance abusers in Taiwan: a preliminary study. Journal of
Substance Abuse 2011;16(6):476-83.
Lee 2013 {published data only}
Lee TG, Kerns SE. Family integrated transitions: a promising
program for reducing recidivism in a cost-effective manner. In:
Thomas CR, Pope K editor(s). The Origins of Antisocial Behavior:
A Developmental Perspective. New York, NY: Oxford University
Press, 2013:219-33.
Lee 2014a {published data only}
Lee JD, Friedmann P, Wilson D, Nunes E, Kinlock T, O'Brien C.
Or14-4 Effectiveness of extended-release naltrexone (xr-ntx)
among criminal justice-involved persons with opioid use
Interventions for female drug-using offenders (Review)









Cochrane Database of Systematic Reviews
disorders. Alcohol and Alcoholism (Oxford, Oxfordshire) 2014;49
Suppl 1:i51-2.
Lee 2014b {published data only}
Lee Hongjik, Shin Sun-Kyung, Park So-Youn. Effects of a
therapeutic community on Korean substance abusers in prison.
Journal of Social Services Research 2014;40(4):481-90.
Lee 2014c {published data only}
Lee JD, Friedmann P, Wilson D, Nunes E, Kinlock T, O'Brien C.
Effectiveness of extended release naltrexone (XR-NTX) among
criminal justice-involved persons with opioid use disorders.
Alcohol and Alcoholism 2014;49 Suppl 1:i51-i52.
Lee 2015a {published data only}
Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Gordon MS,
O’Brien CP. Extended-release naltrexone for opioid relapse
prevention among opioid-dependent, criminal justice-involved
adults. Drug and Alcohol Dependence 2015;156:e125.
Lee 2015b {published data only}
Lee JD, McDonald R, Grossman E, McNeely J, Laska E,
Rotrosen J, et al. Opioid treatment at release from jail
using extended-release naltrexone: a pilot proof-of-concept
randomized effectiveness trial. Addiction 2015;110(6):1008-14.
Lee 2015c {published data only}
Lee JD, Friedmann PD, Boney TY, Hoskinson RA, McDonald R,
Gordon M, et al. Extended-release naltrexone to prevent relapse
among opioid dependent, criminal justice system involved
adults: Rationale and design of a randomized controlled
effectiveness trial. Contemporary Clinical Trials 2015;41:110-7.
Lee 2016a {published data only}
Lee J, Gordon M, Friedmann P, Nunes E, O'Brien C. Extended-
release naltrexone to prevent opioid relapse among adults
with criminal justice system involvement. American Journal of
Addictions 2016;25(4):345.
Lee 2016b {published data only}
Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY,
Hoskinson RA Jr, et al. Extended-release naltrexone to prevent
opioid relapse in criminal justice offenders. New England
Journal of Medicine 2016;374(13):1232-42.
Lefevre 2018 {published data only}
Lefevre T, Denis C, Marchand C, Vidal C, Gagnayre R, Chariot P.
Multiple brief interventions in police custody: the MuBIC
randomized controlled study for primary prevention in police
custody. Protocol and preliminary results of a feasibility study
in the Paris metropolitan area, France. Journal of Forensic and
Legal Medicine 2018;57:101-8. [DOI: 10.1016/j.jflm.2016.05.019]
Lehman 2015 {published data only}
Lehman WE, Rowan GA, Greener JM, Joe GW, Yang Y, Knight K.
Evaluation of WaySafe: a disease-risk reduction curriculum
for substance-abusing offenders. Journal of Substance Abuse
Treatment 2015;58:25-32.
Le Page 2018 {published data only}
LePage JP, Lewis AA, Crawford AM, Washington EL, Parish-
Johnson JA, Cipher DJ, et al. Vocational rehabilitation for
veterans with felony histories and mental illness: 12-month
outcomes. Psychological Services 2018;15(1):56-64. [DOI:
10.1037/ser0000114]
Lerch 2017 {published data only}
Lerch J, Walters ST, Tang L, Taxman FS. Effectiveness of a
computerized motivational intervention on treatment initiation
and substance use: results from a randomized trial. Journal of
Substance Abuse Treatment 2017;80:59-66.
Liddle 2011 {published data only}
Liddle HA, Dakof GA, Henderson C, Rowe C. Implementation
outcomes of Multidimensional Family Therapy-Detention to
Community: a reintegration program for drug-using juvenile
detainees. International Journal of Offender Therapy and
Comparative Criminology 2011;55(4):587-604.
Lin 2018 {published data only}
Lin C, Lan CW, Li L, Rou K. Service providers adherence to
methadone maintenance treatment protocol in China. The
International Journal on Drug Policy 2018;56:1.
Lintzeris 2006 {published data only}
Lintzeris N, Strang J, Metrebian N, Byford S, Hallam C, Lee S, et
al. Methodology for the randomised injecting opioid treatment
trial (RIOTT): Evaluating injectable methadone and injectable
heroin treatment versus optimised oral methadone treatment
in the UK. Harm Reduction Manual 2006;3:28.
Little 1993 {published data only}
Little GL, Robinson KD, Burnette KD. Cognitive behavioral
treatment of felony drug offenders: a five-year recidivism
report. Psychological Reports 1993;73(3 Pt 2):1089-90.
Lo 2012 {published data only}
Lo Sasso AT, Byro E, Jason LA, Ferrari JR, Olson B. Benefits and
costs associated with mutual-help community-based recovery
homes: The Oxford House model. Evaluation and Program
Planning 2012;35(1):47-53.
Lobmann 2007 {published data only}
Lobmann R. Diamorphine substitution therapy and criminal
activity [Diamorphingestutzte behandlung und kriminalitat].
Sucht 2007;53(5):288-95.
Lopez 2019 {published data only}
López-Castro T, Smith KZ, Nicholson RA, Armas A, Hien DA.
Does a history of violent offending impact treatment response
for comorbid PTSD and substance use disorders? A secondary
analysis of a randomized controlled trial. Journal of Substance
Abuse Treatment 2019;97:47-58.
Luciano 2014 {published data only}
Luciano A, Belstock J, Malmberg P, McHugo GJ, Drake RE, Xie H,
et al. Predictors of incarceration among Urban adults with co-
occurring severe mental illness and a substance use disorder.
Psychiatric Services 2014;65(11):1325-31.
Interventions for female drug-using offenders (Review)









Cochrane Database of Systematic Reviews
Magura 2009 {published data only}
Magura S, Lee JD, Hershberger J, Joseph H, Marsch L,
Shropshire C, et al. Buprenorphine and methadone
maintenance in jail and post-release: A randomized clinical trial.
Drug and Alcohol Dependence 2009;99(1-3):222-30.
Malouf 2017 {published data only}
Malouf ET, Youman K, Stuewig J, Witt EA, Tangney JP. A pilot
RCT of a values-based mindfulness group intervention with jail
inmates: Evidence for reduction in post-release risk behavior.
Mindfulness 2017;8(3):603-14.
March 2006 {published data only}
March JC, Oviedo-Joekes E, Perea-Milla E, Carrasco F, team
Pepsa. Controlled trial of prescribed heroin in the treatment
of opioid addiction. Journal of Substance Abuse Treatment
2006;31(2):203-11.
Marinelli-Casey 2008 {published data only}
Marinelli-Casey P, Gonzales R, Hillhouse M, Ang A, Zweben J,
Cohen J, et al. Drug court treatment for methamphetamine
dependence: Treatment response and posttreatment outcomes.
Journal of Substance Abuse Treatment 2008;34(2):242-8.
Marlowe 2008 {published data only}
Marlowe DB, Festinger DS, Dugosh KL, Arabia PL, Kirby KC.
An effectiveness trial of contingency management in a felony
preadjudication drug court. Journal of Applied Behaviour
Analysis 2008;41(4):565-77.
Marlowe 2009 {published data only}
Marlowe DB, Festinger DS, Arabia PL, Dugosh KL, Benasutti KM,
CroL JR. Adaptive interventions may optimize outcomes
in drug courts: a pilot study. Current Psychiatric Reports
2009;11(5):370-6.
Martin 2010 {published data only}
Martin M, Vanichseni S, Suntharasamai P, Mock PA,
van Griensven F, Pitisuttithum P, et al. Drug use and the risk of
HIV infection amongst injection drug users participating in an
HIV vaccine trial in Bangkok, 1999-2003. International Journal of
Drug Policy 2010;21(4):296-301.
Martin 2011 {published data only}
Martin M, Vanichseni S, Suntharasamai P, Sangkum U,
Chuachoowong R, Mock PA, et al. Enrollment characteristics
and risk behaviors of injection drug users participating in the
Bangkok Tenofovir study, Thailand. PLoSONE 2011;6(9):e25127.
Martin 2014 {published data only}
Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Mock PA,
Leethochawalit M, et al. Risk behaviors and risk factors for HIV
infection among participants in the Bangkok Tenofovir Study,
an HIV pre-exposure prophylaxis trial among people who inject
drugs. PLoSONE 2014;9(3):e92809.
Martin 2015 {published data only}
Martin M, Vanichseni S, Suntharasamai P, Sangkum U,
Mock PA, Leethochawalit M, et al. The impact of adherence
to preexposure prophylaxis on the risk of HIV infection
among people who inject drugs. Topics of Antiviral Medicine
2015;29(7):819-24.
Martin 2017 {published data only}
Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Mock PA,
Chaipung B, et al. Factors associated with the uptake of and
adherence to HIV pre-exposure prophylaxis in people who have
injected drugs: an observational, open-label extension of the
Bangkok Tenofovir Study. Lancet HIV 2017;4(2):e59-66.
Mazerolle 2000 {published data only}
Mazerolle LG, Price JF, Roehl J. A randomized field trial in
Oakland, California. Evaluation Review 2000;24(2):212-41.
McAuliffe 1990 {published data only}
McAuliffe WE. A randomized controlled trial of recovery training
and self-help for opioid addicts in New England and Hong Kong.
Journal of Psychoactive Drugs 1990;22(2):197-209.
McCarter 2016 {published data only}
McCarter SA. Holistic representation: a randomized pilot study
of wraparound services for first-time juvenile offenders to
improve functioning, decrease motions for review, and lower
recidivism. Family Court Review 2016;54(2):250-60.
McCollister 2014 {published data only}
McCollister KE, Scott CK, Dennis ML, Freitas DM, French MT,
Funk RR. Economic costs of a postrelease intervention for
incarcerated female substance abusers: recovery management
checkups for women offenders (RMC-WO). Journal of Offender
Rehabilitation 2014;53(7):543-61.
McCollister 2015 {published data only}
McCollister KE, French MT, Sheidow AJ, Henggeler SW, Halliday-
Boykins CA. Estimating the differential costs of criminal
activity for juvenile drug court participants: Challenges and
recommendations: Erratum. The Journal of Behaviour Health
Services and Research 2015;42(4):554.
McCollister 2016 {published data only}
McCollister K, Yang X, McKay JR. Cost-effectiveness analysis of
a continuing care intervention for cocaine-dependent adults.
Drug and Alcohol Dependence 2016;158:38-44.
McCollister 2017 {published data only}
McCollister K, Yang X, Sayed B, French MT, Leff JA,
Schackman BR. Monetary conversion factors for economic
evaluations of substance use disorders. Journal of Substance
Abuse Treatment 2017;81:25-34.
McKenzie 2012 {published data only}
McKenzie M, Zaller N, Dickman SL, Green TC, Parihk A,
Friedmann PD, et al. A randomized trial of methadone
initiation prior to release from incarceration. Substance Abuse
2012;33(1):19-29.
Meade 2018 {published data only}
Meade AM, Bird SM, Strang J, Pepple T, Nichols LL,
Mascarenhas M, et al. Methods for delivering the UK's multi-
centre prison-based naloxone-on-release pilot randomised trial
Interventions for female drug-using offenders (Review)









Cochrane Database of Systematic Reviews
(N-ALIVE): Europe's largest prison-based randomised controlled
trial. Drug and Alcohol Review 2018;37(4):487-98.
Metrebian 2015 {published data only}
Metrebian N, Groshkova T, Hellier J, Charles V, Martin A,
Forzisi L, et al. Drug use, health and social outcomes of
hard-to-treat heroin addicts receiving supervised injectable
opiate treatment: secondary outcomes from the Randomized
Injectable Opioid Treatment Trial (RIOTT). Addiction
2015;110(3):479-90.
Mitchell 2013 {published data only}
Mitchell SG, Gryczynski J, Schwartz RP, O'Grady KE, Olsen YK,
Jaffe JH. A randomized trial of intensive outpatient (IOP) vs.
standard outpatient (OP) buprenorphine treatment for African
Americans. Drug and Alcohol Dependence 2013;128(3):222-9.
Mitchell 2014 {published data only}
Mitchell SG, Gryczynski J, Kelly SM, O'Grady KE, Jaffe JH,
Olsen YK, et al. Treatment outcomes of African American
buprenorphine patients by parole and probation status. Journal
of Drug Issues 2014;44(1):69-82.
Murphy 2017 {published data only}
Murphy SM, Polsky D, Lee JD, Friedmann PD, Kinlock TW,
Nunes EV, et al. Cost-effectiveness of extended release
naltrexone to prevent relapse among criminal justice-involved
individuals with a history of opioid use disorder. Addiction
2017;112(8):1440-50.
NCT03556618 {published data only}
NCT03556618. A pilot trial of a network intervention for youth
aLer incarceration. clinicaltrials.gov/show/NCT03556618 (first
received 14 June 2018).
Nemes 1999 {published data only}
Nemes S, Wish ED, Messina N. Comparing the impact of
standard and abbreviated treatment in a therapeutic
community - findings from the District of Columbia Treatment
Initiative Experiment. Journal of Substance Abuse Treatment
1999;17(4):339-47.
Nirenberg 2013 {published data only}
Nirenberg T, Baird J, Longabaugh R, Mello MJ. Motivational
counseling reduces future police charges in court referred
youth. Accident: Analysis and Prevention 2013;53:89-99.
Nirenberg 2013a {published data only}
Nirenberg T, Longabaugh R, Baird J, Mello MJ. Treatment
may influence self-report and jeopardize our understanding
of outcome. Journal of Studies on Alcohol and Drugs
2013;74(5):770-6.
Nosyk 2010 {published data only}
Nosyk B, Geller J, Guh DP, Oviedo-Joekes E, Brissette S,
Marsh DC, et al. The effect of motivational status on
treatment outcome in the North American Opiate Medication
Initiative (NAOMI) study. Drug and Alcohol Dependence
2010;111(1-2):161-5.
Nyamathi 2014a {published data only}
Nyamathi A, Salem B, Farabee D, Hall E, Zhang S, Khalilifard F, et
al. Predictors of high level of hostility among homeless men on
parole. Journal of Offender Rehabilitation 2014;53(2):95-115.
Nyamathi 2014b {published data only}
Nyamathi AM, Salem BE, Farabee D, Hall E, Zhang S, Marfisee M,
et al. Correlates of heroin and methamphetamine use among
homeless male ex-jail and prison offenders. Addiction Research
and Theory 2014;22(6):463-73.
Nyamathi 2015 {published data only}
Nyamathi A, Salem BE, Zhang S, Farabee D, Hall B, Khalilifard F,
et al. Nursing case management, peer coaching, and hepatitis
a and B vaccine completion among homeless men recently
released on parole: randomized clinical trial. Nursing Research
2015;64(3):177-89.
Nyamathi 2016 {published data only}
Nyamathi AM, Zhang SX, Wall S, Hall EA, Salem BE, Farabee D,
et al. Drug use and multiple sex partners among homeless ex-
offenders: secondary findings from an experimental study.
Nursing Research 2016;65(3):179-90.
O'Brien 2015 {published data only}
O'Brien CP, Friedmann PD, Nunes E, Lee JD, Kinlock TW.
Depot naltrexone as relapse prevention for opioid-dependent
parolees. Drug and Alcohol Dependence 2015;146:e54-5.
O'Brien 2017 {published data only}
O'Brien MD. Preparing sex offenders for treatment. In: Boer
DP, Beech AR, Ward T, Craig LA, Rettenberger M, Marshall LE,
Marshall WL editor(s). The Wiley Handbook on the Theories,
Assessment, and Treatment of Sexual Offending. Vol. 1, John
Wiley and Sons, 2017:1541-57.
Owens 2016 {published data only}
Owens MD, McCrady BS. A pilot study of a brief motivational
intervention for incarcerated drinkers. Journal of Substance
Abuse Treatment 2016;68:1-10.
Owens 2017 {published data only}
Owens MD. A randomized clinical trial of a brief motivational
intervention for incarcerated drinkers. Dissertation Abstracts
International Section B: The Sciences and Engineering 2017;
Vol. 78, issue 3-B(E).
Page 1982 {published data only}
Page RC, Miehl H. Marathon groups: facilitating the personal
growth of male illicit drug users. The International Journal of the
Addictions 1982;17(2):393-7.
Parmar 2017 {published data only}
Parmar MK, Strang J, Choo L, Meade AM, Bird SM. Randomized
controlled pilot trial of naloxone-on-release to prevent post-
prison opioid overdose deaths. Addiction 2017;112(3):502-15.
Pettus-Davis 2017 {published data only}
Pettus-DC, Dunnigan A, Veeh CA, Howard MO, Scheyett AM,
Roberts-LA. Enhancing social support post incarceration: results
Interventions for female drug-using offenders (Review)









Cochrane Database of Systematic Reviews
from a pilot randomized controlled trial. Journal of Clinical
Psychology 2017;73(10):1226-46.
Pierce 2018 {published data only}
Pierce M, Bird SM, Hickman M, Marsden J, Dunn G, Seddon T, et
al. Effect of initiating drug treatment on the risk of drug-related
poisoning death and acquisitive crime among offending heroin
users. International Journal of Drug Policy 2018;51:42-51.
Pijl 2017 {published data only}
Pijl EM, Bourque S, Martens M, Cherniwchan A. Take-home
naloxone kit distribution: a pilot project involving people who
use drugs and who are newly released from a correctional
facility. Canadian Journal of Criminology and Criminal Justice
2017;59(4):559-71.
Pitre 1997 {published data only}
Pitre U, Dees SM, Dansereau DF, Simpson DD. Mapping
techniques to improve substance abuse treatment in criminal
justice settings. Journal of Drug Issues 1997;27(2):431-44.
Pitre 1998 {published data only}
Pitre U, Dansereau DF, Newbern D, Simpson DD. Residential
drug abuse treatment for probationers: Use of node-link
mapping to enhance participation and progress. Journal of
Substance Abuse Treatment 1998;15(6):535-43.
Poblete 2017 {published data only}
Poblete F, Barticevic NA, Zuzulich MS, Portilla R, Castillo-
CA, Sapag JC, et al. A randomized controlled trial of a brief
intervention for alcohol and drugs linked to the Alcohol,
Smoking and Substance Involvement Screening Test (ASSIST) in
primary health care in Chile. Addiction 2017;112(8):1462-9.
Polcin 2018 {published data only}
Polcin DL, Korcha R, Witbrodt J, Mericle AA, Mahoney E.
Motivational interviewing case management (MICM) for persons
on probation or parole entering sober living houses. Criminal
Justice Behaviour 2018;45(11):1634-59.
Prendergast 2015 {published data only}
Prendergast ML, Hall EA, Grossman J, Veliz R, Gregorio L,
Warda US, et al. Effectiveness of using incentives to improve
parolee admission and attendance in community addiction
treatment. Criminal Justice and Behaviour 2015;42(10):1008-31.
Prendergast 2017 {published data only}
Prendergast ML, McCollister K, Warda U. A randomized study
of the use of screening, brief intervention, and referral to
treatment (SBIRT) for drug and alcohol use with jail inmates.
Journal of Substance Abuse Treatment 2017;74:54-64.
Randall 2018 {published data only}
Randall J, Cunningham PB, Henggeler SW. The development
and transportability of multisystemic therapy-substance abuse:
a treatment for adolescents with substance use disorders.
Journal of Child & Adolescent Substance Abuse 2018;27(2):59-66.
Reingle Gonzalez 2018 {published data only}
Reingle Gonzalez JM, Businelle MS, Kendzor D, Staton M,
North CS, Swartz M. Using mHealth to increase treatment
utilization among recently incarcerated homeless adults
(Link2Care): protocol for a randomized controlled trial. JMIR
Research Protocol 2018;7(6):e151.
Rich 2015 {published data only}
Rich JD, McKenzie M, Larney S, Wong JB, Tran L, Clarke J,
et al. Methadone continuation versus forced withdrawal on
incarceration in a combined US prison and jail: a randomised,
open-label trial. Lancet 2015;386(9991):350-9.
Roll 2005 {published data only}
Roll JM, Prendergast ML, Sorensen K, Prakash S, Chudzynski JE.
A comparison of voucher exchanges between criminal justice
involved and noninvolved participants enrolled in voucher-
based contingency management drug abuse treatment
programs. American Journal of Drug and Alcohol Abuse
2005;31(3):393-401.
Rowe 2007 {published data only}
Rowe M, Bellamy C, Baranoski M, Wieland M, O'Connell MJ,
Benedict P, et al. A peer-support, group intervention to reduce
substance use and criminality among persons with severe
mental illness. Psychiatric Services 2007;58(7):955-61.
Rowland 2008 {published data only}
Rowland MD, Chapman JE, Henggeler Scott W. Sibling
outcomes from a randomized trial of evidence-based
treatments with substance abusing juvenile offenders. Journal
of Child and Adolescent Substance Abuse 2008;17(3):11-26.
Sajatovic 2013 {published data only}
Sajatovic M, Levin J, Ramirez LF, Hahn DY, Tatsuoka C, Bialko CS,
et al. Prospective trial of customized adherence enhancement
plus long-acting injectable antipsychotic medication in
homeless or recently homeless individuals with schizophrenia
or schizoaffective disorder. Journal of Clinical Psychology
2013;74(12):1249-55.
Saxena 2014 {published data only}
Saxena P, Messina N, Grella CE. Who benefits from gender-
responsive treatment? Accounting for abuse history on
longitudinal outcomes for women in prison. Criminal Justice
and Behaviour 2014;41(4):417-32.
Schaeffer 2014 {published data only}
Schaeffer CM, Henggeler SW, Ford JD, Mann M, Chang R,
Chapman JE. RCT of a promising vocational/employment
program for high-risk juvenile offenders. Journal of Substance
Abuse Treatment 2014;46(2):134-43.
Scott 2017 {published data only}
Scott CK, Dennis ML, Lurigio AJ. The effects of specialized
probation and recovery management checkups (RMCs) on
treatment participation, substance use, HIV risk behaviors, and
recidivism among female offenders: Main findings of a 3-year
experiment using subject by intervention interaction analysis.
Journal of Experimental Criminology 2017;13(1):53-77.
Seitz-Brown 2015 {published data only}
Seitz-Brown C, DeGeorge D, Blevins E, Williams J, Lejuez CW,
Daughters SB. A brief behavioral activation treatment for
Interventions for female drug-using offenders (Review)









Cochrane Database of Systematic Reviews
substance use associated with lower rates of recidivism
at a one-year follow-up. Drug and Alcohol Dependence
2015;146:e93-.
Shaul 2016 {published data only}
Shaul L, Koeter MW, Schippers GM. Brief motivation enhancing
intervention to prevent criminal recidivism in substance-
abusing offenders under supervision: randomized trial.
Psychology Crime and Law 2016;22(9):903-14.
Sheard 2007 {published data only}
Sheard L, Adams CE, Wright NM, El-Sayeh H, Dalton R,
Tompkins CN. The Leeds Evaluation of Efficacy of Detoxification
Study (LEEDS) prisons project pilot study: protocol for a
randomised controlled trial comparing dihydrocodeine and
buprenorphine for opiate detoxification. Trials 2007;8:1.
Sheard 2009a {published data only}
Sheard L, Wright NM, El-Sayeh HG, Adams CE, Li R,
Tompkins CN. The Leeds Evaluation of Efficacy of Detoxification
Study (LEEDS) prisons project: a randomised controlled trial
comparing dihydrocodeine and buprenorphine for opiate
detoxification. Substance Abuse Treatment, Prevention and
Policy 2009;4:1.
Sheard 2009b {published data only}
Sheard L, Wright NMJ, Adams CE, Bound N, Rushforth B,
Hart R, et al. The Leeds evaluation of efficacy of detoxification
study (LEEDS) prisons project study: protocol for a
randomised controlled trial comparing methadone and
buprenorphine for opiate detoxification. Trials 2009;10:53. [DOI:
10.1186/1745-6215-10-53.]
Shearer 2003 {published data only}
Shearer J, Wodak A, Van Beek I, Mattick RP, Lewis J. Pilot
randomized double blind placebo-controlled study of
dexamphetamine for cocaine dependence. Addiction
2003;98(8):1137-41.
Shearer 2007 {published data only}
Shearer J, Wodak A, Dolan K. Evaluation of a prison-based
naltrexone program. International Journal of Prisoner Health
2007;3(3):214-24.
Sinha 2003 {published data only}
Sinha R, Easton C, Renee-Aubin L, Carroll KM. Engaging young
probation-referred marijuana-abusing individuals in treatment:
A pilot trial. American Journal of Addictions 2003;12(4):314-23.
Smelson 2019 {published data only}
Smelson D, Farquhar I, Fisher W, Pressman K, Pinals DA,
Samek B, et al. Integrating a co-occurring disorders intervention
in drug courts: an open pilot trial. Community Mental Health
Journal 2019;55(2):222-31.
Smith 2017 {published data only}
Smith LR, Strathdee SA, Metzger D, Latkin C. Evaluating
network-level predictors of behavior change among injection
networks enrolled in the HPTN 037 randomized controlled trial.
Drug and Alcohol Dependence 2017;175:164-70.
Soares 2018 {published data only}
Soares WE, Wilson D, Rathlev N, Lee JD, Gordon M, Nunes EV,
et al. Healthcare utilization in adults with opioid dependence
receiving extended release naltrexone compared to treatment
as usual. Journal of Substance Abuse Treatment 2018;85:66-9.
Soares 2019 {published data only}
Soares WE 3rd, Wilson D, Gordon MS, Lee JD, Nunes EV,
O'Brien CP, et al. Incidence of future arrests in adults involved
in the criminal justice system with opioid use disorder receiving
extended release naltrexone compared to treatment as usual.
Drug Alcohol Dependence 2019;194:482-6.
Somers 2013 {published data only}
Somers JM, Rezansoff SN, Moniruzzaman A, Palepu A,
Patterson M. Housing first reduces re-offending among formerly
homeless adults with mental disorders: results of a randomized
controlled trial. PLoSONE 2013;8(9):e72946.
Spohr 2015 {published data only}
Spohr SA, Taxman FS, Walters ST. The relationship between
electronic goal reminders and subsequent drug use and
treatment initiation in a criminal justice setting. Addiction
Behaviour 2015;51:51-6.
Spohr 2018 {published data only}
Spohr SA, Livingston MD, Taxman FS, Walters ST. What's the
influence of social interactions on substance use and treatment
initiation? A prospective analysis among substance-using
probationers. Addictive Behaviors 2018;89:143-50.
Springer 2017 {published data only}
Springer SA, Altice FL, Herme M, Paola A. Design and methods
of a double blind randomized placebo-controlled trial of
extended-release naltrexone for alcohol dependent and
hazardous drinking prisoners with HIV who are transitioning to
the community". Contemporary Clinical Trials 2017;37(2):209-18.
Springer 2018 {published data only}
Springer SA, Di Paola A, Azar MM, Barbour R, Biondi BE,
Desabrais M, et al. Extended-release naltrexone improves viral
suppression among incarcerated persons living with HIV with
opioid use disorders transitioning to the community: results of
a double-blind, placebo-controlled randomized trial. Journal of
Acquired Immune Deficiency Syndrome 2018;78(1):43-53.
Stein 2011 {published data only}
Stein LA, Lebeau R, Colby SM, Barnett NP, Golembeske C,
Monti PM. Motivational interviewing for incarcerated
adolescents: effects of depressive symptoms on reducing
alcohol and marijuana use aLer release. Journal of Studies on
Alcohol and Drugs 2011;72(3):497-506.
Sticca 2014 {published data only}
Sticca VD, Perrone C. Sickness awareness in subjects who
have among the requirements imposed by the judge for their
anticipated freedom treatment for substance use. [Conciencia
de enfermedad en sujetos que tienen entre los requisitos
impuestos por el juez para su libertad anticipada tratamiento
por el consumo de sustancias]. [Thesis]. Catholic University of
Córdoba, Argentina, 2014.
Interventions for female drug-using offenders (Review)









Cochrane Database of Systematic Reviews
Stillwell 2017 {published data only}
Stillwell G, Jones H, Shaw J, Farrell M, Marsden J. An evaluation
of opioid substitution treatment in prison on risk of mortality
in period immediately aLer prison: does leaving prison on
OST reduce the risk of death?. Drug and Alcohol Dependence
2017;171:e197.
Strang 2000 {published data only}
Strang J, Marsden J, Cummins M, Farrell M, Finch E, Gossop M,
et al. Randomized trial of supervised injectable versus oral
methadone maintenance: report of feasibility and 6-month
outcome. Addiction 2000;95(11):1631-45.
Sundell 2008 {published data only}
Sundell K, Hansson K, Lofholm CA, Olsson T, Gustle LH,
Kadesjo C. The transportability of multisystemic therapy
to Sweden: short-term results from a randomized trial of
conduct-disordered youths. Journal of Family Psychology
2008;22(4):550-60.
Swogger 2016 {published data only}
Swogger MT, Conner KR, Caine ED, Trabold N, Parkhurst MN,
Prothero LM, et al. A test of core psychopathic traits as a
moderator of the efficacy of a brief motivational intervention
for substance-using offenders. Journal of Consulting and Clinical
Psychology 2016;84(3):248-58.
Thompson 2018 {published data only}
Thompson TP, Callaghan L, Hazeldine E, Quinn C, Walker S,
Byng R. Health trainer-led motivational intervention plus
usual care for people under community supervision compared
with usual care alone: a study protocol for a parallel-group
pilot randomised controlled trial (STRENGTHEN). BMJ Open
2018;8(6):e023123.
Tolou-Shams 2011 {published data only}
Tolou-Shams M, Houck C, Conrad SM, Tarantino N, Stein LA,
Brown LK. HIV prevention for Juvenile drug court offenders: a
randomized controlled trial focusing on affect management.
Journal of Correctional Health Care 2011;17(3):226-32.
Vagenas 2017 {published data only}
Vagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL,
et al. Corrigendum to an evaluation of hepatic enzyme
elevations among HIV-infected released prisoners enrolled in
two randomized placebo-controlled trials of extended release
naltrexone. Journal of Substance Abuse Treatment. Pergamon
Press - An Imprint of Elsevier Science, 2017; Vol. 77:44.
Van der pol 2018 {published data only}
van der Pol TM, Hendriks V, Rigter H, Cohn MD, Doreleijers TAH,
van Domburgh L, et al. Multidimensional family therapy
in adolescents with a cannabis use disorder: long-term
effects on delinquency in a randomized controlled trial. Child
Adolescent Psychiatry Mental Health 2018;12:44. [DOI: 10.1186/
s13034-018-0248-x.]
van Stelle 2004 {published data only}
Van Stelle KR, Moberg DP. Outcome data for MICA clients aLer
participation in an institutional therapeutic community. Journal
of Offender Rehabilitation 2004;39(1):37-62.
Vaucher 2016 {published data only}
Vaucher P, Michiels W, Joris Lambert S, Favre N, Perez B,
Baertschi A, et al. Benefits of short educational programmes
in preventing drink-driving recidivism: a ten-year follow-up
randomised controlled trial. International Journal of Drug Policy
2016;32:70-6.
Villagra 2013 {published data only}
Villagra Lanza P, Menendez AG. Acceptance and commitment
therapy for drug abuse in incarcerated women [Terapia de
aceptacion y compromiso para el abuso de sustancias en
mujeres encarceladas]. Psicothema 2013;25(3):307-12.
Warren 2006 {published data only}
Warren E, Viney R, Shearer J, Shanahan M, Wodak A, Dolan K.
Value for money in drug treatment: economic evaluation
of prison methadone. Drug and Alcohol Dependence
2006;84(2):160-6.
Welsh 2014 {published data only}
Welsh WN, Zajac G, Bucklen KB. For whom does prison-based
drug treatment work? Results from a randomized experiment.
Journal of Experimental Criminology 2014;10(2):151-77.
White 2018 {published data only}
White B, Haber PS, Lintzeris N, Roberts J, Cretikos M, Mackson J,
et al. Assessing the safety and feasibility of long-acting depot
of buprenorphine in adults requiring treatment for opioid use
disorder in NSW custodial settings. Drug and Alcohol Review
2018;37:S75.
Wimberley 2018 {published data only}
Wimberly AS, Engstrom M, Layde M, McKay JR. A randomized
trial of yoga for stress and substance use among people living
with HIV in reentry. Journal of Substance Abuse Treatment
2018;94:97-104.
Wimberly 2018 {published data only}
Wimberly AS. A yoga intervention for substance use and stress
for returning citizens. Dissertation Abstracts International
Section A: Humanities and Social Sciences 2018; Vol. 79, issue 1-
A(E).
Witkiewitz 2014 {published data only}
Witkiewitz K, Warner K, Sully B, Barricks A, Stauffer C,
Thompson BL, et al. Randomized trial comparing mindfulness-
based relapse prevention with relapse prevention for women
offenders at a residential addiction treatment center. Substance
Use and Misuse 2014;49(5):536-46.
Wolff 2012 {published data only}
Wolff N, Frueh BC, Shi J, Schumann BE. Effectiveness of
cognitive-behavioral trauma treatment for incarcerated women
with mental illnesses and substance abuse disorders. Journal of
Anxiety Disorders 2012;26(7):703-10.
Wooditch 2015 {published data only}
Wooditch A, Taxman F, Murphy A. Residential mobility and
housing instability among justice-involved African-American
opioid abusers. Journal of Drug Issues 2015;146:e26-.
Interventions for female drug-using offenders (Review)









Cochrane Database of Systematic Reviews
Wooditch 2017 {published data only}
Wooditch A, Sloas LB, Taxman FS. A multisite randomized block
experiment on the seamless system of care model for drug-
involved probationers. Journal of Drug Issues 2017;47(1):50-73.
Wright 2011 {published data only}
Wright NM, Sheard L, Adams CE, Rushforth BJ, Harrison W,
Bound N, et al. Comparison of methadone and buprenorphine
for opiate detoxification (LEEDS trial): a randomised controlled
trial. British Journal of General Practice 2011;61(593):e772-80.
Zlotnick 2003 {published data only}
Zlotnick C, Najavits LM, Rohsenow DJ, Johnson DM. A cognitive-
behavioral treatment for incarcerated women with substance
abuse disorder and posttraumatic stress disorder: Findings




Ahmed F, Hogg-Johnson S, Stewart DE, Skinner HA, Glazier RH,
Levinson W. Computer assisted screening for intimate partner
violence and control: a randomized trial. Annals of Internal
Medicine 2009;151(2):93-102.
Amato 2005
Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP.
An overview of systematic reviews of effectiveness of opiate
maintenance therapies: available evidence to inform clinical
practice and research. Journal of Substance Abuse Treatment
2005;28(4):321-9.
Amato 2013
Amato L, Davoli M, Minozzi S, Ferroni E, Ali R, Ferri M.
Methadone at tapered doses for the management of opioid
withdrawal. Cochrane Database of Systematic Reviews 2013,
Issue 2. [DOI: 10.1002/14651858.CD003409]
Andrews 1990
Andrews DA, Zinger I, Hoge RD, Bonta J, Gendreau P, Cullen FT.
Does correctional treatment work? A clinically relevant
and psychologically informed meta analysis. Criminology
1990;28(3):369-404.
Austin 1994
Austin CD, McLelland RW. Case management in human services:
Reflections on public policy. Journal of Case Management
1994;6(3):119-26.
Berzins 2004
Berzins LG, Trestman RL. The development and implementation
of dialectical behavior therapy in forensic settings. International
Journal of Forensic Mental Health 2004;3:93-103. [DOI:
10.1080/14999013.2004.10471199]
Bloom 2004
Bloom B, Owen B, Covington S. Women offenders and
gendered effects of public policy. Review of Policy Research
2004;21(1):31-48.
Calhoun 2009
Calhoun S, Messina N, Cartier J. Focus group findings: Women
in prison project. Manuscript submitted for publication 2009.
Carson 2018
Carson AE. Prisoners in 2016. Bureau of Justice Statistics,
Bulletin NCJ 251149 January 2018.
Catania 2003
Catania H. Prison health needs in prisons. Harm reduction
news. Newsletter of the International Harm Reduction
Development Program of the Open Society Institute 2003; Vol. 4,
issue 11:13.
Deeks 2017
Deeks JJ, Higgins JP, Altman DG, editor(s), on behalf of the
Cochrane Statistical Methods Group. Chapter 9: Analysing data
and undertaking meta-analyses. In: Higgins JP, Churchill R,
Chandler J, Cumpston MS, editor(s). Cochrane Handbook for
Systematic Reviews of Interventions version 5.2.0 (updated
June 2017). The Cochrane Collaboration, 2017. Available from
www.training.cochrane.org/handbook.
Dobkin 2002
Dobkin PL, Civita MD, Paraherakis A, Gill K. The role of
functional social support in treatment retention and outcomes
among outpatient adult substance abusers. Addiction
2002;97:347-56.
Faggiano 2003
Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone
maintenance at different dosages for opioid dependence.
Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI:
10.1002/14651858.CD002208]
Fareed 2012
Fareed A, Vayalapalli S, Casarella J, Drexler K. Effect of
buprenorphine dose on treatment outcome. Journal of
Addictive Diseases 2012;31(1):8-18.
FBI 2011
Federal Bureau of Investigation. Crime in the United States,
2010. www.fbi.gov/about-us/cjis/ucr/crime-in-the-u.s/2010/
crime-in-the-u.s.-2010 (accessed 30 November 2013).
Fiscella 2004
Fiscella K, Moore A, Engerman J, Meldrum S. Jail
management of arrestees/inmates enrolled in community
methadone maintenance programs. Journal of Urban Health
2004;81(4):645-54.
Forsythe 2009
Forsythe L, Adams K. Mental health, abuse, drug use and
crime: Does gender matter?. www.questia.com/library/
journal/1P3-1982210181/mental-health-abuse-drug-use-and-
crime-does-gender (accessed 30 November 2013).
Garcia 2007
Garcia CA, Correa GC, Viver AD, Hernandez BS, Kinlock TW,
Gordon MS, et al. Buprenorphine-naloxone treatment for pre-
Interventions for female drug-using offenders (Review)









Cochrane Database of Systematic Reviews
release opioid-dependent inmates in Puerto Rico. Journal of
Addiction Medicine 2007;1(3):126-32.
Gibson 2007
Gibson AE, Degenhardt LJ. Mortality related to
pharmacotherapies for opioid dependence: a comparative
analysis of coronial records. Drug and Alcohol Review
2007;26(4):405-10.
Grella 2008
Grella CE. From generic to gender-responsive treatment:
Changes in social policies, treatment services, and outcomes of
women in substance abuse treatment. Journal of Psychoactive
Drugs 2008;Suppl 5:327−43.
Guerino 2011
Guerino P, Harrison PM, Sabol WJ. Prisoners in 2010.
www.ncjrs.gov/App/Publications/abstract.aspx?ID=258085
(accessed 30 November 2013).
Higgins 2011
Higgins JP, Green S, editor(s). Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0 (updated
March 2011). The Cochrane Collaboration, 2011. Available from
handbook.cochrane.org.
Holahan 2004
Holahan CJ, Moors RH, Holahan CK, Cronkite RC, Randall PK.
Unipolar depression, life context vulnerabilities and drinking
to cope. Journal of Consulting and Clinical Psychology
2004;72:269-75.
Lazarus 1984
Lazarus R, Folkman S. Stress, Appraisal and Coping. New York:
NY: Springer, 1984.
Leukefeld 2009
Leukfeld C, Oser CB, Havens J, Staton Tindall M, Mooney J,
Duvall JB, et al. Drug abuse treatment beyond the prison walls.
Addiction Science and Clinical Practice 2009;5:24-30.
Light 2013
Light M, Grant E, Hopkins K, Ministry of Justice Analytical
Services. Gender differences in substance misuse and mental
health among prisoners. www.antoniocasella.eu/archipsy/
Light_2013.pdf 2013.
Lipsey 1998
Lipsey MW, Wilson DB. Effective intervention for serious juvenile
offenders: A synthesis of research. In: Loeber RM, Farrington DP
editor(s). Serious and Violent Juvenile Offenders: Risk Factors
and Successful Intervention. Thousand Oaks, California: Sage
Publications, 1998:313-45.
Lipsey 2007
Lipsey M, Landenberger NA, Wilson SJ. Effects of
Cognitive Programs for Criminal offenders: A systematic
review. 173.231.132.82/sites/default/files/documents/
Effects_of_Cognitive_Behavior.pdf (accessed 30 November
2013).
Lobmaier 2008
Lobmaier P, Kornor H, Kunoe N, Bjorndal A. Sustained-
release naltrexone for opioid dependence. Cochrane
Database of Systematic Reviews 2008, Issue 2. [DOI:
10.1002/14651858.CD006140.pub2]
Lussier 2006
Lussier JP, Heil SH, Mongeon JA, Badger GJ, Higgins ST. A
meta-analysis of voucher-based reinforcement therapy for
substance use disorders. Addiction 2006;101(2):192-203.
[10.1111/j.1360-0443.2006.01311.x s.]
Marlowe 2003a
Marlowe D, Elwork A, Festinger D, McLellan AT. Drug policy by
popular referendum: this, too, shall pass. Journal of Substance
Abuse Treatment 2003;25(3):213-21.
Marsch 1998
Marsch LA. The efficacy of methadone maintenance
interventions in reducing illicit opiate use, HIV risk behaviours
and criminality: a meta-analysis. Addiction 1998;93(4):515-32.
Mattick 2009
Mattick RP, Breen C, Kimber J, Davoli M. Methadone
maintenance therapy versus no opioid replacement therapy for
opioid dependence. Cochrane Database of Systematic Reviews
2009, Issue 3. [DOI: 10.1002/14651858.CD002209.pub2]
McMillan 2009
MacMillan HL, Wathen CN, Jamieson E, Boyle MH, Shannon HS,
Ford-Gilboe M, et al. Screening for intimate partner
violence in health care settings: a randomised trial. JAMA
2009;302(5):493-501.
Messina 2007
Messina N, Grella C, Burdon W, Prendergast M. Childhood
adverse events and current traumatic distress: A comparison
of men and women drug-dependent prisoners. Criminal Justice
and Behavior 2007;34(11):1385−401.
Miller 1976
Miller JB. Toward a New Psychology of Women. Boston: Beacon
Press, 1976.
Ministry of Justice 2017
Ministry of Justice. Offender management statistics quarterly:
April to June 2017. London: Ministry of Justice 2017.
Minozzi 2011
Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A.
Oral naltrexone maintenance treatment for opioid dependence.
Cochrane Database of Systematic Reviews 2011, Issue 4. [DOI:
10.1002/14651858.CD001333.pub4]
Minozzi 2013
Minozzi S, Amato L, Vecchi S, Ferri M, Davoli M. Maintenance
agonist treatments for opiate-dependent pregnant women.
Cochrane Database of Systematic Reviews 2013, Issue 12. [DOI:
10.1002/14651858.CD006318.pub3]
Interventions for female drug-using offenders (Review)









Cochrane Database of Systematic Reviews
Mitchell 2012
Mitchell O, Mackenzie LD, Wilson D. The effectiveness of
incarcerated based drug treatment on criminal behaviour:
A systematic review. www.drugsandalcohol.ie/15992/1/
Campbell_Collaboration_Mitchell_The_effectiveness_of_incarceration.pdf
(accessed 30 November 2013).
Moller 2007
Moller L, Gathere A, Juergens R, Stover H, Nikogosian H.
Health in Prisons. A WHO Guide to the Essentials in Prison
Health. www.euro.who.int/__data/assets/pdf_file/0009/99018/
E90174.pdf (accessed 30 November 2013).
Najavits 2006
Najavits LM, Gallop RJ, Weiss RD. Seeking safety therapy for
adolescent girls with PTSD and substance use disorder: A
randomized controlled trial. Journal of Behavioral Health
Services and Research 2006;33(4):453-63.
Nee 2005
Nee C, Farman S. Female prisoners with borderline personality
disorder: some promising treatment developments. Criminal
Behavior and Mental Health 2005;15(1):2-16. [DOI: 10.1002/
cbm.33]
Nelson 2012
Nelson HD, Bougatsos C, Blazina I. Screening women for
intimate partner violence: a systematic review to update the
US preventive Services Task Force recommendation. Annals of
Internal Medicine 2012;156:796-808.
Ost 2008
Ost LG. Efficacy of the third wave of behavioral therapies: a
systematic review and meta-analysis. Behavioral Research and
Therapy 2008;46:296-321.
Partridge 2004
Partridge S. Examining case management models for
community sentences. collection.europarchive.org/
tna/20080205132101/homeoffice.gov.uk/rds/pdfs04/
rdsolr1704.pdf (accessed 30 November 2013).
Pearson 1999
Pearson FS, Lipton DS. A meta-analytic review of the
effectiveness of corrections-based treatment for drug abuse.
Prison Journal 1999;79(4):384-410.
Pelissier 2003
Pelissier BM, Camp SD, Gaes GG, Saylor WG, Rhodes W.
Gender differences in outcomes from prison-based
residential treatment. Journal of Substance Abuse Treatment
2003;24(2):149-60.
Perry 2015a
Perry AE, Neilson M, Martyn-St James M, Glanville JM,
Woodhouse R, Godfrey C, et al. Pharmacological interventions
for drug-using offenders. Cochrane Database of Systematic
Reviews 2015, Issue 6. [DOI: 10.1002/14651858.CD010862.pub2]
Perry 2019
Perry AE, Martyn-St James M, Burns L, Hewitt C,
Glanville JM, Aboaja A, et al. Interventions for drug-using
offenders with co-occuring mental illness. Cochrane
Database of Systematic Reviews 2019, Issue 10. [DOI:
10.1002/14651858.CD010901.pub3]
Powers 2009
Powers MB, Zum MB, Emmelkamp PM. Acceptance and
commitment therapy: a meta-analytic review. Psychotherapy
and Psychosomatics 2009;78(2):73-80.
Prendergast 2011
Prendergast M, Frisman L, Sacks JY, Staton-Tindall M,
Greenwell L, Lin HJ, et al. A multi-site, randomized study of
strengths-based case management with substance-abusing
parolees. Journal of Experimental Criminology 2011;7(3):225-53.
Review Manager 2014 [Computer program]
Nordic Cochrane Centre, The Cochrane Collaboration. Review
Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic
Cochrane Centre, The Cochrane Collaboration, 2014.
Reynaud-Maurupt 2005
Reynaud-Maurupt C, Caer Y, Escaffre N, Gagneau M, Galinier A,
Marzo NJ, et al. High-dose buprenorphine substitution during
incarceration. Presse Medicale 2005;34(7):487-90.
Sacks 2012
Sacks JY, McKendrick K, Hamilton ZK. A randomized clinical
trial of a therapeutic community treatment for female inmates:
outcomes at 6 and 12 months aLer prison release. Journal of
Addictive Diseases 2012;31(3):258-69. [CRSREF: 3037436].
Salem 2013
Salem BE, Nyamathi A, Keenan C, Zhang S, Marlow E,
Khalilifard F, et al. Correlates of risky alcohol and
methamphetamine use among currently homeless male
parolees. Journal of Addictive Diseases 2013;32(4):365-76. [DOI:
10.1080/10550887.2013.849973]
SAMHSA 2012
SAMHSA. Model Programs. Effective Substance Abuse and
Mental Health Programs for Everybody. www.samhsa.gov 2012.
Schunemann 2013
Schünemann H, Brożek J, Guyatt G, Oxman A, editor(s).
Handbook for grading the quality of evidence and the
strength of recommendations using the GRADE approach
(updated October 2013). GRADE Working Group, 2013.
Available from gdt.guidelinedevelopment.org/app/handbook/




Shelton D, Kesten K, Zhang W, Trestman R. Impact of a
dialectic behavior therapy-corrections modified (DBT-
CM) upon behaviourally challenged incarcerated male
adolescents. Journal of Child and Adolescent Psychiatry Nursing
2011;24(2):105-13. [DOI: 10.1111/j.1744-6171.2011.00275.x]
Interventions for female drug-using offenders (Review)









Cochrane Database of Systematic Reviews
Sorenson 2003
Sorenson JL, Dilley J, London J, Okin RL, Delucchi KL,
Phibbs CS. Case management for substance abusers with HIV/
AIDS: A randomised clinical trial. American Journal of Drug and
Alcohol Abuse 2003;29(1):133-50.
Stallwitz 2007
Stallwitz A, Stover H. The impact of substitution treatment in
prisons−a literature review. International Journal on Drug
Policy 2007;18(6):464-74.
Taxman 2002
Taxman F. Systematic review title: Outpatient treatment for
drug-involved offenders. www.aic.gov.au/campbellcj/reviews/
titles.html (accessed 30 November 2013).
Tsai 2013
Tsai J, Kasprow WJ, Rosenheck RA. Alcohol and drug
use disorders among homeless veterans: Prevalence
and association with supported housing outcomes.
Addictive Behaviours 2013;39(2):455-60. [DOI: 10.1016/
j.addbeh.2013.02.002]
 
References to other published versions of this review
Perry 2006
Perry A, Coulton S, Glanville J, Godfrey C, Lunn J, McDougall C,
et al. Interventions for drug-using offenders in the courts,
secure establishments and the community. Cochrane Database
of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.]
Perry 2014a
Perry AE, Neilson M, Martyn-St James M, Glanville JM, McCool R,
Duffy S, et al. Interventions for female drug-using offenders.
Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI:
10.1002/14651858.CD010910]
Perry 2014b
Perry AE, Coulton S, Glanville JM, Godfrey C, Lunn J,
McDougall C, et al. Withdrawn: Interventions for drug-using
offenders in the courts, secure establishments and the
community. Cochrane Database of Systematic Reviews 2014,
Issue 2. [DOI: 10.1002/14651858.CD005193.pub3]
Perry 2015b
Perry AE, Neilson M, Martyn-St James M, Glanville JM,
Woodhouse R, Hewitt C. Interventions for female drug-using
offenders. Cochrane Database of Systematic Reviews 2015, Issue
6. [DOI: 10.1002/14651858.CD010910.pub2]
 
* Indicates the major publication for the study
 
C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Study design: RCT
Study grouping: parallel group
Participants • 36 adults
• Mean age 31.8 (SD 8.4)
• 100% female
• 89% white
• 100 drug users
• Alcohol use: yes – percentage not available
• 54.3% prescribed medication for mental illness
Eligibility criteria: adult women, opioid dependent, interest in treatment for opioid dependence, no
contraindications for buprenorphine, due for release from residential treatment within month, return-
ing to the community, release into the immediate residential area
Interventions Community-based pharmacological intervention versus placebo
Experimental intervention
The group was started on 2 mg of buprenorphine, increased to target dose of 8 mg at discharge. Only
37.2% reached target dose at discharge. (Doses were lower than standard induction as participants had
been in a controlled environment for some time without access to opiates). Doses were then titrated up
to a maximum of 32 mg per day in the community, as clinically indicated. Participants were assessed
weekly for side effects, given drug testing, and counselled by study physician if using drugs (n = 15).
Cropsey 2011 
Interventions for female drug-using offenders (Review)









Cochrane Database of Systematic Reviews
Setting: prison into the community
Length of treatment: 12 weeks
Length of follow-up: 3 months
Control
The control group was given a placebo on the same regimen as the intervention group. The placebo
was dispensed by the pharmacy in identical pill bottles, and given to the participants by the study staff
during the weekly evaluations. Participants were evaluated weekly by the study physician and given
the placebo on a weekly basis (n = 12).
Setting: prison into the community
Length of treatment:12 weeks
Length of follow-up: 3 months
Outcomes % injection drug use and % urine opiates at end of treatment and 3 months follow-up
Notes Funding: This project was supported by funding from NIDA R21DA019838 and product support from
Reckitt Benckiser Pharmaceuticals Inc.
The views expressed in this paper are solely the responsibility of the authors and do not necessarily re-
flect the views of NIH or NIDA.
Conflict of interest: no declaration of interest reported by the authors
Country: USA
Adverse effects: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk The first nine participants were deliberately allocated to the intervention for
practical reasons. Subsequently a random number table was used to allocate
the remaining sample to the intervention or placebo.
Allocation concealment
(selection bias)
High risk The first nine participants were deliberately allocated to the intervention for










Low risk Participants and personnel were blind to all outcome measures
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Participants and personnel were blind to all outcome measures
Blinding of outcome as-
sessment (detection bias) 
subjective measures
Unclear risk No evidence to provide information about whether the assessors who con-
ducted the outcome assessments were blind
Cropsey 2011  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
objective measures
Unclear risk No evidence to provide information about whether the assessors who con-




High risk A total of eight individuals (22%) were not included in the final analysis after
randomisation. It is unclear whether an ITT analysis was conducted.
Selective reporting (re-
porting bias)




Methods Study design: RCT
Study grouping: Parallel group
Participants • 191 adults
• Mean age 34.2 (SD 11.4)
• 100% female
• 67% black
• 51% reported use of any illicit drug use in the past 30 days
• 42% reported binge drinking
Eligibility criteria: 1) being aged 18 or older, (2) having a mailing address, (3) reporting illicit drug use,
binge drinking or receiving drug treatment in the past six months and (4) reporting an intimate rela-
tionship with a male and/or female partner in the past year.
Interventions Single session computerised intervention for intimate partner violence versus single session case man-
ager delivered intervention for intimate partner violence.
Experimental intervention
Single session computerised intervention containing psychosocial education, enhancing motivation,
screening for IPV and risk assessment, safety planning, enhancing social support, goal setting and iden-
tification of service needs. The average length of the session was 44.63 minutes for the single comput-
erised intervention. Sesssion adherence was confirmed with 99% of participants attending and com-
pleting all activities within the intervention (n = 94).
Setting: community
Length of treatment: 45 minutes
Length of follow-up: 3 months
Control
Single session of case manager delivered intervention for intimate partner violence (n = 97)
Setting: community
Length of treatment:45 minutes
Length of follow-up: 3 months
Outcomes Number of days not using drugs (in the past 30 days)
Notes Funding: This study was supported by the National Institute on Drug Abuse (NIDA), grant no.
R34DA031325.
Gilbert 2015 
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Conflict of interest: NIDA staff had no further role in study design, data collection, data analysis and
interpretation, manuscript preparation or the decision to submit the manuscript for publication
Country: USA
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk The computer-generated randomisation algorithm was designed to balance
the number of women per arm and site.
Allocation concealment
(selection bias)











Low risk Being aware of receiving a psychosocial treatment is part of the therapeutic ef-
fect
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Being aware of receiving a psychosocial treatment is part of the therapeutic ef-
fect
Blinding of outcome as-
sessment (detection bias) 
subjective measures
Unclear risk Not reported
Blinding of outcome as-
sessment (detection bias) 
objective measures




Low risk Multiple imputation was used to handle missing data because of loss to fol-
low-up. Ten imputed data sets were generated. Multiple imputation uses a
participant’s measured information to predict values of variables for which of
that individual's information is missing.
Selective reporting (re-
porting bias)




Methods Study design: RCT
Study grouping: Parallel group
Participants • 211 adults
• 39.08 mean age
• 30% female
• % black not reported
• % reported use of any illicit drug use in the past 30 days not reported
Gordan 2017 
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• % reported binge drinking not reported
Eligibility criteria: in order to be eligible for study participation, consenting prisoners had to: be at
least 18 years of age; be within 3–9 months prior to scheduled release; have met DSM-IV criteria for opi-
oid dependence in the year prior to incarceration; be considered by the study physician to be medically
suitable for buprenorphine; and plan to live in Baltimore after release.
Interventions Buprenorphine prior to release from prison versus buprenorphine following release into the communi-
ty
Experimental intervention
All participants were expected to complete an individual counselling assessment and to attend 12
weekly sessions of group-based substance abuse counselling prior to release. Just prior to discharge,
an individual discharge planning session with the study counsellor was also available. In addition, par-
ticipants were expected to attend 12 weekly group-based substance abuse counselling sessions that
were largely psychoeducational in nature. Buprenorphine treatment in prison was provided by the
medical and nursing staff from a community-based programme. Daily dosing of buprenorphine/nalox-
one was directly administered by nursing staff with a goal of starting at 1 mg daily and increasing slow-
ly (initially by 1 mg per week until reaching 4 mg per day, and subsequently by 2 mg per week until
reaching 8 mg). (n = 106)
Setting: in prison
Length of treatment: 12 weeks
Length of follow-up: 12 months
Control
As above but buprenorphine was not given until post-release in the community (n = 105).
Setting: post-release in the community
Length of treatment: 12 weeks
Length of follow-up: 12 months
Outcomes Heroin use (in the past 30 days)
Urine testing (proportion positive)
Notes Funding: This study was supported by the National Institute on Drug Abuse (NIDA), Buprenorphine for
Prisoners (PI: Kinlock; R01DA021579).
Conflict of interest: This study was supported by an unrestricted, unsolicited investigator initiated
request from Reckitt Benckiser Pharmaceuticals, Inc. (provided study drug only) who had no role in
study design; collection, analysis and interpretation of data; in the writing of the manuscript; or in the
decision to submit the manuscript for publication. The authors alone are responsible for the content
and writing of this manuscript. Drs Gordon, Kinlock, and Fitzgerald received funding from Alkermes
on a prior study. Dr Schwartz did a one-time consultation for Reckitt-Benckiser on behalf of his em-
ployer (the Friends Research Institute). Dr O’Grady has in the past received funding for his time from
Reckitt-Benckiser. Dr Vocci has consulted with and received other funding (meals, travel expenses)
from the following companies: Braeburn Pharmaceuticals, Demerx, Indivior, Pinney Associates. He has
received travel and meal expenses from Intratab Labs Inc, and received consulting fees from Alkermes
and Usona Institute. All of Dr Vocci's consulting fees go to his employer, Friends Research Institute, Inc.
Country: USA
Risk of bias
Bias Authors' judgement Support for judgement
Gordan 2017  (Continued)
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Random sequence genera-
tion (selection bias)
Low risk Sequence was generated by computer
Allocation concealment
(selection bias)
Low risk The research assistant opened a sealed, opaque envelope that was numbered












Low risk Being aware of receiving a psychosocial treatment is part of the therapeutic ef-
fect
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Being aware of receiving a psychosocial treatment is part of the therapeutic ef-
fect
Blinding of outcome as-
sessment (detection bias) 
subjective measures
Unclear risk Not reported
Blinding of outcome as-
sessment (detection bias) 
objective measures




High risk We were only able to obtain urine samples on 64% of the 211 participants,
mainly due to reincarceration, or to an interview conducted by Timeline Fol-
lowback after its due date. While treatment retention data were obtained for
nearly the entire sample (through examination of the programme records), be-
cause an increasing number of participants were not available for interview
during incarceration, the self-reported findings may have been influenced by
differential attrition across the follow-up times.
Selective reporting (re-
porting bias)
Low risk The study protocol is available and all of the study's prespecified (primary and





Methods Study design: RCT
Study grouping: Parallel group
Participants • 188 adults
• Mean age 34.7 (SD 9.2)
• 100% female
• 57.4% African-American
• Addiction Severity Index: 50.5 (intervention) 51.6 (control)
• Alcohol use: 7.7% intervention, 5.6% control
• Beck Depression Inventory mean: 14.6 (intervention) 14.6 (control)
Guydish 2011 
Interventions for female drug-using offenders (Review)









Cochrane Database of Systematic Reviews
Eligibility criteria: willing to enter substance use treatment, residents of San Francisco, 18 years of age
or older, substance use, involved in the criminal justice system.
Excluded if multiple violent episodes, current involvement in drug court, court order to receive proba-
tion case management services, or referral by probation officer directly to the probation case manage-
ment programme
Interventions Community case management intervention versus treatment as usual
Experimental intervention
Probation case management, client contact at least twice per month. Officers would attend treatment
planning meetings, make home visits, and accompany the client to important meetings. Could also
refer client to other appropriate agencies. Included therapeutic and advocacy orientation and coun-
selling (n = 92).
Setting: community
Length of treatment: not reported
length of follow-up: 6 and 12 months
Control
Treatment as usual was standard probation services including preparation of reports for court, super-
vision of offender, enforcement of probation conditions, assistance to offender in accessing necessary
services (n = 96)
Setting: community
Length of treatment: not reported
length of follow-up: 6 and 12 months
Outcomes • Percentage participants arrested and mean time to first arrest (from administrative data) during 12
month follow-up period
• Addiction Severity Index composite scores, reported as relative risk, at 6 months and 12 months
• Beck Depression Inventory
• Brief Symptom Inventory
• Service utilisation
Notes Funding: This study was supported by the Center for Substance Abuse Treatment (1UD8TI11215), by
the National Institute on Drug Abuse (NIDA) San Francisco Treatment Research Center (P50-DA09253),
and by the California–Arizona node of the NIDA Clinical Trials Network (U10-DA15815).
Conflict of interest: no declaration of interest reported by the authors
Country: USA
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)








Low risk Being aware of receiving a psychosocial treatment is part of the therapeutic ef-
fect
Guydish 2011  (Continued)
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Low risk Being aware of receiving a psychosocial treatment is part of the therapeutic ef-
fect
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Being aware of receiving a psychosocial treatment is part of the therapeutic ef-
fect
Blinding of outcome as-
sessment (detection bias) 
subjective measures
Unclear risk No evidence to provide information about whether the assessors were blind
Blinding of outcome as-
sessment (detection bias) 
objective measures




Low risk Follow-up rates at each time point did not differ significantly between the
groups. At 12 months 82.6% of the probation case management and 78.0% of
the standard probation were followed up
Selective reporting (re-
porting bias)




Methods Study design: RCT
Study grouping: Parallel group
Participants • 476 adults (n = 77 women)
• Men mean age 34.4 years (SD 8.6); women mean age 35.6 years (SD 8.5)
• 82% male
• 51% black
• 82% used primary drug in pre-prison 6 months
• 63% men and 39% women self-reported alcohol use during pre-prison 6 months
• 25% lifetime depression
Eligibility criteria: at least 18 years of age, English speaking, probable drug dependence immediately
prior to incarceration (score of 3 or more on drug screen), substance use treatment as a mandated or
recommended condition of parole, moderate to high risk of drug use relapse and/or recidivism (score
of 7 or more on LCSF).
Interventions Community collaborative behavioural management intervention versus treatment as usual
Experimental intervention
Collaborative behavioural management (n = 221). 12-week intervention based on premise that rein-
forcement of desired behaviour is more likely to result in sustained positive change than punishment of
undesired behaviour. Involves treatment sessions with offender, officer, and substance use counsellor
at least once every 2 weeks, plus further officer/offender contacts.
Setting: community
Length of treatment: 12 weeks
Johnson 2011 
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Length of follow-up: 9 months
Control
Treatment as usual was standard parole supervision (n = 210) including weekly to monthly face-to-
face officer/client contact, and drug testing. Officers were affiliated with a substance abuse treatment
programme. Average 1 to 4 contacts per month.
Setting: community
Length of treatment: 12 weeks
Length of follow-up: 9 months
Outcomes Percentage reincarcerated (self-reported) at 9-month follow-up
Percentage using primary drug (self-reported) during 9-month follow-up
Notes Funding: Dr Johnson is supported by K23DA021159 from NIDA. The Step'N Out study was funded as
part of CJ-DATS under a cooperative agreement from NIDA and the National Institutes of Health (NIH),
with support from SAMHSA's CSAT; the Centers for Disease Control and Prevention; the Centers for Dis-
ease Control and Prevention; the National Institute on Alcohol Abuse and Alcoholism (all part of the US
Department of Health and Human Services); and from the Bureau of Justice Assistance of the US De-
partment of Justice.
Conflict of interest: no declaration of interest reported by the authors
Country: USA
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "Subjects were randomised using urn randomisation to ensure balance of gen-
der and other factors"
Allocation concealment
(selection bias)











Low risk Being aware of receiving a psychosocial treatment is part of the therapeutic ef-
fect
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Being aware of receiving a psychosocial treatment is part of the therapeutic ef-
fect
Blinding of outcome as-
sessment (detection bias) 
subjective measures
Unclear risk No evidence to provide information about whether the assessors were blind
Blinding of outcome as-
sessment (detection bias) 
objective measures
Unclear risk No evidence to provide information about whether the assessors were blind
Johnson 2011  (Continued)
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Unclear risk Some attrition and loss is reported in the sample. 476 were interviewed at
baseline but it is unclear how many were randomised and the number of can-
didates rejected is not reported with reasons for exclusion
Selective reporting (re-
porting bias)




Methods Study design: RCT
Study grouping: Parallel group
Participants • 38 adults
• Average age: 35 years (SD 9.2)
• 100% female
• 18% Hispanic, 18% African American
• 58% cocaine dependence, 24% opiate dependence, 21% marijuana dependence, 21% sedative/hyp-
notic dependence
• 58% alcohol dependence
• 100 % psychiatric history
 
Criteria used for mental health diagnoses – “MDD as determined by the Structured Clinical Interview
for DSM-IV Axis I Disorders (SCID-I) after at least 4 weeks of abstinence and prison substance use treat-
ment”
Description of mental health problem – MDD
Eligibility criteria: primary MDD as determined by the Structured Clinical Interview for DSM-IV Axis I
Disorders after at least 4 weeks of abstinence and prison substance use treatment, minimum 17-item
Hamilton Depression Scale score of 18, substance use disorder one month prior to incarceration as de-
termined by the SCID, 10-24 weeks away from prison release.
Interventions Interpersonal psychotherapy versus psychoeducational control
Experimental group
Intervention participants received manualised 60-75 min group sessions three times per week for 8
weeks plus pre-group, mid-group, and post-group individual sessions in prison for the treatment of
substance misuse and mental health problems. Participants in both conditions also received 6 week-
ly post-release individual sessions to help maintain gains and address crises as women transitioned
to the community. Session lengths varied between 60 and 75 min because of time taken to assemble
women within the facilities, occasional early prison counts, and other facility logistics (n = 19).
Setting: prison
Length of treatment: 60-75 minutes, 3 times per week for 8 weeks, plus pre-/mid- and post-group indi-
vidual sessions and 6-weekly post-release individual sessions to support transition into the communi-
ty.
Length of follow-up: end of treatment at 8 weeks
Control group
Control condition participants received attention-matched manualised in-prison and post-release psy-
choeducation, which is described as co-occurring mental health and substance use disorders (PSY-
CHOED). The psychoeducation condition was adapted from a class on co-occurring disorders for pris-
Johnson 2012 
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oners which had been used at the women's facilities in the past, but was not being used at the time of
the study. It was designed to be credible and engaging without focusing on the theorised active ingredi-
ents of interpersonal psychotherapy (e.g. focus on social support, relationships, life changes, analysis
of communication, and exploration of emotions). The stated purpose of PSYCHOED was to help women
become informed and empowered consumers of mental health treatment services. The 24 in-prison
sessions focused on the meaning of dual diagnosis, women’s experience with dual diagnosis, major
depression, bipolar disorder, each of the anxiety disorders, post-traumatic stress disorder, personali-
ty disorders, psychotic disorders, eating disorders, and self-care. Sessions for each disorder described
symptoms (including relevant self-reported tests), interactions between the disorder and substance
use, effects of the disorder on women in prison (including film clips and written stories), and disorder
specific medication and psychosocial treatment options. When a woman in group had symptoms of a
disorder, the group discussed her treatment options and preferences. The six post-release sessions fo-
cused on women’s symptoms and connection with various mental health and substance use treatment
options in the community. Study treatments took place in addition to prison treatment as usual. Treat-
ment as usual consisted of prison residential or day treatment for a substance use disorder (SUD: typ-
ically 16 to 30 hrs per week) for all participants and prison mental health treatment as usual for most
participants (n = 19).
Setting: prison
Length of treatment: 60-75 minutes, 3 times per week for 8 weeks, plus pre-/mid- and post-group indi-
vidual sessions and 6 weekly post-release individual sessions to support transition into the community
Length of follow-up: end of treatment at 8 weeks
Outcomes Relapse within 3-month follow-up period, defined as using drugs on at least 10% of non-incarcerated
days or any positive breath test/urine drug screen. HRSD scores
Notes Funding: work supported by United States National Institute of Drug Abuse
Conflict of interest: no declarations of interest are noted by the authors
Country: USA
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Wave randomisation used with at least 8 weeks between allocation to avoid
contamination across prison wings
Allocation concealment
(selection bias)
Low risk Random sequence generated by person independent of rest of study. Alloca-
tion adequately concealed from principal investigator and research assistants.
An independent individual concealed the assignment of each wave before the
study started. After the intake assessment was complete, the principal investi-











Low risk Being aware of receiving a psychosocial treatment is part of the therapeutic ef-
fect
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Being aware of receiving a psychosocial treatment is part of the therapeutic ef-
fect
Johnson 2012  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
subjective measures
Low risk Adequate blinding throughout study. Research assistants who conducted the
follow-up assessment at 3 months after prison release were kept blind to the
condition.
Blinding of outcome as-
sessment (detection bias) 
objective measures
Low risk Adequate blinding throughout study. Research assistants who conducted the






No loss to follow-up, ITT analysis
Selective reporting (re-
porting bias)





Methods Study design: RCT
Study grouping: Parallel group
Participants • 50 adults
• Average age: overall mean 33.2 (SD 7.2) (range: 21-49)
• (CBT 35.2 (mean) ACT 31.1 (mean); control 33.1 (mean))
• 100% female
• Not recorded % white
• % drug users: CBT 100%, ACT 83.3%, control 100%
• % alcohol CBT 0%, ACT 16.7%, control 100%
•  % psychiatric history: 86% had at least one mental disorder
Eligibility criteria
• Met diagnostic criteria for current substance use disorder
• Serving sentence of more than 6 months
Interventions CBT versus ACT versus waiting list control
Experimental intervention one
CBT was used to change behaviour through cognitive restructuring where therapist works with offend-
er to identify  thoughts that cause distress and uses CBT to alter resulting behaviour. After treatment,
offenders were assessed by the therapist, and follow-up was conducted at six months. The main out-
come of the CBT intervention was to increase abstinence from drug use, this was measured and corrob-
orated by urine analysis testing (N = 19).
Setting: prison
length of treatment: 16 weekly group sessions lasting 90 minutes each
Length of follow-up: 6, 12, 18 months
Experimental intervention two
ACT seeks to undermine the grip of the literal verbal content of cognition that provokes avoidance be-
haviour and constructs an alternative context in which behaviour aligned with one's values is more
likely to occur. Sessions involve both experiential and didactic learning to enable clients to experi-
ence and understand the size key ACT processes. ACT helps offenders to respond to previously avoid-
ed events in new ways and uses validation and empowerment. The ACT therapy was aimed at increas-
Lanza 2014 
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ing substance use abstinence within the prison population. After treatment, offenders were assessed
by the therapist, and follow-up was conducted at six months (N = 18).
Setting: prison
length of treatment: 16 weekly group sessions lasting 90 minutes each
Length of follow-up: 6, 12, 18 months
Control
Control group received a mental health assessment at the same time as the experimental groups and
were placed on a waiting list. After 6 months follow-up they received treatment. The offenders received
a re-educational programme during incarceration (n = 13).
Setting: prison
length of treatment: 16 weekly group sessions lasting 90 minutes each
Length of follow-up: 6, 12, 18 months 
Outcomes • Abstinence: from drug use, corroborated by urinalysis
• Percentage of abstinence
Notes Funding: work supported by Trust for the Promotion of Scientific Applied Research and Technology in
Asturias, Spain
Conflict of interest: no conflict of interest reported by authors
Country: Spain
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Use of random number table noted
Allocation concealment
(selection bias)











Low risk Being aware of receiving a psychosocial treatment is part of the therapeutic ef-
fect
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Being aware of receiving a psychosocial treatment is part of the therapeutic ef-
fect
Blinding of outcome as-
sessment (detection bias) 
subjective measures
Low risk Urinalysis was used to corroborate self-reported abstinence
Blinding of outcome as-
sessment (detection bias) 
Low risk The clinician who conducted the baseline assessments was also in charge of
the administration of the measures
Lanza 2014  (Continued)
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Low risk Similiar loss to follow-up across all three groups. A total of 9/50 lost (n = 4 for
ACT, n = 3 for CBT and n = 2 for control)
Selective reporting (re-
porting bias)





Methods Study design: RCT
Study grouping: Parallel group
Participants • 115 women




• Alcohol use not reported
• 79% reported a history of depression, 26% met the criteria for PTSD
Eligibility criteria: women with a history of substance use with between 6 and 24 months leL to serve
on the sentence
Interventions CBT and other therapies versus prison-based TC programme
Experimental intervention
The Gender Responsive Treatment (GRT) model encompasses manualised curricula designed to be rel-
evant to the needs of drug-dependent women in correctional programmes. Each provides a facilitator's
guide and a participant's workbook. Both curricula use CBT approaches, mindfulness meditation, ex-
periential therapies (guided imagery, visualisation, art therapy, movement), psychoeducational, rela-
tional, and expressive arts techniques. Helping Women Recover is a 17-session programme organised
into four modules.
• Self-module: women discover what the 'self' is; learn that addiction can be understood as a disorder
of the self; learn the sources of self-esteem; consider the effects of sexism, racism, and stigma on a
sense of self; and learn that recovery includes the growth of the self.
• Relationship module: women explore their roles in their families of origin; discuss myths and realities
about motherhood and their relationships with their mothers; review relationship histories; and con-
sider how they can build healthy support systems.
• Sexuality module: women explore the connections between addiction and sexuality and discuss body
image, sexual identity, sexual abuse, and the fear of sex when sober.
• Spirituality module: women are introduced to the concepts of spirituality, prayer, and meditation.
Spirituality deals with transformation, connection, meaning, and wholeness.
Beyond Trauma consists of 11 sessions focused on three areas: teaching women what trauma and
abuse are, helping them to understand typical reactions to trauma and abuse, and developing coping
skills (n = 60).
Setting: prison
length of treatment: 6 months
Length of follow-up: 6 and 12 months
Messina 2010 
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Control
Prison-based TC programmes in California are based on the traditional aspects of TC treatment and in-
clude the following.
• Activities that embody positive values that start a process of socialisation.
• Treatment staff who provide positive role models (and many are recovering addicts themselves)
• An alternative concept of inmates that is usually much more positive than the prevailing beliefs and
attitudes held by correctional staff.
Programming takes place during the week, and participants spend approximately 20 hours per week in
treatment. A voluntary aftercare component for graduates from the prison-based TC programmes pro-
vides funding for up to 6 months of continued treatment (residential or outpatient services) in the com-
munity following release to parole. Typically, gender issues and trauma histories were not addressed in
these prison TC programmes. In addition, both men and women were employed as treatment staff to
facilitate the groups and counsel the women (n = 55).
Setting: prison
length of treatment: 6 months
Length of follow-up: 6 and 12 months
Outcomes • Community-based aftercare participation
• Drug use




Notes Funding: This study was funded by the National Institute on Drug Abuse (Grant R21 DAO18699-01A1)
and an Interagency Agreement between University of California, Davis (Contract 07-002467), and UCLA
Integrated Substance Abuse Programs (ISAP). The findings and conclusions of this study are those of
the authors and do not necessarily represent the official policies of the California Department of Cor-
rections and Rehabilitation.
Conflict of interest: no declaration of interest reported by the authors
Country: USA
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random sequence based on an even and odd identification number
Allocation concealment
(selection bias)











Low risk Being aware of receiving a psychosocial treatment is part of the therapeutic ef-
fect
Messina 2010  (Continued)
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Blinding (performance
bias and detection bias) 
All outcomes
Low risk Being aware of receiving a psychosocial treatment is part of the therapeutic ef-
fect
Blinding of outcome as-
sessment (detection bias) 
subjective measures
Unclear risk No evidence to provide information about whether the assessors were blind
Blinding of outcome as-
sessment (detection bias) 
objective measures




Low risk ITT analysis was conducted
Selective reporting (re-
porting bias)




Methods Study design: RCT
Study grouping: Parallel group
Participants • 704 adults
• Mean age 34.7 (SD not reported)
• 100% female
• Ethnicity not reported
• 88.4% drug users in the past 6 months
• Alcohol use: 47.7% received alcohol or substance abuse treatment in 12 months before incarceration
• Mental health not reported
Eligibility criteria
Not reported, but reports that Health Link staff sought to enrol clients facing significant barriers to suc-
cessful reintegration. Nearly 90% of the female clients reported drug use, 54% lacked high school diplo-
mas, 36% had been homeless during the preceding year, and nearly one-fiLh were HIV positive. More
than 90% of the adolescent males had not graduated from high school, 85% reported recent drug use,
and 47% said that illegal activities were their primary source of income.
Interventions Intensive discharge planning services and community-based case management services versus less in-
tensive discharge planning and no community-based services: referred to as 'jail services only'.
Experimental intervention
Health Link (community-based services): to provide support to women on community health problems
and other needs in the community upon release from prison. The goals of the programme were to ac-
cess drug treatment and primary health care, engagement in supportive social networks and enrol-
ment in training or school. The programme aimed to reduce drug use, rearrest rates and HIV risk behav-
iour. During voluntary group meetings case workers helped clients identify personal problems, build
peer support and develop trusting caseworker-client relationships. Individual group counselling sup-
plemented the group sessions (n = 352).
Setting: prison into community
Length of treatment: not reported
Needles 2005 
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Length of follow-up: during 12 months follow-up
Control
Were offered less intensive discharge planning services and did not have access to Health Link services
(n = 352).
Setting: prison into community
Length of treatment: not reported
Length of follow-up: during 12 months
Outcomes The following were measured during a 1-year follow-up period.
• Arrested
• Had serious arrest charge, including murder or assault, robbery, and burglary,
• Had drug charge, including drug,law violations related to drug sales or drug possession
• Convicted on at least one charge
• Sentenced to incarceration
• Self-reported use of any drug in past 3 months
• Self-reported use of any hard drug in past 3 months
• Self-reported use of marijuana in past 3 months
• Cocaine/crack negative hair test results
• Cocaine/crack positive hair test results
• Marijuana negative hair test results
• Marijuana positive hair test results
Notes Funding: The Robert Wood Johnson Foundation funded the Evaluation of the Health Link Program
through a contract to Mathematica Policy Research, Inc. The Robert Wood Johnson Foundation also
funded the Health Link demonstration service delivery under separate contracts to the Fortune Society
and the Hunter College Center on AIDS, Drugs, and Community Health.
Conflict of interest: not reported
Country: USA
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Methods for the random sequence generation not reported
Allocation concealment
(selection bias)











Low risk Being aware of receiving a psychosocial treatment is part of the therapeutic ef-
fect
Blinding (performance
bias and detection bias) 
Low risk Being aware of receiving a psychosocial treatment is part of the therapeutic ef-
fect
Needles 2005  (Continued)
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All outcomes
Blinding of outcome as-
sessment (detection bias) 
subjective measures
High risk Follow-up interviewers could not be blind to allocation of intervention be-
cause interview questions addressed participants' interaction with Health
Link, the organisation offering the intervention.
Blinding of outcome as-
sessment (detection bias) 
objective measures
Low risk Follow-up interviewers could not be blind to allocation of intervention be-
cause interview questions addressed participants' interaction with Health
Link, the organisation offering the intervention. However, objective outcomes




High risk Results reported for completers with what appears to be > 10% withdraw-
ing/missing data for all study groups
Selective reporting (re-
porting bias)
Unclear risk The stated outcomes of interest were reported. However, there is no confirma-
tory evidence of a published trial protocol. It is therefore not possible to com-




Methods Study design: RCT
Study grouping: Parallel group
Participants • 689 adults and young offenders (women n = 144)




• Alcohol use not reported
• Psychiatric history not reported
Eligibility criteria: offenders with a history of drug use who were eligible for work release or parole
and about to be released from prison
Interventions Secure establishment-based TC programme versus routine work release
Experimental intervention
CREST work-release TC 1 month of orientation followed by 2 months of primary treatment followed by
3 months of work release. This was intensive given the nature of the intervention (n = 248).
Setting: prison
Length of treatment: 6 months
Length of follow-up: 6, 18 months
Control
Routine work-release (n = 441)
Duration also 6 months, intensity not reported
Setting: prison
Length of treatment: 6 months
Nielsen 1996 
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Length of follow-up: 6, 18 months
Outcomes Drug use (self-reported) during the last 6 months at 6-month follow-up
Drug use (self-reported) during the last 18 months at 18-months follow-up
Recidivism (arrested and charged) for any offence (self-reported) during the last 6 months at 6-month
follow-up
Recidivism (arrested and charged) for any offence (self-reported) during the last 18 months at 18-
months follow-up
Notes Funding: This research was supported by PHS Grants R18 DAO6948 and R37 DAO6124 from the Nation-
al Institute on Drug Abuse.
Conflict of interest: no declaration of interest reported by the authors
Country: USA
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information reported
Allocation concealment
(selection bias)











Low risk Being aware of receiving a psychosocial treatment is part of the therapeutic ef-
fect
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Being aware of receiving a psychosocial treatment is part of the therapeutic ef-
fect
Blinding of outcome as-
sessment (detection bias) 
subjective measures
Unclear risk No evidence to provide information about whether the assessors were blind
Blinding of outcome as-
sessment (detection bias) 
objective measures




Unclear risk No ITT analysis conducted. No explanation of the impact of withdrawals
Selective reporting (re-
porting bias)
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Methods Study design: RCT
Study grouping: Parallel group
Participants • 130 adults
• Mean age 38.6 (SD 11.3)
• 100% female
• 41% black
• 69% drug use during the last 6 months based on urine analysis
• Alcohol use: 41.5% had used in the past 6 months
• 44.6% reported depressive symptomology
Eligibility criteria
• Having used drugs prior to their most recent incarceration
• Ages 18–65 years
• Were considered homeless prior to discharge from incarceration
Interventions DBT-CM versus health promotion comparator
Experimental intervention
DBT-CM consisted of six weekly group sessions (with 5 to 7 individuals per group) and six weekly one-
on-one sessions, each lasting, on average, 45–60 minutes for a total of 12 weeks. The six DBT-CM ses-
sions were organised into the following topics: avoiding and eliminating cues to use, burning bridges
over substance use, building a life worth living, observing urges, adaptive denial and alternative rebel-
lion. Each session included signing in, mindfulness, and diary card/review of homework. Six individual
sessions were also included (n = 65).
Setting: community
length of treatment: 12 weeks
Length of follow-up: 6 months
Control
Health promotion programme, a dedicated nurse and two community health workers were trained
to deliver a programme focused on common chronic diseases that homeless women face and Health
promotion activities for these chronic diseases using six weekly group sessions and six individual ses-
sions. The six health promotion sessions conducted weekly focused on: diabetes, heart disease, sexual-
ly transmitted infections including HIV, parenting skills, community and family reintegration and other
topics (n = 65).
Setting: community
length of treatment: 6 weeks
Length of follow-up: 6 months
Outcomes All outcomes measured at 6 months
• Positive drug use in urine analyses, confirmation by self-report
• No marijuana use in urine analyses, confirmation by self-report
• No crack cocaine use in urine analyses, confirmation by self-report
• No cocaine use in urine analyses, confirmation by self-report
• No heroin use in urine analyses, confirmation by self-report
• No methamphetamine in urine analyses, confirmation by self-report
• Not any drug use in self-report
Nyamathi 2017 
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• Not any drug use in urine analyses, confirmation by self-report
Notes Funding: The study was funded by the National Institute on Drug Abuse (R34DA035409, NIAID K01 AI1
18559). The project was supported by the National Center for Advancing Transnational Sciences, Na-
tional Institutes of Health, through Grant UL1 TR0001241.
Conflict of interest: The authors have no conflicts of interest to report.
Country: USA
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)















Low risk Being aware of receiving a psychosocial treatment is part of the therapeutic ef-
fect
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Being aware of receiving a psychosocial treatment is part of the therapeutic ef-
fect
Blinding of outcome as-
sessment (detection bias) 
subjective measures
Unclear risk Not reported if outcome assessors were blinded or not
Blinding of outcome as-
sessment (detection bias) 
objective measures




High risk Outcome data reported for 58/65 (89%) in both study groups for participants
who completed programme activities Although missing outcome data are
equal across intervention groups, the authors do not state whether there was
an imbalance in the reasons for missing data in the two groups.
Selective reporting (re-
porting bias)
High risk The number of visits to healthcare or social service providers was stated as
a secondary outcome in the protocol but was not reported in the published
study. The identification of baseline predictors of outcome success (absti-
nence) was reported in the study as a secondary outcome but was not men-




Methods Study design: RCT
Sacks 2008 
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Study grouping: Parallel group
Participants • 573 adult women




Eligibility criteria: female inmates with at least 6 months remaining until parole with serious sub-
stance abuse problems requiring treatment and presenting a minimum/medium security risk
Interventions TC programme versus treatment as usual
Experimental intervention
TCs were initially designed for use in community-based residential settings, and the model has been
successfully adapted for inmate populations. The model has been further modified for male inmates
with co-occurring serious mental and substance use disorders, with previous evidence showing posi-
tive outcomes for reincarceration, substance use, and mental health symptoms. The intervention in-
volved a 6-month tenure in separate residential building with programme activities 4 hours per day.
The programme followed TC principles, with additional gender specific aspects (n = 257).
Setting: prison
Length of treatment: 5 days per week for 4 hours per day (and supplemented on a weekend with an
additional 4 hours per day) average length of time spent was 6.5 months
Length of follow-up: 6, 12, 18 months post-prison release
Control group
The control programme, based at Colorado Department of Corrections (CDOC) standard treatment,
known in the CDOC system as the Intensive Outpatient Programme (IOP). This is the standard treat-
ment that CDOC offers to all female offenders who have been classified as substance abusers. The in-
tervention is designed to address substance abuse and criminality, with a focus on prevention of re-
lapse and recidivism. The Intensive Outpatient Programme substance abuse treatment curriculum
consists of a 90-hour course, presented in an educational format, utilising a cognitive behavioural for-
mat to address underlying issues of substance use/abuse and criminal behaviour. The women in the In-
tensive Outpatient Programme can participate in multiple other services, including mental health as-
sessments (n = 211).
Setting: prison
Length of treatment: 2 days per week for 2 hours per week. Duration was approximately between 6 and
9 months
Length of follow-up: 6, 12, and 18 months post-prison release
Outcomes • Criminal activity
• Arrest
• Parole violation
• Drug-related activity (self-reported)
• Criminal record data (% incarcerated, mean days to incarceration)
• Self-reported illegal drug use
Notes Funding: Work supported by US Department of Health and Human Services (DHHS), National Institutes
of Health (NIH), National Institute on Drug Abuse (NIDA)
Conflict of interest: no declarations of interest are noted by the authors
Country: USA
Sacks 2008  (Continued)
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information other than "were randomly assigned"
Allocation concealment
(selection bias)











Low risk Being aware of receiving a psychosocial treatment is part of the therapeutic ef-
fect
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Being aware of receiving a psychosocial treatment is part of the therapeutic ef-
fect
Blinding of outcome as-
sessment (detection bias) 
subjective measures
Unclear risk No evidence to provide information about whether the assessors were blind
Blinding of outcome as-
sessment (detection bias) 
objective measures




High risk No loss to follow-up for reincarceration outcome but unclear loss to follow-up
for other outcomes. ITT reported. Differences also noted between data collect-








Methods Study design: RCT
Study grouping: Parallel group
Participants • 103 female inmates




• Alcohol use not reported
Eligibility criteria: female inmates requesting intensive substance abuse treatment
Interventions CBT and standard therapy versus treatment as usual
Zlotnick 2009 
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Experimental intervention
Intervention group - CBT using a Seeking Safety programme plus standard therapy.
The primary goals of the intervention include the development of coping skills to help clients attain
safety from both PTSD and substance use disorder (SUD). The intervention is present-focused, absti-
nence-oriented, and emphasises an empowering, compassionate approach. The intervention is con-
ducted using a group modality for 90 min, typically three times per week for 6 to 8 weeks while the
women were in prison, with three to five women per group. Standard therapy comprises 180-240 hours
of group treatment over 6-8 weeks. After release from prison, each woman was offered weekly individ-
ual 60 min "booster" sessions for 12 weeks to reinforce material from the group sessions (n = 27).
Setting: prison
Length of treatment: 6-8 weeks followed by a further 12 weeks booster session
Length of follow -up: 3 and 6 months
 
Control
Women in the treatment as usual group (or standard therapy) were enrolled in a substance use treat-
ment programme in the minimum security wing (approximately 30 hours per week). Women typically
attend this programme for 3 to 6 months, depending on the length of their sentences. Substance use
treatment was abstinence-oriented, focused on the 12-step model (Alcoholics Anonymous, Cocaine
Anonymous, Narcotics Anonymous), and took place in a psychoeducational large-group format, with
weekly individual case management and drug counselling. To remain in the treatment as usual pro-
gramme, the women had to attend all components of the treatment. Psychoeducational groups includ-
ed attention to women's health, domestic violence, affect management, relapse prevention, career ex-
ploration, anger management, and parenting, conducted by the same clinicians who conducted the
Seeking Safety treatment. This programme did not offer any treatment specifically for trauma. Prior
to prison release, the women received case management services, although this discontinued once
the women were released from prison. All women leaving prison were referred for further substance
use treatment. The treatment as usual programme was similar to other state prison substance use pro-
grammes in that more than 75% of states offer programmes in TC settings, in day treatment settings,
teach relapse prevention, and offer substance use education (n = 22).
Setting: prison
Length of treatment: 3 to 6 months
Length of follow-up: 3 and 6 months
 
Outcomes • Drug use (self-reported)
• Recidivism
Notes Funding: This study was supported by a grant to Caron Zlotnick from the National Institute of Drug
Abuse (DA013935-03).
Conflict of interest: no declaration of interest reported by the authors
Country: USA
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information reported other than "random"
Zlotnick 2009  (Continued)
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Allocation concealment
(selection bias)











Low risk Being aware of receiving a psychosocial treatment is part of the therapeutic ef-
fect
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Being aware of receiving a psychosocial treatment is part of the therapeutic ef-
fect
Blinding of outcome as-
sessment (detection bias) 
subjective measures
High risk The assessors were not blind and were aware of the assignment
Blinding of outcome as-
sessment (detection bias) 
objective measures




Low risk Very low and equally balanced attrition indicated in flow chart
Selective reporting (re-
porting bias)
Unclear risk No protocol identified
Zlotnick 2009  (Continued)
ACT: acceptance and commitment therapy
CBT: cognitive behavioural therapy
DBT-CM - dialectic behavioural therapy with case management
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition
ITT: intention-to-treat
LCSF: lifestyle criminality screening form
MDD: major depressive disorder
PTSD: post-traumatic stress disorder




Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
AAAP 2017 Conference proceedings only; not enough available data to extract
Alemagno 2009 Not measuring drug or crime outcomes
Alemi 2010 Not female offenders
Allen 2017 Not measuring drug or crime outcomes
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Study Reason for exclusion
Andersen 2018 No relevant outcomes
Anonymous 2004 Not an offender population
Anonymous 2015 Conference proceeding only; not enough data provided to be extracted
Anonymous 2016a Not measuring drug or crime outcomes
Anonymous 2018 Conference proceedings only; not enough data provided to be extracted
Barrett 2015 Not measuring drug or crime outcomes
Bartlett 2015 Not measuring drug or crime outcomes
Bawor 2014 Not an offender population
Bazazi 2017 Not a randomised controlled trial
Berman 2004 Not a female population
Brahen 1976 Not a randomised controlled trial
Brinkley 2018 Not a female offender population
Brodie 2009 This is not a female population
Brovko 2016 Not measuring drug or crime outcomes
Brown 2013 Not a female population
Brown 2014 Not a randomised controlled trial
Burraston 2014 Not a randomised controlled trial
Bustos 2016 Not measuring drug or crime outcomes
Calcaterra 2014 Not a randomised controlled trial
Calsyn 2005 Not an offender population
Carrieri 2017 Not an offender population
Carroll 2006 Not a female population
Carroll 2012 Not a female population
Chaple 2014 This does not contain a female population
Chaple 2016 This does not contain a female population
Cheesman 2016 Not a randomised controlled trial
Cihlar 2014 Not a randomised controlled trial
Clair 2013 Not a randomised controlled trial
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Study Reason for exclusion
Clair-Michaud 2016 Not measuring drug or crime outcomes
Clark 2002 Not a randomised controlled trial
Clayton 2013 Not measuring drug or crime outcomes
Compton 2016 Not a randomised controlled trial
Cowell 2018 Not a female offender population
CPDD 2014 Conference proceeding only; not enough data provided to be extracted
Cullen 2012 This is not a female population
Curtis 2015 Not a randomised controlled trial
Czuchry 2000 Not measuring drug or crime outcomes
Czuchry 2003 Not measuring drug or crime outcomes
D'Amico 2013 This is not a female population
Dakof 2010 This is not a female population
Dakof 2015 This is not a female population
Daughters 2018 Not an offender population
Davis 2015 This is not a randomised controlled trial
Day 2006 This is not an offender population
Demaret 2015 This is not an offender population
Di Paola 2014 This is not a female population
Dickson 2017 This is not a randomised controlled trial
Dolan 2003 This is not a female population
Dolan 2005 This is not a female population
Dole 1969 This is not a female population
Doyle 2015 This is not a randomised controlled trial
Doyle 2016 This is not a randomised controlled trial
Dunlop 2017 This is not an offender population
Easton 2007 This is not a randomised controlled trial
Easton 2018 Not a female offender population
Egg 2000 This is not a female population
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Study Reason for exclusion
Ellison 2018 Not a female offender population
Europad 2016 Conference proceeding only; not enough data provided to be extracted
Friedmann 2015 Conference proceeding only; not enough data to be extracted
Friedmann 2017 This is not a female population
Ginsberg 2012 Not measuring drug or crime outcomes
Ginsberg 2015 Not measuring drug or crime outcomes
Ginsberg 2015a Not measuring drug or crime outcomes
Gisev 2015 This is not a randomised controlled trial
Gisev 2015a This is not a randomised controlled trial
Gisev 2015b This is not a randomised controlled trial
Goddard-Eckrich 2018 This is not measuring drug or crime outcomes
Goorden 2015 Not an offender population
Gordon 2014 This is not measuring drug or crime outcomes
Gordon 2015 This is not a randomised controlled trial
Gordon 2018 Not a female offender population
Gottfredson 2005 This is not a female population
Gould 2014 This is not an offender population
Haig 2003 This is not a randomised controlled trial
Hanlon 1975 This is not a female population
Hanlon 1977 This is not a female population
Harada 2012 This is not measuring drug or crime outcomes
Heimer 2006 This is not a randomised controlled trial
Henderson 2010 This is not a female population
Henderson 2016 This is not a female population
Hendriks 2011 This is not an offender population
Henggeler 2006 This is not a female population
Herrman 2016 This is not an offender population
Himelstein 2014 This is not measuring drug or crime outcomes
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Study Reason for exclusion
Himelstein 2015 This is not a randomised controlled trial
Hoffman 1996 This is not an offender population
Holloway 2006 This is not a female population
Horn 2018 Not a RCT design
Hser 2013 This is not an offender population
Jalali 2017 This is not measuring drug or crime outcomes
Jason 2007 This is not an offender population
Jason 2015 This is not a female population
Jason 2016 This is not a randomised controlled trial
Jerrell 1995 This is not an offender population
Joe 1997 This is not an offender population
Jouhanneau 2018 Not a RCT design
Kearley 2018 This is not a female population
Kelly 2016 This is not measuring drug or crime outcomes
Khawcharoenporn 2018 No relevant outcomes
Kinlock 2007 This is not a female population
Kinlock 2009 This is not a female population
Kirkpatrick 2018 Not a female offender population
Knight 2016 This is not measuring drug or crime outcomes
Knudsen 2014 This is not measuring drug or crime outcomes
Knudsen 2016 This is not a randomised controlled trial
Kongsakon 2005 This is not measuring drug or crime outcomes
Konstenius 2014 This is not a female population
Kopak 2015 This is not a randomised controlled trial
Korchmaros 2018 Not a RCT design
Korchmaros 2018b Not a RCT design
Krebs 2017 This is not a randomised controlled trial
Kubiak 2016 This is not a randomised controlled trial
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Study Reason for exclusion
Kurland 1975 This is not a female population
Kurniasanti 2014 This is not a randomised controlled trial
Le Page 2018 Not a RCT design
Lee 2011 This is not measuring drug or crime outcomes
Lee 2013 This is not a randomised controlled trial
Lee 2014a This is not measuring drug or crime outcomes
Lee 2014b This is not measuring drug or crime outcomes
Lee 2014c Conference proceedings only; not enough data to be extracted
Lee 2015a Conference proceedings only; not enough data to be extracted
Lee 2015b This is not a female population
Lee 2015c This is not a female population
Lee 2016a This is not a female population
Lee 2016b This is not a female population
Lefevre 2018 No appropriate outcome measures
Lehman 2015 This is not measuring drug or crime outcomes
Lerch 2017 This is not a female population
Liddle 2011 This is not measuring drug or crime outcomes
Lin 2018 No relevant outcome measures
Lintzeris 2006 This is not an offender population
Little 1993 This is not an offender population
Lo 2012 This is not a female population
Lobmann 2007 This is not a female population
Lopez 2019 Not an offender population
Luciano 2014 This is not an offender population
Magura 2009 This is not a female population
Malouf 2017 This is not a female population
March 2006 This is not a female population
Marinelli-Casey 2008 This is not a randomised controlled trial
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Study Reason for exclusion
Marlowe 2008 This is not a female population
Marlowe 2009 This is not a female population
Martin 2010 This is not measuring drug or crime outcomes
Martin 2011 This is not an offender population
Martin 2014 This is not an offender population
Martin 2015 This is not measuring drug or crime outcomes
Martin 2017 This is not an offender population
Mazerolle 2000 This is not an offender population
McAuliffe 1990 This is not an offender population
McCarter 2016 This is not a female population
McCollister 2014 This is not a randomised controlled trial
McCollister 2015 Conference proceeding only; not enough data to be extracted
McCollister 2016 This is not an offender population
McCollister 2017 This is not a randomised controlled trial
McKenzie 2012 This is not a female population
Meade 2018 Not a female population
Metrebian 2015 This is not an offender population
Mitchell 2013 This is not an offender population
Mitchell 2014 This is not an offender population
Murphy 2017 This is not a female population
NCT03556618 Not a female offender population
Nemes 1999 This is not a female population
Nirenberg 2013 This is not measuring drug or crime outcomes
Nirenberg 2013a This is not measuring drug or crime outcomes
Nosyk 2010 This is not an offender population
Nyamathi 2014a This is not a randomised controlled trial
Nyamathi 2014b This is not a randomised controlled trial
Nyamathi 2015 This is not measuring drug or crime outcomes
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Study Reason for exclusion
Nyamathi 2016 This is not a randomised controlled trial
O'Brien 2015 This is not a randomised controlled trial
O'Brien 2017 This is not a randomised controlled trial
Owens 2016 This is not measuring drug or crime outcomes
Owens 2017 This is not measuring drug or crime outcomes
Page 1982 This is not measuring drug or crime outcomes
Parmar 2017 This is not a female population
Pettus-Davis 2017 This is not measuring drug or crime outcomes
Pierce 2018 This is not a randomised controlled trial
Pijl 2017 This is not a randomised controlled trial
Pitre 1997 This is not measuring drug or crime outcomes
Pitre 1998 This is not measuring drug or crime outcomes
Poblete 2017 This is not an offender population
Polcin 2018 Not a female offender population
Prendergast 2015 This is not measuring drug or crime outcomes
Prendergast 2017 This is not a female population
Randall 2018 Not a RCT
Reingle Gonzalez 2018 No relevant outcomes
Rich 2015 This is not a female population
Roll 2005 This is not an offender population
Rowe 2007 This is not an offender population
Rowland 2008 This is not a randomised controlled trial
Sajatovic 2013 This is not an offender population
Saxena 2014 This is not measuring drug or crime outcomes
Schaeffer 2014 This is not a female population
Scott 2017 This is not measuring drug or crime outcomes
Seitz-Brown 2015 This is a conference proceeding only; not enough data to be extracted
Shaul 2016 This is not a female population
Interventions for female drug-using offenders (Review)









Cochrane Database of Systematic Reviews
Study Reason for exclusion
Sheard 2007 This is not a randomised controlled trial
Sheard 2009a This is not a female population
Sheard 2009b This is not a female population
Shearer 2003 This is not an offender population
Shearer 2007 This is not a randomised controlled trial
Sinha 2003 This is not a female population
Smelson 2019 Not a RCT design
Smith 2017 This is not an offender population
Soares 2018 No relevant outcome data
Soares 2019 Not a female offender population
Somers 2013 This is not measuring drug or crime outcomes
Spohr 2015 This is not measuring drug or crime outcomes
Spohr 2018 No relevant outcomes
Springer 2017 This is not measuring drug or crime outcomes
Springer 2018 Not a female offender population
Stein 2011 This is not a female population
Sticca 2014 This is not a randomised controlled trial
Stillwell 2017 This is not a randomised controlled trial
Strang 2000 This is not an offender population
Sundell 2008 This is not a female population
Swogger 2016 This is not a female population
Thompson 2018 Not a female offender population
Tolou-Shams 2011 This is not measuring drug or crime outcomes
Vagenas 2017 This is not measuring drug or crime outcomes
Van der pol 2018 Not an offender population
van Stelle 2004 This is not a randomised controlled trial
Vaucher 2016 This is not measuring drug or crime outcomes
Villagra 2013 This is not a female population
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Study Reason for exclusion
Warren 2006 This is not an offender population
Welsh 2014 This is not measuring drug or crime outcomes
White 2018 Not a RCT design
Wimberley 2018 Not a female offender population
Wimberly 2018 This is not measuring drug or crime outcomes
Witkiewitz 2014 This is not measuring drug or crime outcomes
Wolff 2012 This is not a randomised controlled trial
Wooditch 2015 This is not a randomised controlled trial
Wooditch 2017 This is not measuring drug or crime outcomes
Wright 2011 This is not a female population
Zlotnick 2003 This is not measuring drug or crime outcomes
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Collaborative case management versus treatment as usual





Statistical method Effect size
1 Use of primary drug during 9
month follow-up
1 77 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.20, 2.12]
2 Reincarceration at 9 months 1 77 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.32, 1.57]
3 Number of arrests 1 113 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.83, 1.49]
 
 
Analysis 1.1.   Comparison 1 Collaborative case management versus
treatment as usual, Outcome 1 Use of primary drug during 9 month follow-up.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Johnson 2011 4/39 6/38 100% 0.65[0.2,2.12]
   
Total (95% CI) 39 38 100% 0.65[0.2,2.12]
Total events: 4 (Case management), 6 (Standard parole)  
Favours case management 1000.01 100.1 1 Favours standard parole
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Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=0.71(P=0.47)  
Favours case management 1000.01 100.1 1 Favours standard parole
 
 
Analysis 1.2.   Comparison 1 Collaborative case management
versus treatment as usual, Outcome 2 Reincarceration at 9 months.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Johnson 2011 8/39 11/38 100% 0.71[0.32,1.57]
   
Total (95% CI) 39 38 100% 0.71[0.32,1.57]
Total events: 8 (Case management), 11 (Standard parole)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.85(P=0.39)  
Favours case management 1000.01 100.1 1 Favours standard parole
 
 
Analysis 1.3.   Comparison 1 Collaborative case management
versus treatment as usual, Outcome 3 Number of arrests.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Guydish 2011 39/60 31/53 100% 1.11[0.83,1.49]
   
Total (95% CI) 60 53 100% 1.11[0.83,1.49]
Total events: 39 (Case management), 31 (Standard parole)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.71(P=0.48)  
Favours case management 1000.01 100.1 1 Favours standard parole
 
 
Comparison 2.   Community-based buprenorphine versus placebo





Statistical method Effect size
1 End of treatment drug use 1 36 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.27, 1.20]
2 Drug use at 3 months follow-up 1 36 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.25, 1.35]
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Analysis 2.1.   Comparison 2 Community-based buprenorphine
versus placebo, Outcome 1 End of treatment drug use.
Study or subgroup Buprenorphine Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Cropsey 2011 8/24 7/12 100% 0.57[0.27,1.2]
   
Total (95% CI) 24 12 100% 0.57[0.27,1.2]
Total events: 8 (Buprenorphine), 7 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.48(P=0.14)  
Favours buprenorphine 1000.01 100.1 1 Favours placebo
 
 
Analysis 2.2.   Comparison 2 Community-based buprenorphine
versus placebo, Outcome 2 Drug use at 3 months follow-up.
Study or subgroup Buprenorphine Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Cropsey 2011 7/24 6/12 100% 0.58[0.25,1.35]
   
Total (95% CI) 24 12 100% 0.58[0.25,1.35]
Total events: 7 (Buprenorphine), 6 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.25(P=0.21)  
Favours buprenorphine 1000.01 100.1 1 Favours placebo
 
 
Comparison 3.   Interpersonal psychotherapy versus psychoeducational control




Statistical method Effect size
1 Relapse to drug use at 3 months 1 38 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.30, 1.50]
 
 
Analysis 3.1.   Comparison 3 Interpersonal psychotherapy versus
psychoeducational control, Outcome 1 Relapse to drug use at 3 months.
Study or subgroup Psychotherapy Psychoed-
ucational
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Johnson 2012 6/19 9/19 100% 0.67[0.3,1.5]
   
Total (95% CI) 19 19 100% 0.67[0.3,1.5]
Total events: 6 (Psychotherapy), 9 (Psychoeducational)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.98(P=0.33)  
Favours psychotherapy 1000.01 100.1 1 Favours psychoeducational
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Comparison 4.   Acceptance and commitment therapy (ACT) versus waiting list control





Statistical method Effect size
1 Self-reported ASI drug use 1 31 Mean Difference (IV, Fixed, 95% CI) -0.04 [-0.37, 0.29]
2 Abstinence from drug use 1 31 Risk Ratio (M-H, Fixed, 95% CI) 2.89 [0.73, 11.43]
 
 
Analysis 4.1.   Comparison 4 Acceptance and commitment therapy
(ACT) versus waiting list control, Outcome 1 Self-reported ASI drug use.
Study or subgroup Acceptance
commitment
Waiting list control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Lanza 2014 15 0.4 (0.6) 16 0.4 (0.4) 100% -0.04[-0.37,0.29]
   
Total *** 15   16   100% -0.04[-0.37,0.29]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.23(P=0.81)  
Favours ACT 10050-100 -50 0 Favours WLC
 
 
Analysis 4.2.   Comparison 4 Acceptance and commitment therapy
(ACT) versus waiting list control, Outcome 2 Abstinence from drug use.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Lanza 2014 8/18 2/13 100% 2.89[0.73,11.43]
   
Total (95% CI) 18 13 100% 2.89[0.73,11.43]
Total events: 8 (Acceptance Commitment), 2 (Waiting list control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.51(P=0.13)  
Favours ACT 1000.01 100.1 1 Favours WLC
 
 
Comparison 5.   Cognitive behavioural therapy and other therapies versus prison therapeutic community





Statistical method Effect size
1 Reincarceration at 12 months 1 115 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.43, 1.12]
2 Arrested for any crime at 6
months
1 314 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.52, 1.03]
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Statistical method Effect size
3 Criminal activity at 6 months 1 314 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.63, 1.03]
4 Drug-related crime at 6
months
1 314 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.68, 1.32]
4.1 New Subgroup 1 314 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.68, 1.32]
5 Self-reported drug use at 6
months
1 314 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.58, 1.27]
6 Arrested (not parole violation)
at 6 months
1 314 Risk Ratio (M-H, Random, 95% CI) 0.43 [0.25, 0.77]
6.1 Arrested (not parole viola-
tion)
1 314 Risk Ratio (M-H, Random, 95% CI) 0.43 [0.25, 0.77]
 
 
Analysis 5.1.   Comparison 5 Cognitive behavioural therapy and other therapies
versus prison therapeutic community, Outcome 1 Reincarceration at 12 months.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Messina 2010 19/60 25/55 100% 0.7[0.43,1.12]
   
Total (95% CI) 60 55 100% 0.7[0.43,1.12]
Total events: 19 (CBT and other therapies), 25 (Therapeutic community)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.5(P=0.13)  
Favours CBT 1000.01 100.1 1 Favours TC
 
 
Analysis 5.2.   Comparison 5 Cognitive behavioural therapy and other therapies
versus prison therapeutic community, Outcome 2 Arrested for any crime at 6 months.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Sacks 2008 42/163 53/151 100% 0.73[0.52,1.03]
   
Total (95% CI) 163 151 100% 0.73[0.52,1.03]
Total events: 42 (CBT and other therapies), 53 (Therapeutic community)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.79(P=0.07)  
Favours CBT 1000.01 100.1 1 Favours TC
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Analysis 5.3.   Comparison 5 Cognitive behavioural therapy and other therapies
versus prison therapeutic community, Outcome 3 Criminal activity at 6 months.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Sacks 2008 65/163 75/151 100% 0.8[0.63,1.03]
   
Total (95% CI) 163 151 100% 0.8[0.63,1.03]
Total events: 65 (CBT and other therapies), 75 (Therapeutic community)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.74(P=0.08)  
Favours CBT 1000.01 100.1 1 Favours TC
 
 
Analysis 5.4.   Comparison 5 Cognitive behavioural therapy and other therapies
versus prison therapeutic community, Outcome 4 Drug-related crime at 6 months.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
5.4.1 New Subgroup  
Sacks 2008 49/163 48/151 100% 0.95[0.68,1.32]
Subtotal (95% CI) 163 151 100% 0.95[0.68,1.32]
Total events: 49 (CBT and other therapies), 48 (Therapeutic community)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.33(P=0.74)  
   
Total (95% CI) 163 151 100% 0.95[0.68,1.32]
Total events: 49 (CBT and other therapies), 48 (Therapeutic community)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.33(P=0.74)  
Favours CBT 1000.01 100.1 1 Favours TC
 
 
Analysis 5.5.   Comparison 5 Cognitive behavioural therapy and other therapies
versus prison therapeutic community, Outcome 5 Self-reported drug use at 6 months.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Sacks 2008 36/163 39/151 100% 0.86[0.58,1.27]
   
Total (95% CI) 163 151 100% 0.86[0.58,1.27]
Total events: 36 (CBT and other therapies), 39 (Therapeutic community)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.78(P=0.44)  
Favours CBT 1000.01 100.1 1 Favours TC
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Analysis 5.6.   Comparison 5 Cognitive behavioural therapy and other therapies versus
prison therapeutic community, Outcome 6 Arrested (not parole violation) at 6 months.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.6.1 Arrested (not parole violation)  
Sacks 2008 15/163 32/151 100% 0.43[0.25,0.77]
Subtotal (95% CI) 163 151 100% 0.43[0.25,0.77]
Total events: 15 (CBT and other therapies), 32 (Therapeutic community)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.86(P=0)  
   
Total (95% CI) 163 151 100% 0.43[0.25,0.77]
Total events: 15 (CBT and other therapies), 32 (Therapeutic community)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.86(P=0)  
Favours CBT and standard 1000.01 100.1 1 Favours therapeutic comm
 
 
Comparison 6.   Cognitive behavioural therapy and standard therapy versus treatment as usual





Statistical method Effect size
1 Incarceration at 3 months 1 44 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.04, 4.68]
2 Incarceration at 6 months 1 44 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.20, 1.27]
3 ASI drug score at 3 months 1 44 Mean Difference (IV, Fixed, 95%
CI)
0.02 [-0.05, 0.09]





Analysis 6.1.   Comparison 6 Cognitive behavioural therapy and standard
therapy versus treatment as usual, Outcome 1 Incarceration at 3 months.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Zlotnick 2009 1/23 2/21 100% 0.46[0.04,4.68]
   
Total (95% CI) 23 21 100% 0.46[0.04,4.68]
Total events: 1 (CBT and standard therapy), 2 (Treatment as Usual)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.66(P=0.51)  
Favours CBT & therapy 1000.01 100.1 1 Favours TAU
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Analysis 6.2.   Comparison 6 Cognitive behavioural therapy and standard
therapy versus treatment as usual, Outcome 2 Incarceration at 6 months.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Zlotnick 2009 5/23 9/21 100% 0.51[0.2,1.27]
   
Total (95% CI) 23 21 100% 0.51[0.2,1.27]
Total events: 5 (CBT and standard therapy), 9 (Treatment as Usual)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.45(P=0.15)  
Favours CBT & therapy 1000.01 100.1 1 Favours TAU
 
 
Analysis 6.3.   Comparison 6 Cognitive behavioural therapy and standard
therapy versus treatment as usual, Outcome 3 ASI drug score at 3 months.
Study or subgroup CBT and stan-
dard therapy
Treatment as Usual Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Zlotnick 2009 23 0.2 (0.1) 21 0.2 (0.1) 100% 0.02[-0.05,0.09]
   
Total *** 23   21   100% 0.02[-0.05,0.09]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.57(P=0.57)  
Favours CBT & therapy 10050-100 -50 0 Favours TAU
 
 
Analysis 6.4.   Comparison 6 Cognitive behavioural therapy and standard
therapy versus treatment as usual, Outcome 4 ASI drug score at 6 months.
Study or subgroup CBT and stan-
dard therapy
Treatment as Usual Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Zlotnick 2009 23 0.2 (0.1) 21 0.2 (0.1) 100% -0.02[-0.09,0.05]
   
Total *** 23   21   100% -0.02[-0.09,0.05]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.53(P=0.6)  
Favours CBT & therapy 10050-100 -50 0 Favours TAU
 
 
Comparison 7.   Single computerised session versus single session of case management





Statistical method Effect size
1 Number of days not using drugs (in the past 30
days) at 3 months




Interventions for female drug-using offenders (Review)









Cochrane Database of Systematic Reviews
 
 
Analysis 7.1.   Comparison 7 Single computerised session versus single session of case
management, Outcome 1 Number of days not using drugs (in the past 30 days) at 3 months.
Study or subgroup Computer session Case management Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Gilbert 2015 87 16.2 (13.3) 84 17.1 (13) 100% -0.89[-4.83,3.05]
   
Total *** 87   84   100% -0.89[-4.83,3.05]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.44(P=0.66)  
Favours computer 10050-100 -50 0 Favours case management
 
 
Comparison 8.   Dialectic behaviour therapy and case management versus a health promotion scheme





Statistical method Effect size
1 Positive drug test using urine sample
at 6 months
1 116 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.43, 1.03]
2 Number not using marijuana at 6
months
1 116 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.95, 1.59]
3 Number not using crack at 6 months 1 116 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.87, 1.14]
4 Number not using cocaine at 6
months
1 116 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.93, 1.12]
5 Number not using heroin at 6 months 1 116 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.98, 1.13]
6 Number not using methampheta-
mine at 6 months
1 116 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.87, 1.20]
7 Self-report of no drug use at 6
months
1 116 Risk Ratio (M-H, Fixed, 95% CI) 1.2 [0.92, 1.56]
 
 
Analysis 8.1.   Comparison 8 Dialectic behaviour therapy and case management versus a
health promotion scheme, Outcome 1 Positive drug test using urine sample at 6 months.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Nyamathi 2017 20/58 30/58 100% 0.67[0.43,1.03]
   
Total (95% CI) 58 58 100% 0.67[0.43,1.03]
Total events: 20 (DBT & case management), 30 (Health promotion)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.83(P=0.07)  
Favours DBT & case manage 1000.01 100.1 1 Favours health promotion
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Analysis 8.2.   Comparison 8 Dialectic behaviour therapy and case management versus
a health promotion scheme, Outcome 2 Number not using marijuana at 6 months.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Nyamathi 2017 43/58 35/58 100% 1.23[0.95,1.59]
   
Total (95% CI) 58 58 100% 1.23[0.95,1.59]
Total events: 43 (DBT & case management), 35 (Health promotion)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.56(P=0.12)  
Favours DBT & case manage 1000.01 100.1 1 Favours health promotion
 
 
Analysis 8.3.   Comparison 8 Dialectic behaviour therapy and case management
versus a health promotion scheme, Outcome 3 Number not using crack at 6 months.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Nyamathi 2017 51/58 51/58 100% 1[0.87,1.14]
   
Total (95% CI) 58 58 100% 1[0.87,1.14]
Total events: 51 (DBT & case management), 51 (Health promotion)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours DBT & case manage 1000.01 100.1 1 Favours health promotion
 
 
Analysis 8.4.   Comparison 8 Dialectic behaviour therapy and case management
versus a health promotion scheme, Outcome 4 Number not using cocaine at 6 months.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Nyamathi 2017 55/58 54/58 100% 1.02[0.93,1.12]
   
Total (95% CI) 58 58 100% 1.02[0.93,1.12]
Total events: 55 (DBT & case management), 54 (Health promotion)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.39(P=0.7)  
Favours DBT & case manage 1000.01 100.1 1 Favours health promotion
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Analysis 8.5.   Comparison 8 Dialectic behaviour therapy and case management
versus a health promotion scheme, Outcome 5 Number not using heroin at 6 months.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Nyamathi 2017 58/58 55/58 100% 1.05[0.98,1.13]
   
Total (95% CI) 58 58 100% 1.05[0.98,1.13]
Total events: 58 (DBT & case management), 55 (Health promotion)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.51(P=0.13)  
Favours DBT & case manage 1000.01 100.1 1 Favours health promotion
 
 
Analysis 8.6.   Comparison 8 Dialectic behaviour therapy and case management versus a
health promotion scheme, Outcome 6 Number not using methamphetamine at 6 months.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Nyamathi 2017 49/58 48/58 100% 1.02[0.87,1.2]
   
Total (95% CI) 58 58 100% 1.02[0.87,1.2]
Total events: 49 (DBT & case management), 48 (Health promotion)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.25(P=0.8)  
Favours DBT & case manage 1000.01 100.1 1 Favours health promotion
 
 
Analysis 8.7.   Comparison 8 Dialectic behaviour therapy and case management
versus a health promotion scheme, Outcome 7 Self-report of no drug use at 6 months.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Nyamathi 2017 42/58 35/58 100% 1.2[0.92,1.56]
   
Total (95% CI) 58 58 100% 1.2[0.92,1.56]
Total events: 42 (DBT & case management), 35 (Health promotion)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.36(P=0.17)  
Favours DBT & case manage 1000.01 100.1 1 Favours health promotion
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Comparison 9.   Therapuetic community versus work release





Statistical method Effect size
1 Incarcerated for drug offences at 18
months
1 112 Risk Ratio (M-H, Fixed, 95% CI) 1.45 [0.87, 2.42]
2 Marijuana use at 6 months 1 51 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.19, 5.65]
3 Marijuana use at 18 months 1 28 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.45]
4 Heroin use at 6 months 1 68 Risk Ratio (M-H, Fixed, 95% CI) 1.59 [0.49, 5.14]
5 Heroin use at 18 months 1 37 Risk Ratio (M-H, Fixed, 95% CI) 1.92 [0.24, 15.37]
6 Crack use at 6 months 1 55 Risk Ratio (M-H, Fixed, 95% CI) 2.07 [0.41, 10.41]
7 Crack use at 18 months 1 34 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [0.19, 14.06]
8 Cocaine use at 6 months 1 211 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.79, 1.50]
9 Cocaine use at 18 months 1 139 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.64, 1.35]
 
 
Analysis 9.1.   Comparison 9 Therapuetic community versus work
release, Outcome 1 Incarcerated for drug offences at 18 months.
Study or subgroup Therapuetic
community
Work release Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Nielsen 1996 27/62 15/50 100% 1.45[0.87,2.42]
   
Total (95% CI) 62 50 100% 1.45[0.87,2.42]
Total events: 27 (Therapuetic community), 15 (Work release)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.43(P=0.15)  
Favours TC 1000.01 100.1 1 Favours work release
 
 
Analysis 9.2.   Comparison 9 Therapuetic community versus work release, Outcome 2 Marijuana use at 6 months.
Study or subgroup Therapuetic
community
Work release Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Nielsen 1996 2/20 3/31 100% 1.03[0.19,5.65]
   
Total (95% CI) 20 31 100% 1.03[0.19,5.65]
Total events: 2 (Therapuetic community), 3 (Work release)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.04(P=0.97)  
Favours TC 1000.01 100.1 1 Favours work release
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Analysis 9.3.   Comparison 9 Therapuetic community versus work release, Outcome 3 Marijuana use at 18 months.
Study or subgroup Therapuetic
community
Work release Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Nielsen 1996 1/14 1/14 100% 1[0.07,14.45]
   
Total (95% CI) 14 14 100% 1[0.07,14.45]
Total events: 1 (Therapuetic community), 1 (Work release)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours TC 1000.01 100.1 1 Favours work release
 
 
Analysis 9.4.   Comparison 9 Therapuetic community versus work release, Outcome 4 Heroin use at 6 months.
Study or subgroup Therapuetic
community
Work release Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Nielsen 1996 6/33 4/35 100% 1.59[0.49,5.14]
   
Total (95% CI) 33 35 100% 1.59[0.49,5.14]
Total events: 6 (Therapuetic community), 4 (Work release)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.78(P=0.44)  
Favours TC 1000.01 100.1 1 Favours work release
 
 
Analysis 9.5.   Comparison 9 Therapuetic community versus work release, Outcome 5 Heroin use at 18 months.
Study or subgroup Therapuetic
community
Work release Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Nielsen 1996 4/25 1/12 100% 1.92[0.24,15.37]
   
Total (95% CI) 25 12 100% 1.92[0.24,15.37]
Total events: 4 (Therapuetic community), 1 (Work release)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.61(P=0.54)  
Favours TC 1000.01 100.1 1 Favours work release
 
 
Analysis 9.6.   Comparison 9 Therapuetic community versus work release, Outcome 6 Crack use at 6 months.
Study or subgroup Therapuetic
community
Work release Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Nielsen 1996 4/27 2/28 100% 2.07[0.41,10.41]
   
Favours TC 1000.01 100.1 1 Favours work release
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Study or subgroup Therapuetic
community
Work release Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Total (95% CI) 27 28 100% 2.07[0.41,10.41]
Total events: 4 (Therapuetic community), 2 (Work release)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.89(P=0.38)  
Favours TC 1000.01 100.1 1 Favours work release
 
 
Analysis 9.7.   Comparison 9 Therapuetic community versus work release, Outcome 7 Crack use at 18 months.
Study or subgroup Therapuetic
community
Work release Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Nielsen 1996 3/22 1/12 100% 1.64[0.19,14.06]
   
Total (95% CI) 22 12 100% 1.64[0.19,14.06]
Total events: 3 (Therapuetic community), 1 (Work release)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.45(P=0.65)  
Favours TC 1000.01 100.1 1 Favours work release
 
 
Analysis 9.8.   Comparison 9 Therapuetic community versus work release, Outcome 8 Cocaine use at 6 months.
Study or subgroup Therapuetic
community
Work release Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Nielsen 1996 36/82 52/129 100% 1.09[0.79,1.5]
   
Total (95% CI) 82 129 100% 1.09[0.79,1.5]
Total events: 36 (Therapuetic community), 52 (Work release)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.52(P=0.6)  
Favours TC 1000.01 100.1 1 Favours work release
 
 
Analysis 9.9.   Comparison 9 Therapuetic community versus work release, Outcome 9 Cocaine use at 18 months.
Study or subgroup Therapuetic
community
Work release Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Nielsen 1996 27/62 36/77 100% 0.93[0.64,1.35]
   
Total (95% CI) 62 77 100% 0.93[0.64,1.35]
Total events: 27 (Therapuetic community), 36 (Work release)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.38(P=0.71)  
Favours TC 1000.01 100.1 1 Favours work release
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Comparison 10.   Intensive discharge planning and case management versus prison only





Statistical method Effect size
1 Marijuana use 1 511 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.53, 1.16]
2 Hard drug use 1 511 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.88, 1.43]
3 Positive hair test for crack co-
caine
1 511 Odds Ratio (M-H, Fixed, 95% CI) 1.08 [0.75, 1.54]
4 Positive hair test for marijuana
use
1 511 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.55, 1.03]
5 Arrested 1 511 Risk Ratio (M-H, Fixed, 95% CI) 0.19 [0.04, 0.87]
6 Drug charge 1 511 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.75, 1.53]
7 Incarceration 1 511 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.86, 1.39]
 
 
Analysis 10.1.   Comparison 10 Intensive discharge planning and
case management versus prison only, Outcome 1 Marijuana use.
Study or subgroup Discharge
planning & CM
Jail only Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Needles 2005 36/247 49/264 100% 0.79[0.53,1.16]
   
Total (95% CI) 247 264 100% 0.79[0.53,1.16]
Total events: 36 (Discharge planning & CM), 49 (Jail only)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.2(P=0.23)  
Favours DP & CM 1000.01 100.1 1 Favours prison only
 
 
Analysis 10.2.   Comparison 10 Intensive discharge planning and
case management versus prison only, Outcome 2 Hard drug use.
Study or subgroup Discharge
planning & CM
Jail only Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Needles 2005 87/247 83/264 100% 1.12[0.88,1.43]
   
Total (95% CI) 247 264 100% 1.12[0.88,1.43]
Total events: 87 (Discharge planning & CM), 83 (Jail only)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.91(P=0.36)  
Favours DP & CM 1000.01 100.1 1 Favours prison only
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Analysis 10.3.   Comparison 10 Intensive discharge planning and case
management versus prison only, Outcome 3 Positive hair test for crack cocaine.
Study or subgroup Discharge
planning & CM
Prison only Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Needles 2005 97/247 99/264 100% 1.08[0.75,1.54]
   
Total (95% CI) 247 264 100% 1.08[0.75,1.54]
Total events: 97 (Discharge planning & CM), 99 (Prison only)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.41(P=0.68)  
Favours DP & CM 1000.01 100.1 1 Favours prison only
 
 
Analysis 10.4.   Comparison 10 Intensive discharge planning and case
management versus prison only, Outcome 4 Positive hair test for marijuana use.
Study or subgroup Discharge
planning & CM
Prison only Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Needles 2005 50/247 71/264 100% 0.75[0.55,1.03]
   
Total (95% CI) 247 264 100% 0.75[0.55,1.03]
Total events: 50 (Discharge planning & CM), 71 (Prison only)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.75(P=0.08)  
Favours DP & CM 1000.01 100.1 1 Favours prison only
 
 
Analysis 10.5.   Comparison 10 Intensive discharge planning
and case management versus prison only, Outcome 5 Arrested.
Study or subgroup Discharge
planning & CM
Prison only Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Needles 2005 2/247 11/264 100% 0.19[0.04,0.87]
   
Total (95% CI) 247 264 100% 0.19[0.04,0.87]
Total events: 2 (Discharge planning & CM), 11 (Prison only)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.15(P=0.03)  
Favours DP & CM 1000.01 100.1 1 Favours prison only
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Analysis 10.6.   Comparison 10 Intensive discharge planning and
case management versus prison only, Outcome 6 Drug charge.
Study or subgroup Discharge
planning & CM
Prison only Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Needles 2005 48/247 48/264 100% 1.07[0.75,1.53]
   
Total (95% CI) 247 264 100% 1.07[0.75,1.53]
Total events: 48 (Discharge planning & CM), 48 (Prison only)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.36(P=0.72)  
Favours DP & CM 1000.01 100.1 1 Favours prison only
 
 
Analysis 10.7.   Comparison 10 Intensive discharge planning and
case management versus prison only, Outcome 7 Incarceration.
Study or subgroup Discharge
planning & CM
Prison only Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Needles 2005 88/247 86/264 100% 1.09[0.86,1.39]
   
Total (95% CI) 247 264 100% 1.09[0.86,1.39]
Total events: 88 (Discharge planning & CM), 86 (Prison only)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.73(P=0.47)  
Favours DP & CM 1000.01 100.1 1 Favours prison only
 
 
A P P E N D I C E S




1 exp substance related disorders/ (274070)
2 street drugs/ (10355)
3 designer drugs/ (1439)
4 exp narcotics/ (120114)
5 ((substance$ or drug$ or narcotic$) adj2 (addict$ or depend$ or disorder$ or abuse$ or abusing or misuse$ or misusing or con-
sumption$ or withdraw$ or withdraw$ or detox$)).ti,ab. (100176)
6 (mdma or alcohol$ or opiate$ or opioid$ or opium or heroin or methadone or cocaine or amphetamine$ or marijuana or cannabis
or crack or phencyclidine).ti,ab. (491028)
7 1 or 2 or 3 or 4 or 5 or 6 (713470)
8 crime/ (15534)
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9 criminals/ (4125)
10 prisoners/ (16035)
11 (justice system or remand$ or parole$ or probation or court$ or corrections or correctional or revocation).ti,ab. (56176)
12 (offend$ or criminal$ or convict$ or felon$).ti,ab. (37983)
13 (custody or custodial or gaol$ or jail$ or prison$ or incarcerat$ or inmate$).ti,ab. (29693)
14 (reoffend$ or reincarcerat$ or recidiv$ or ex-offender$).ti,ab. (5525)
15 8 or 9 or 10 or 11 or 12 or 13 or 14 (126620)
16 7 and 15 (16717)
17 randomized controlled trial.pt. (516039)
18 controlled clinical trial.pt. (101743)
19 randomized.ab. (453171)
20 placebo.ab. (210619)




25 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 (4548008)
26 exp animals/ not humans.sh. (4814392)
27 25 not 26 (3934677)
28 16 and 27 (3760)
29 (201404$ or 201405$ or 201406$ or 201407$ or 201408$ or 201409$ or 201410$ or 201411$ or 201412$).ed. (771773)
30 (2015$ or 2016$ or 2017$).ed. (3473901)
31 ("20180101" or "20180102" or "20180103" or "20180104" or "20180105").ed. (19503)
32 29 or 30 or 31 (4265177)
33 28 and 32 (822)
  (Continued)
 
Appendix 2. Embase search strategy via Ovid
 
Embase search
1 substance abuse/ (49037)
2 drug dependence/ (46621)
3 addiction/ (49762)
4 drug abuse/ (49453)
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5 intravenous drug abuse/ (9700)
6 opiate addiction/ (14284)
7 heroin dependence/ (8918)
8 cocaine dependence/ (11405)
9 morphine addiction/ (3077)
10 cannabis addiction/ (8306)
11 alcoholism/ (114191)
12 alcohol abuse/ (25949)
13 ((substance$ or drug$ or narcotic$) adj2 (addict$ or depend$ or disorder$ or abuse$ or abusing or misuse$ or misusing or con-
sumption$ or withdraw$ or withdraw$ or detox$)).ti,ab. (122248)
14 (mdma or alcohol$ or opiate$ or opioid$ or opium or heroin or methadone or cocaine or amphetamine$ or marijuana or cannabis
or crack or phencyclidine).ti,ab. (598185)
15 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 (773484)
16 exp crime/ (77511)
17 criminal behavior/ (7677)
18 criminal justice/ (5597)
19 prisoner/ or offender/ (25391)
20 (justice system or remand$ or parole$ or probation or court$ or corrections or correctional or revocation).ti,ab. (56577)
21 (offend$ or criminal$ or convict$ or felon$).ti,ab. (44660)
22 (custody or custodial or gaol$ or jail$ or prison$ or incarcerat$ or inmate$).ti,ab. (32476)
23 (reoffend$ or reincarcerat$ or recidiv$ or ex-offender$).ti,ab. (6561)
24 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 (186404)
25 clinical trial/ (968061)
26 randomized controlled trial/ (482319)
27 randomization/ (76536)
28 single blind procedure/ (30101)
29 double blind procedure/ (145050)
30 crossover procedure/ (53840)
31 placebo/ (316535)
32 randomi?ed controlled trial$.tw. (170107)
33 rct.tw. (26496)
34 random allocation.tw. (1760)
35 randomly allocated.tw. (28885)
36 allocated randomly.tw. (2297)
37 (allocated adj2 random).tw. (874)
  (Continued)
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38 single blind$.tw. (20390)
39 double blind$.tw. (184823)
40 ((treble or triple) adj blind$).tw. (751)
41 placebo$.tw. (265371)
42 prospective study/ (415317)
43 or/25-42 (1860599)
44 case study/ (51268)
45 case report.tw. (353058)
46 abstract report/ or letter/ (1036148)
47 or/44-46 (1432272)
48 43 not 47 (1813215)
49 15 and 24 and 48 (1488)
50 ("201400" or "201500" or "201600" or "201701" or "201801" or "201802" or "201803").em. (28088822)
51 49 and 50 (1190)
  (Continued)
 




2 Drug dependency/ (12153)
3 Drug Usage/ (16822)
4 Drug Abuse/ (44051)
5 Alcohol Abuse/ (16779)
6 Alcohol rehabiliation/ or drug rehabilitation/ (19802)
7 ((substance$ or drug$ or narcotic$) adj2 (addict$ or depend$ or disorder$ or abuse$ or abusing or misuse$ or misusing or con-
sumption$ or withdraw$ or withdraw$ or detox$)).ti,ab. (74728)
8 (mdma or alcohol$ or opiate$ or opioid$ or opium or heroin or methadone or cocaine or amphetamine$ or marijuana or cannabis
or crack or phencyclidine).ti,ab. (176992)
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 (241511)
10 crime/ (14125)
11 criminal behavior/ (8381)
12 recidivism/ (5324)
13 prisoners/ or prisons/ or incarceration/ (16728)
14 probation/ or parole/ (1864)
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15 criminals/ or female criminals/ or male delinquency/ or juvenile delinquency/ (30689)
16 (justice system or remand$ or parole$ or probation or court$ or corrections or correctional or revocation).ti,ab. (53371)
17 (offend$ or criminal$ or convict$ or felon$).ti,ab. (69723)
18 (custody or custodial or gaol$ or jail$ or prison$ or incarcerat$ or inmate$).ti,ab. (37348)
19 (reoffend$ or reincarcerat$ or recidiv$ or ex-offender$).ti,ab. (8414)
20 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 (142208)
21 (empirical study or treatment outcome clinical trial).md. (2237461)
22 (random$ adj4 trial$).ti,ab. (44037)
23 Placebo/ (5050)
24 (random* or sham or placebo*).ti,ab,hw. (203386)
25 ((singl* or doubl*) adj (blind* or dumm* or mask*)).ti,ab,hw. (23778)
26 21 or 22 or 23 or 24 or 25 (2291604)
27 9 and 20 and 26 (11242)
28 (201404$ or 201405$ or 201406$ or 201407$ or 201408$ or 201409$ or 201410$ or 201411$ or 201412$).up. (164403)
29 (2015$ or 2016$ or 2017$).up. (645836)
30 "20180101".up. (957)
31 28 or 29 or 30 (811196)
32 27 and 31 (2333)
  (Continued)
 




#1TOPIC: (substance* NEAR/2 (addict* or depend* or disorder* or abuse* or abusing or misuse* or misusing or consumption* or with-
draw* or withdraw* or detox*)) OR TOPIC: (drug* NEAR/2 (addict* or depend* or disorder* or abuse* or abusing or misuse* or misus-
ing or consumption* or withdraw* or withdraw* or detox*)) OR TOPIC: (narcotic* NEAR/2 (addict* or depend* or disorder* or abuse*
or abusing or misuse* or misusing or consumption* or withdraw* or withdraw* or detox*))
DocType=All document types; Language=All languages;
#2TOPIC: (mdma or alcohol* or opiate* or opioid* or opium or heroin or methadone or cocaine or amphetamine* or marijuana or
cannabis or crack or phencyclidine)
DocType=All document types; Language=All languages;
#3#2 OR #1
DocType=All document types; Language=All languages;
#4TOPIC: ("justice system" or remand* or parole* or probation or court* or corrections or correctional or revocation) OR TOPIC:
(crime or criminal or offender* or criminal* or convict* or felon*) OR TOPIC: (custody or custodial or gaol* or jail* or prison* or incar-
cerat* or inmate*) OR TOPIC: (reoffend* or reincarcerat* or recidiv* or ex-offender*)
DocType=All document types; Language=All languages;
#5#4 AND #2
DocType=All document types; Language=All languages;
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Appendix 5. The CENTRAL Register of Controlled trials search strategy via Cochrane Library
 
CENTRAL search
#1 MeSH descriptor: [Substance-Related Disorders] explode all trees
#2 MeSH descriptor: [Street Drugs] explode all trees
#3 MeSH descriptor: [Designer Drugs] explode all trees
#4 MeSH descriptor: [Narcotics] explode all trees
#5 (substance* or drug* or narcotic*) near/2 (addict* or depend* or disorder* or abuse* or abusing or misuse* or misusing or con-
sumption* or withdraw$ or withdraw* or detox*):ti,ab,kw (Word variations have been searched)
#6 mdma or alcohol* or opiate* or opioid* or opium or heroin or methadone or cocaine or amphetamine* or marijuana or cannabis
or crack or phencyclidine:ti,ab,kw (Word variations have been searched)
#7 #1 or #2 or #3 or #4 or #5 or #6
#8 MeSH descriptor: [Crime] explode all trees
#9 MeSH descriptor: [Criminals] explode all trees
#10 MeSH descriptor: [Prisoners] explode all trees
#11 (justice system) or remand* or parole* or probation or court* or corrections or correctional or revocation:ti,ab,kw (Word varia-
tions have been searched)
#12 custody or custodial or gaol* or jail* or prison* or incarcerat* or inmate*:ti,ab,kw (Word variations have been searched)
#13 reoffend* or reincarcerat* or recidiv* or ex-offender*:ti,ab,kw (Word variations have been searched)
#14 offend* or criminal* or convict* or felon:ti,ab,kw (Word variations have been searched)
#15 #8 or #9 or #10 or #11 or #12 or #13 or #14
#16 #7 and #15
 
 
Appendix 6. ASSIA search strategy
 
ASSIA search
(ti(substance* NEAR/2 (addict* OR depend* OR disorder* OR abuse* OR abusing OR misuse* OR misusing OR consumption* OR with-
draw* OR withdraw* OR detox*)) OR ab(substance* NEAR/2 (addict* OR depend* OR disorder* OR abuse* OR abusing OR misuse*
OR misusing OR consumption* OR withdraw* OR withdraw* OR detox*)) OR ti(drug* NEAR/2 (addict* OR depend* OR disorder* OR
abuse* OR abusing OR misuse* OR misusing OR consumption* OR withdraw* OR withdraw* OR detox*)) OR ab(drug* NEAR/2 (addict*
OR depend* OR disorder* OR abuse* OR abusing OR misuse* OR misusing OR consumption* OR withdraw* OR withdraw* OR detox*))
OR ti(narcotic* NEAR/2 (addict* OR depend* OR disorder* OR abuse* OR abusing OR misuse* OR misusing OR consumption* OR with-
draw* OR withdraw* OR detox*)) OR ab(narcotic* NEAR/2 (addict* OR depend* OR disorder* OR abuse* OR abusing OR misuse* OR
misusing OR consumption* OR withdraw* OR withdraw* OR detox*)) OR ti(mdma OR alcohol* OR opiate* OR opioid* OR opium OR
heroin OR methadone OR cocaine OR amphetamine* OR marijuana OR cannabis OR crack OR phencyclidine) OR ab(mdma OR alco-
hol* OR opiate* OR opioid* OR opium OR heroin OR methadone OR cocaine OR amphetamine* OR marijuana OR cannabis OR crack
OR phencyclidine)) AND (ti((justice system) OR remand* OR parole* OR probation OR court* OR corrections OR correctional OR re-
vocation) OR ab((justice system) OR remand* OR parole* OR probation OR court* OR corrections OR correctional OR revocation) OR
ti(crime OR offend* OR criminal OR convict* OR felon*) OR ab(crime OR offend* OR criminal* OR convict* OR felon*) OR ti(custody OR
custodial OR gaol* OR jail* OR prison* OR incarcerat* OR inmate*) OR ab(custody OR custodial OR gaol* OR jail* OR prison* OR incar-
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Appendix 7. Health Management Information Consortium (HMIC) search strategy via Ovid
 
HMIC
1 designer drugs/ (6)
2 exp narcotics/ (365)
3 ((substance$ or drug$ or narcotic$) adj2 (addict$ or depend$ or disorder$ or abuse$ or abusing or misuse$ or misusing or con-
sumption$ or withdraw$ or withdraw$ or detox$)).ti,ab. (3032)
4 (mdma or alcohol$ or opiate$ or opioid$ or opium or heroin or methadone or cocaine or amphetamine$ or marijuana or cannabis
or crack or phencyclidine).ti,ab. (6910)
5 1 or 2 or 3 or 4 (9003)
6 crime/ (450)
7 prisoners/ (652)
8 (justice system or remand$ or parole$ or probation or court$ or corrections or correctional or revocation).ti,ab. (3327)
9 (offend$ or criminal$ or convict$ or felon$).ti,ab. (2875)
10 (custody or custodial or gaol$ or jail$ or prison$ or incarcerat$ or inmate$).ti,ab. (2332)
11 (reoffend$ or reincarcerat$ or recidiv$ or ex-offender$).ti,ab. (105)
12 6 or 7 or 8 or 9 or 10 or 11 (7118)
13 5 and 12 (634)
14 limit 13 to yr="2014 -Current" (14)
 
 
Appendix 8. PAIS search strategy
 
PAIS
(ti(substance* NEAR/2 (addict* OR depend* OR disorder* OR abuse* OR abusing OR misuse* OR misusing OR consumption* OR with-
draw* OR withdraw* OR detox*)) OR ab(substance* NEAR/2 (addict* OR depend* OR disorder* OR abuse* OR abusing OR misuse*
OR misusing OR consumption* OR withdraw* OR withdraw* OR detox*)) OR ti(drug* NEAR/2 (addict* OR depend* OR disorder* OR
abuse* OR abusing OR misuse* OR misusing OR consumption* OR withdraw* OR withdraw* OR detox*)) OR ab(drug* NEAR/2 (addict*
OR depend* OR disorder* OR abuse* OR abusing OR misuse* OR misusing OR consumption* OR withdraw* OR withdraw* OR detox*))
OR ti(narcotic* NEAR/2 (addict* OR depend* OR disorder* OR abuse* OR abusing OR misuse* OR misusing OR consumption* OR with-
draw* OR withdraw* OR detox*)) OR ab(narcotic* NEAR/2 (addict* OR depend* OR disorder* OR abuse* OR abusing OR misuse* OR
misusing OR consumption* OR withdraw* OR withdraw* OR detox*)) OR ti(mdma OR alcohol* OR opiate* OR opioid* OR opium OR
heroin OR methadone OR cocaine OR amphetamine* OR marijuana OR cannabis OR crack OR phencyclidine) OR ab(mdma OR alco-
hol* OR opiate* OR opioid* OR opium OR heroin OR methadone OR cocaine OR amphetamine* OR marijuana OR cannabis OR crack
OR phencyclidine)) AND (ti((justice system) OR remand* OR parole* OR probation OR court* OR corrections OR correctional OR re-
vocation) OR ab((justice system) OR remand* OR parole* OR probation OR court* OR corrections OR correctional OR revocation) OR
ti(crime OR offend* OR criminal OR convict* OR felon*) OR ab(crime OR offender* OR criminal* OR convict* OR felon*) OR ti(custody
OR custodial OR gaol* OR jail* OR prison* OR incarcerat* OR inmate*) OR ab(custody OR custodial OR gaol* OR jail* OR prison* OR in-
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TI ( substance* N2 (addict* or depend* or disorder* or abuse* or abusing or misuse* or misusing or consumption* or withdraw* or
withdraw* or detox*) ) OR AB ( substance* N2 (addict* or depend* or disorder* or abuse* or abusing or misuse* or misusing or con-
sumption* or withdraw* or withdraw* or detox*) ) OR TI ( drug* N2 (addict* or depend* or disorder* or abuse* or abusing or misuse*
or misusing or consumption* or withdraw* or withdraw* or detox*) ) OR AB ( drug* N2 (addict* or depend* or disord ...
Search modes - Boolean/Phrase
S2
TI ( mdma or alcohol* or opiate* or opioid* or opium or heroin or methadone or cocaine or amphetamine* or marijuana or cannabis
or crack or phencyclidine ) OR AB ( mdma or alcohol* or opiate* or opioid* or opium or heroin or methadone or cocaine or ampheta-
mine* or marijuana or cannabis or crack or phencyclidine )
Search modes - Boolean/Phrase
S3
S1 OR S2
Search modes - Boolean/Phrase
S4
TI ( justice system) or crime or remand* or parole* or probation or court* or corrections or correctional or revocation ) OR AB ( justice
system) or crime or remand* or parole* or probation or court* or corrections or correctional or revocation ) OR TI ( offend* or crimi-
nal* or convict* or felon* ) OR AB ( offend* or criminal* or convict* or felon* ) OR TI ( custody or custodial or gaol* or jail* or prison* or
incarcerat* or inmate* ) OR AB ( custody or custodial or gaol* or jail* or prison* or ...







LILACS search (via http://lilacs.bvsalud.org/en/).
tw:((remand or prison or prisoner or prisoners or prisäo or cárcere or cárcel or detenidos or detentas or acusados or presidiáriosso-
bre or presidiarias or preso or Privados or recluses or offender$ or infratoras or infratora or infratores or delicuentes or infrator or
criminal$ or probation or probatorio or estagio or court or courts or tribunal or tribunals or secure establishment$ or secure facilit$
or reoffend$ or reincarcerat$ or recidivi$ or reincidencia or recidivante or reincidência or ex-offender$ or jail or jails or gaol or gaols
or incarcerat$ or encarcerados or covict or convicts or convicted or felon or felons or conviction$ or reconviction$ or Convicçöes or
convicciones or inmate$ or internos or high security or prisoners or law enforcement or jurisprudence))) AND (tw:((Substance abuse$
or substance misuse$ or substance use$ or usuários de substâncias or drug dependanc$ or drug abuse$ or drug use$ or drug misuse$
or drug addict$ or narcotics addict$ or narcotics use$ or narcotics misuse$ or narcotics abuse$ or chemical dependenc$ or opiates or
heroin or crack or cocaine or amphetamines or cocaine or heroína or opioides or anfetaminas or opiáceos or opióides or addiction or
adicción or adicciones or dependência or farmacodependente or adición or adiçäo or dependence disorder$ or drug involved or Sub-
stance-related disorders or amphetamine-related disorders or cocaine-related disorders or marijuana abuse or opioid-related disor-
ders or phencyclidine abuse or substance abuse intravenous or street drugs or designer drugs or cocaine or amphetamines or anal-
gesics)))
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Appendix 11. CINHAL Plus
 
S1 TI ( substance* N2 (addict* or depend* or disorder* or abuse* or abusing or misuse* or misusing or
consumption* or withdraw* or withdraw* or detox*) ) OR AB ( substance* N2 (addict* or depend* or
disorder* or abuse* or abusing or misuse* or misusing or consumption* or withdraw* or withdraw*
or detox*) ) OR TI ( drug* N2 (addict* or depend* or disorder* or abuse* or abusing or misuse* or
misusing or consumption* or withdraw* or withdraw* or detox*) ) OR AB ( drug* N2 (addict* or de-
pend* or disord ...
S2 TI ( mdma or alcohol* or opiate* or opioid* or opium or heroin or methadone or cocaine or am-
phetamine* or marijuana or cannabis or crack or phencyclidine ) OR AB ( mdma or alcohol* or opi-
ate* or opioid* or opium or heroin or methadone or cocaine or amphetamine* or marijuana or
cannabis or crack or phencyclidine )
S3 S1 OR S2
S4 TI ( justice system) or crime or remand* or parole* or probation or court* or corrections or correc-
tional or revocation ) OR AB ( justice system) or crime or remand* or parole* or probation or court*
or corrections or correctional or revocation ) OR TI ( offend* or criminal* or convict* or felon* )
OR AB ( offend* or criminal* or convict* or felon* ) OR TI ( custody or custodial or gaol* or jail* or
prison* or incarcerat* or inmate* ) OR AB ( custody or custodial or gaol* or jail* or prison* or ...
S5 S3 AND S4
 
 







Low risk The investigators describe a random component in the sequence generation process
such as: random number table; computer random number generator; coin tossing; shuf-
fling cards or envelopes; throwing dice; drawing of lots; minimisation.
  High risk The investigators describe a non-random component in the sequence generation process
such as: odd or even date of birth; date (or day) of admission; hospital or clinic record
number; alternation; judgement of the clinician; results of a laboratory test or a series of
tests; availability of the intervention.
  Unclear risk Insufficient information about the sequence generation process to permit judgement of




Low risk Investigators enrolling participants could not foresee assignment because one of the fol-
lowing, or an equivalent method, was used to conceal allocation: central allocation (in-
cluding telephone, web-based, and pharmacy-controlled randomisation); sequential-
ly numbered drug containers of identical appearance; sequentially numbered, opaque,
sealed envelopes.
  High risk Investigators enrolling participants could possibly foresee assignments because one of
the following methods was used: open random allocation schedule (e.g. a list of random
numbers); assignment envelopes without appropriate safeguards (e.g. if envelopes were
unsealed or non opaque or not sequentially numbered); alternation or rotation; date of
birth; case record number; any other explicitly unconcealed procedure.
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  Unclear risk Insufficient information to permit judgement of low or high risk. This is usually the case if











No blinding or incomplete blinding, but the review authors judge that the outcome is not
likely to be influenced by lack of blinding; blinding of participants and key study person-










Blinding of participants and providers and unlikely that the blinding could have been bro-
ken.
 
  High risk No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of
blinding;
blinding of key study participants and personnel attempted, but likely that the blinding
could have been broken, and the outcome is likely to be influenced by lack of blinding.
  Unclear risk Insufficient information to permit judgement of low or high risk.








No blinding of outcome assessment, but the review authors judge that the outcome mea-
surement is not likely to be influenced by lack of blinding; blinding of outcome assess-
ment ensured, and unlikely that the blinding could have been broken.







No blinding of outcome assessment, but the review authors judge that the outcome mea-
surement is not likely to be influenced by lack of blinding; blinding of outcome assess-
ment ensured, and unlikely that the blinding could have been broken.
  High risk No blinding of outcome assessment, and the outcome measurement is likely to be influ-
enced by lack of blinding; blinding of outcome assessment, but likely that the blinding
could have been broken, and the outcome measurement is likely to be influenced by lack
of blinding.












No missing outcome data;
Reasons for missing outcome data unlikely to be related to true outcome (for survival da-
ta, censoring unlikely to be introducing bias);
Missing outcome data balanced in numbers across intervention groups, with similar rea-
sons for missing data across groups;
For dichotomous outcome data, the proportion of missing outcomes compared with ob-
served event risk not enough to have a clinically relevant impact on the intervention ef-
fect estimate;
  (Continued)
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For continuous outcome data, plausible effect size (difference in means or standardised
difference in means) among missing outcomes not enough to have a clinically relevant
impact on observed effect size;
Missing data have been imputed using appropriate methods;
All randomised participants are reported/analysed in the group they were allocated to by
randomisation irrespective of non-compliance and co-interventions (intention-to-treat).
  High risk Reason for missing outcome data likely to be related to true outcome, with either imbal-
ance in numbers or reasons for missing data across intervention groups;
For dichotomous outcome data, the proportion of missing outcomes compared with ob-
served event risk enough to induce clinically relevant bias in intervention effect estimate;
For continuous outcome data, plausible effect size (difference in means or standardised
difference in means) among missing outcomes enough to induce clinically relevant bias
in observed effect size;
‘as-treated’ analysis done with substantial departure of the intervention received from
that assigned at randomisation.
  Unclear risk Insufficient information to permit judgement of low or high risk (e.g. number randomised





Low risk The study protocol is available and all of the study’s prespecified (primary and secondary)
outcomes that are of interest in the review have been reported in the prespecified way;
The study protocol is not available but it is clear that the published reports include all ex-
pected outcomes, including those that were prespecified (convincing text of this nature
may be uncommon).
  High risk Not all of the study's prespecified primary outcomes have been reported;
One or more primary outcomes is reported using measurements, analysis methods or
subsets of the data (e.g. subscales) that were not prespecified;
One or more reported primary outcomes were not prespecified (unless clear justification
for their reporting is provided, such as an unexpected adverse effect);
One or more outcomes of interest in the review are reported incompletely so that they
cannot be entered in a meta-analysis;
The study report fails to include results for a key outcome that would be expected to have
been reported for such a study.
  Unclear risk Insufficient information to permit judgement of low or high risk.
9. Other bias Low risk Evidence to suggest other problems identified with the study which might threaten the
validity of the random allocation, attrition or data integrity and results of the trial.
  High risk Evidence to suggest that the trial might be underpowered/problems with the random al-
location process leading to potential self-selection bias/issues of analysis not conduct-
ed using intention-to-treat analysis or evidence of missing data. Concerns of attrition and
measurement error including reliance on self-reported measures.
  Unclear risk  Insufficient information to permit judgement of low or high risk.
  (Continued)
 
Interventions for female drug-using offenders (Review)









Cochrane Database of Systematic Reviews
W H A T ' S   N E W
 
Date Event Description
6 February 2019 New search has been performed This update represents an additional three trials; bringing the
total number of trials in this review to 13. The search strategies
are complete up until February 2019. The 13 trials represent 2560
participants and 15 publications.




H I S T O R Y
Review first published: Issue 1, 2014
 
Date Event Description
18 May 2015 New citation required and conclusions
have changed
Conclusions are quite different for some outcomes
11 July 2014 New search has been performed This update represents an additional three trials; bringing the to-
tal number of trials in this review to nine. The search strategies
are complete up until May 2014.
24 January 2014 Amended Plain language summary title correction
28 May 2013 New search has been performed This review has been updated using searches to 21 March 2013.
This review represents one in a family of four reviews. The oth-
er three reviews cover pharmacological and non-pharmacologi-
cal interventions for drug using offenders and interventions for
drug-using offenders with co-occurring mental illness. This re-
view on drug-using female offenders concerns a total of 11 new
randomised controlled trials, representing 1236 participants.
2 March 2012 New search has been performed The updated edit of this review produced a new document with
additional findings with searches up to 11 November 2011. Five
new authors have been added to this version of the review.
These include Steven Duffy, Rachael McCool, Matthew Neilson,
Catherine Hewitt and Marrissa Martyn-St James.
1 July 2011 Amended Converted to new review format
8 June 2011 New search has been performed Review has been substantially updated




C O N T R I B U T I O N S   O F   A U T H O R S
Searches were constructed and conducted by KW. The independent review team inspected the search hits by reading the titles and
abstracts. Each potentially relevant study located in the search was obtained as a full article and was independently assessed for inclusion
by the review team. In the case of discordance, a third independent review author arbitrated. Where it was not possible to evaluate the
study because of language problems or missing information, the studies were classified as 'translation/information required to determine
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decision' until a translation or further details were provided. The team of reviewers conducted data extraction for the papers. The results
were compiled and organised by AEP, LB and CH, the review team and all authors contributed towards the final draL text.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We have split the original review, Perry 2006, into different reviews (Perry 2015a; Perry 2015b; Perry 2019), and so there is no dedicated
protocol for this particular review. We had planned to perform a sensitivity analysis, excluding studies at high risk of bias, however, we
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